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CHAPTER I 
 
OVERVIEW 
 
 Cellular adhesions are important interactions formed between a cell and a 
neighboring cell or between a cell and the extracellular matrix (ECM).  These cellular 
connections contribute to the form and function of cells in metazoans.  In this 
dissertation, I use the interaction of platelets (a type of blood cell) with collagens (ECM 
proteins), an interaction vital in hemostasis, as a model of cellular adhesion.  To analyze 
this interaction, I examined the roles of the two surface receptors for collagens on 
platelets: α2β1 integrin (α2β1) and glycoprotein VI (GPVI)/Fc receptor γ-chain (FcRγ) 
complex.  The two central questions I address are: 1) What are the contributions of 
integrins on the cell-surface to cellular adhesion to the ECM? 2) Is cellular adhesion to 
the ECM through integrins influenced by the activation of other cell-surface receptors 
such as G protein-coupled receptors (GPCRs)?  My studies on α2β1, GPVI/FcRγ, and 
GPCRs address these questions and include novel observations on the interactions of 
platelets with collagens that could have broader implications on cell adhesion in general.   
 Through my studies, I identified a novel role of platelet surface receptors (GPCRs 
and GPVI/FcRγ) in increasing platelet adhesion to collagens.  The increase in platelet 
adhesion occurs through a priming mechanism of α2β1 that is stimulated by Gαq-linked 
GPCRs or GPVI/FcRγ and increases the resting platelets’ adhesiveness (avidity) towards 
collagens through phospholipase C (PLC) signaling pathways.  Mechanistically, 
modulation of integrin avidity on the cell surface can happen in several ways: changing 
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the affinity of individual integrins for their ligand, increasing the surface expression of 
the integrin, or altering the number of integrins participating in the ligation without 
increasing the total surface population.  The priming mechanism of α2β1 stimulated by 
suboptimal activation of Gαq-linked GPCRs seems to be an actin-guided redistribution of 
the integrin on the platelet surface before the integrin is converted into its high affinity 
conformer.  This effect of α2β1 on platelets could have relevance in other cell types for 
increasing the adhesiveness during formation of cell adhesions or in strengthening 
preexisting adhesions.  The stimulated increase in platelet avidity for collagens occurs 
independently of integrin activation but does seem to be associated with a change in cell 
morphology of the platelet and a physical connection between α2β1 and the actin 
cytoskeleton.   
 I postulate that the priming mechanism of α2β1 on platelets modulates platelet 
avidity for collagens through a redistribution of α2β1 on the cell surface that is directed 
by the actin cytoskeletal dynamics associated with reshaping of the cell.  This priming 
mechanism of α2β1 could apply to other types of integrins and have relevance in 
adhesions formed by migrating cells (e.g. leukocytes and metastatic cancer cells) as well 
as the dynamic maintenance of adhesions in non-migrating cells (e.g. muscle cells and 
endothelial cells).  It is also intriguing to consider the application of this paradigm to 
adhesive interactions formed by cells within a developing embryo where cell-cell and 
cell-ECM interactions are present in a continuously changing environment.   
 My identification and analysis of this α2β1 priming mechanism in platelet 
adhesion to collagens, as well as my studies on the role of GPVI/FcRγ in this interaction, 
are detailed in chapters II-VI.  An introduction to hemostasis and platelet adhesion to the 
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ECM at vascular wound sites and the key surface receptors involved in this complex 
process are highlighted in chapter II.  I show in chapter III that α2β1-mediated platelet 
adhesion to collagens can be increased through suboptimal activation (levels where αIIbβ3 
is not activated) of Gαq-linked GPCRs (specifically protease-activated receptor 4; PAR4) 
utilizing a PLC-dependent signaling pathway, and the material in chapter III is adapted 
from my paper published in the Journal of Biological Chemistry.  I further analyze this 
PAR4-induced α2β1 priming mechanism of platelet adhesion to collagen in chapter IV 
and show that PAR4 induces a modulation of α2β1 avidity that is not caused by a change 
in α2β1 conformation or its affinity for collagen.  Rather, this modulation seems to be 
linked with a possible change in α2β1 valency through a transient association with the 
platelet actin cytoskeleton.  In chapter V, I analyzed aspects of GPVI/FcRγ-mediated 
platelet processes involved in hemostasis and thrombosis and show the importance of 
GPVI/FcRγ as the primary signaling receptor for collagen and show that direct activation 
of GPVI/FcRγ by convulxin can cause enhanced α2β1-mediated platelet adhesion.  I 
conclude in chapter VI by discussing future research directions and proposing an 
amended mechanism for platelet adhesion to collagens.  I believe this work will have 
broader implications in biology in general and in the design of better anti-platelet drugs. 
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CHAPTER II 
 
INTRODUCTION 
 
 Blood is a vital tissue of vertebrates that exists as a colloidal fluid composed of 
cells (erythrocytes, leukocytes, and platelets) suspended in plasma, a complex aqueous 
solution of salts and organic molecules.  The liquid state of blood and an intact 
vasculature through which it circulates are critical for normal functions and viability of 
an organism.  Platelets are crucial elements for maintaining an intact circulatory system, 
but also have a significant role in thrombotic pathologies.  This dissertation aims to 
determine the contributions that the two platelet surface receptors, α2β1 integrin (α2β1) 
and glycoprotein VI (GPVI)/Fc receptor γ-chain (FcRγ) complex, make toward the 
platelet’s interaction with collagens, specifically collagen type I, at vascular wound sites.  
A discussion is included on platelet adhesion and signaling involved in hemostasis and 
thrombosis, substrate/integrin interactions, and anti-platelet therapies.   
 
Hemostasis and Thrombosis 
 Maintenance of intact and unblocked blood vessels is vital to sustain life in 
humans and other vertebrates.  The blood’s fluidity enables the heart to pump and 
circulate it through the series of tubes made up of arteries, veins, and capillaries that form 
the vascular network.  This network provides direct and indirect links to all the cells of 
the body, which is necessary for transport of nutrients, oxygen, and molecular signals to 
the cells and to remove cellular secretions like metabolic waste (carbon dioxide).  
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Perfusion of blood throughout the tissues of an organism is critical for cell survival and 
normal tissue function.  When perfusion is stopped through arteries or veins, the 
organism must restore the ability of blood to permeate into the damaged tissue or 
pathologies can develop such as myocardial infarction, stroke, or venous thrombosis 
causing morbidity or mortality. 
Hemostasis is the process that has evolved in vertebrates to stop hemorrhage due 
to vascular injury by producing a thrombus, or blood clot, at the wound site and involves 
an intricate balance between antithrombotic and prothrombotic cellular and molecular 
components (1,2).  The cellular components in this complex process include blood cells, 
primarily thrombocytes (also called platelets), the endothelial cells (ECs) that form the 
luminal surface of the vascular wall, and the smooth muscle cells (SMCs) that form the 
muscular lining of blood vessels (Figure 2-1A).  Under normal blood circulation 
conditions, ECs lining the blood vessels provide a smooth surface for the blood to flow 
over as well as produce antithrombotic agents, which create an inhibitory environmental 
barrier for thrombus formation.  Some antithrombotic agents ECs produce are nitric oxide 
(NO), prostacyclin (PGI2), and ecto-ADPases (CD39) to inhibit platelet activation as well 
as thrombomodulin (TM) and heparan sulfate to modulate the coagulase activity of 
thrombin (2,3).  Upon vascular injury, endothelial cells are damaged causing a change in 
their cellular activities that promotes vasoconstriction by SMCs; platelet adhesion, 
activation, and aggregation; thrombin activation and fibrin formation and the underlying 
extracellular matrix (ECM) of the vessel wall is exposed, which all promote the 
production of a thrombus at the wound site (2,4). 
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FIGURE 2-1:  Arterial hemostasis and platelet adhesion to collagen.  A, Arterial hemostasis is 
a complex process involving multiple steps in forming a stable thrombus at the site of the 
vascular injury under the shear stresses created by laminar flow of blood.  Platelets are forced to 
the periphery of the vessel where they normally flow over the endothelial layer in inactive state 
supported by secretion of inhibitors (NO and PGI2). At vascular injury sites, endothelial cells are 
damaged causing exposure of the subendothelial ECM, which platelets interact with in three steps 
that involve ligation of adhesion receptors on the platelet surface.  These interactions as well as 
the actions of other platelet activators (ADP, TXA2, and thrombin) form a stable platelet 
aggregate at the wound site.  B, Platelet adhesion to collagen involves the direct interaction of 
α2β1 and GPVI/FcRγ with specific collagen binding sites.  Indirect platelet adhesion to collagen 
occurs through the association of VWF with collagen that allows GPIb/V/IX and αIIbβ3 to bind 
VWF.  C, Scanning electron micrograph of human platelets adhering to collagen I and illustrating 
the dramatic morphological changes platelets undergo during the adhesive process. 
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Thrombus development intimately involves platelets and the blood coagulation 
system, however the role platelets serve is dependent on where the thrombus formation 
occurs in the vasculature.  Platelets are more relevant for thrombus formation in arteries 
and capillaries where blood flow conditions produce higher shear stresses and are less 
relevant for venous thrombus formation, which seems to rely more on the coagulation 
pathway (1,5). When the prothrombotic activity outweighs the antithrombotic activity, 
hemostasis is induced at the site of the vessel injury and proceeds through three 
successive but integrated steps (Fig. 2-1A) (2,6-8).   
The first step in hemostasis involves the translocation of platelets over the 
exposed ECM through the interaction of the platelet receptor GPIb/V/IX complex with 
von Willebrand factor (VWF).  VWF is a large soluble serum protein that can form 
polymers and bind to collagen I contained in the ECM, which immobilizes VWF and, 
with shear stress alters its conformation to create a surface that platelets can loosely 
interact with (9).  This labile interaction causes the platelets to roll across the vessel 
subendothelium and decelerate from the rate of the blood flow (6,10,11).  The tethering 
of platelets promotes binding of their collagen receptors, α2β1 and GPVI/FcRγ, to 
collagen I and leads to step 2: stable adhesion and activation of the platelets (6,7,12,13). 
Step 2 involves platelet adhesion and activation at the vascular wound site and 
this part of hemostasis will be the focus of this dissertation.  Stable adhesion of platelets 
to the ECM immobilizes them and promotes their activation through agonists in the 
microenvironment (collagen I, thrombin, ADP, and thromboxane A2).  Evidence suggests 
that the stable adhesion of platelets to subendothelial collagens especially under high 
shear stress conditions is mediated by α2β1, whereas the activation of platelets is 
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transduced through GPVI/FcRγ signaling.  However, the exclusivity of these roles and 
the sequence of the collagen interactions of α2β1 and GPVI/FcRγ between themselves 
and with other surface receptors (αIIbβ3 and GPIb/V/IX) have cause for dispute in the 
field (Figure 2-1B).  Platelet activation is characterized by a change in cell morphology, 
activated αIIbβ3, generation and release of thromboxane A2 (TXA2), secretion of dense 
and α-granules, and microvesicle formation that lead to step 3: thrombus formation 
(5,14,15).   
Thrombus formation is the third step in hemostasis and involves platelet 
aggregation and fibrin production.  Thrombin proteolytically cleaves serum fibrinogen 
into fibrin that polymerizes to form an insoluble network of fibers (16).  The aggregation 
of platelets predominantly occurs through integrin ligation, primarily by activated αIIbβ3 
binding to fibrinogen and fibrin, which crosslinks platelets to produce the blood clot 
(5,15).   This is the current model of hemostasis but there are still significant gaps in 
knowledge of how the hemostatic process works.  Under normal hemostatic conditions, 
all of the above processes of thrombus formation are spatially and temporally contained 
to the wound site, but when this does not occur, pathologies can develop (4). 
Thrombosis is the pathological formation of a blood clot within the vascular 
system and is caused by a dysregulation in the hemostatic processes.  Like hemostasis, 
thrombosis involves the same elements used in clot formation, but unlike hemostasis, the 
clot production exceeds normal limits and causes problems by obstructing or fully 
occluding an artery or vein.  These aberrant clots can produce severe pathologies such as 
myocardial infarction (heart disease) or stroke, which are the first and third leading 
causes of death in the U.S., respectively (17).  Both diseases account for a large 
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percentage of the national health expenditure and it is estimated that the direct and 
indirect costs for cardiovascular disease (CVD) and stroke in the United States in 2010 
will total $503.2 billion (17,18).  For these reasons, it is important to understand the 
mechanisms involved in hemostasis and thrombosis, so that better treatments and 
preventatives can be developed. 
 
Blood Rheology 
Blood rheology (i.e. the physics of blood flow) has a significant impact on 
cellular and molecular events during both normal and pathological thrombus 
development (19).  The focus here will be on the characteristics of blood flow found in 
arterial hemostasis and thrombosis as this is where platelets have a crucial role because of 
the higher flow rates and shear stresses present in these vessels.  
The fluid dynamics of liquid blood are defined as non-Newtonian, where the 
liquid viscosity is dependent on the shear rates between adjacent fluid layers in a laminar 
flow system due in part to the different cell types that create a complex viscosity profile 
(19).  However, if analysis is focused at the vascular wall where platelets are selectively 
concentrated by the laminar flow, the dynamics can be described as a simple Newtonian 
fluid and independent of the liquid viscosity (19,20).  Under these parameters, the 
laminar flow of blood through an artery produces a flow profile having the maximum 
flow velocity at the center of the vessel that decreases to the slowest velocity at the wall 
(Figure 2-1A).  The difference in flow velocities between parallel fluid layers produces a 
shear stress (the force per unit area between adjacent fluid layers) and a shear rate (the 
relative change in velocity between adjacent fluid layers) both of which are highest at the 
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blood/artery wall interface (19).  Shear rates at the arterial wall are in the range of 1,000-
10,000 s-1 and can be significantly increased at sites of pathological stenoses caused by 
an occlusive thrombus or atherosclerotic plaque (shear rates > 10,000 s-1) (21).  Stenosis 
of an artery also produces turbulent flow that diverges from laminar flow producing 
zones of flow deceleration and acceleration, streamline separation, and flow vortices that 
impact thrombus development (19).   
Blood rheology is a significant factor in regulating platelet adhesion, aggregation, 
and thrombus formation.  A study using rabbit blood flowed over aortic subendothelium 
showed a direct dependence on shear rate and thrombus formation (22).  This dependence 
on shear rate was also evident in a study on patients’ blood who suffered from platelet 
aggregation diseases: Bernard-Soulier Syndrome (BSS) (loss of platelet glycoprotein 
(GP) Ib-V-IX complex), Glanzmann’s thrombasthenia (GT) (loss of platelet αIIbβ3 
integrin), type 3 von Willebrand disease (VWD) (loss of von Willebrand factor (VWF)), 
and congenital afibrogenemia (Af) (loss of fibrinogen) (23).  This study showed that 
when blood from a normal donor was flowed over a subendothelial ECM protein 
(collagen) platelet adhesion and aggregation was enhanced with increasing shear rate.  
Using blood from BSS, GT, vWD, or Af patients, they further showed a role for the 
platelet receptor GPIb-V-IX interaction with VWF in initiating and promoting stable 
platelet adhesion to collagen as well as a stabilizing role for the interaction between 
platelet αIIbβ3 integrin and fibrinogen in platelet aggregation (23).  Another study 
identified platelet aggregation to be shear gradient-dependent during in vivo thrombus 
development at wound sites (24).  There is still a lot to be learned about what effects the 
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physical forces of blood flow have on thrombus development but it is clear that platelets 
play a vital role in the hemodynamic environment. 
 
The Vascular Subendothelial Extracellular Matrix and Collagens 
 Upon vascular injury, the subendothelial ECM, which is normally masked by the 
ECs, is exposed to the blood.  The rheologic properties of blood and the forces produced 
by its flow promote the interaction of the unmasked ECM with platelets.  This interaction 
is crucial for the development of a platelet thrombus at an arterial wound site. 
The subendothelial ECM of an artery is an organized and very insoluble structural 
support system composed of various proteins that the cells interact with through surface 
receptors.  The wall contains two types of ECM: the basement membrane and the 
interstitial ECM.  The basement membrane (BM) directly underlies the ECs lining the 
luminal surface of the blood vessel and is comprised mainly of collagens (type IV, XV, 
and XVIII), laminin, nidogen, and perlecan (25,26).  Below the BM, the interstitial ECM 
envelops the SMCs and is made up of fibrillar collagens (type I and III), fibronectins, 
tenascins, vitronectin, proteoglycans, and elastin (25).  Fibrillar collagen type I is the 
most abundant protein in humans and is prevalent in the ECM of the arterial wall where it 
is known to be a potent activator of platelets (27,28).  When ECs are damaged, these 
subendothelial ECM proteins including collagen I are exposed to the blood and help 
stimulate thrombus formation. 
Collagens are a family of 28 extracellular matrix proteins that exist as trimers of 
α-chains that contain triple helical domains.  The collagen α-chains have amino acid 
sequences consisting of regions of a repeating glycine-X-Y motif (-GXY-; X and Y being 
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any amino acid) where oftentimes proline (P) is at the X position and 4-hydroxyproline 
(O) is at the Y position (29).  The repetitive -GXY- motif as well as the association of the 
noncollagenous domains promotes the formation of the triple helical protomer that can 
further oligomerize to form suprastructures such as fibrils, networks, and microfibrils 
(30).  Collagen I and III are fibril-forming collagens where as collagen IV of the BM 
forms a two-dimensional network, and all serve to help construct particular 
microenvironments for cellular functions (29,30).  When these ideally positioned 
collagens (I, III, and IV) in the vessel wall are exposed to blood at vascular injury sites, 
platelets and serum proteins are able to interact with them and help activate hemostasis 
(Figure 2-1A and B). 
 
The Platelet 
The first accurate description of platelets from human blood was by Max Schultze 
in 1865; he described platelets as normal constituents of blood that are colorless little 
spherules with the potential to clump and extend protrusions in response to the 
coagulation of fibrous material (31).  Schultze realized the importance of these spherules 
and recommended further study of this blood component.  In an 1882 paper, Giulio 
Bizzozero further supported the idea that platelets were a normal cellular component of 
circulating blood, but most importantly through in vivo and in vitro microscopic analyses, 
he determined that platelet adhesion and aggregation at vascular wound sites was 
involved in thrombus formation (31).  These groundbreaking studies elucidated the 
platelet’s function, and since then the platelet has been a major focus of studies on 
hemostasis and thrombosis. 
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Under normal conditions, platelets circulate in blood as small discoid, anuclear 
cytoplasts (average d × h of 3.0 × 0.5µm) at a concentration range of 150-350 × 109 
platelets/L for about 10 days before being removed by the spleen or liver (14,32).  
Platelets are produced by megakaryocytes in the bone marrow through a unique terminal 
differentiation event where the megakaryocyte transforms into a very large cell with a 
polyploid nucleus and highly active gene transcription and translation that sheds many 
cytoplasts into the blood stream (33).  The amount of platelets in circulation is critical for 
its function in hemostasis and is precisely controlled through the hormone, 
thrombopoietin (TPO), by regulating the proliferation and maturation of megakaryocytes 
(32,33).  During platelet formation, the megakaryocyte packages about 103 platelets with 
all the organelles, granules, and molecular components necessary to perform their cellular 
functions (34). 
Inactive discoid platelets circulate through about 60,000 miles of blood vessels in 
the human body until they come into contact with a vascular injury site.  At arterial injury 
sites, platelets are forced by the characteristics of blood flow to interact with the damaged 
region (Figure 2-1A).  This causes platelets to weakly adhere and translocate over the 
injury site leading to deceleration and formation of stable adhesions that promote platelet 
activation and secretion followed by platelet aggregation and thrombus formation (6,15).  
Within the region of injury, platelets are exposed to multiple cell activators, which are 
secreted by endothelial cells and activated platelets or deposited from the serum.  
However, the serum coagulase, thrombin, and fibrillar collagens of the subendothelial 
ECM are arguably the most potent activators of platelets.  Upon platelet activation, the 
cell morphology rapidly and dramatically changes from the inactive discoid to a sphere 
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that extends filopodia which the platelet mass spreads out over through dynamic 
rearrangement of the actin cytoskeleton (Figure 2-1C).  These morphological changes of 
the platelet result in coverage of the wound site by the platelet plug to prevent any further 
blood loss from the vasculature.   
Along with cell morphology changes, activated platelets secrete molecules that 
serve to promote and amplify hemostasis by recruiting more platelets to the wound site 
(Figure 2-1A).  Activated platelets generate thromboxane A2 (TXA2) in their cytoplasm 
by a cyclooxygenase-1 (COX-1)-dependent mechanism and release TXA2 by passive 
diffusion across the plasma membrane to the extracellular space where it activates 
platelets further (1).  Other molecules are released by platelets through three types of 
secretory vesicles: α-granules, dense granules, and lysosomes (35).  The α-granules 
contain a variety of soluble and membrane-associated proteins such as adhesion 
molecules (P-selectin, vWF, αIIbβ3 and α2β1 integrins, and fibrinogen), chemokines 
(CXCL4, CCL5, and CXCL8), coagulation factors (Prothrombin, factor V and VIII), 
fibrinolytic factors (antithrombin III, plasminogen, and PAI-1) as well as many other 
proteins (35,36).  The dense granules hold small molecules like ions (Ca2+ and Mg2+), 
nucleotides (ADP and ATP), and serotonin and have a lot fewer proteins associated with 
them (35).  The lysosomes in platelets are homologous to lysosomes of other cell types 
and contain acid hydrolases and cathepsins (35).  The dense and α-granules are found 
only in megakaryocytes and platelets, and the secretion of these granules by platelets is 
important in promoting their hemostatic functions. 
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Platelet Surface Receptors 
For platelets to interact with agonists and substrates within the wound 
environment, a variety of cell surface receptors are expressed on platelets.  These 
receptors consist of integrins, immune-like receptors, and G protein-coupled receptors 
(GPCRs).  There are five integrins (α2β1, α5β1, α6β1, αIIbβ3, αVβ3) present on the surface 
of platelets, which have varying substrates (Figure 2-2).  The two most studied immune-
like receptors on the platelet surface are GPVI/FcRγ and GPIb/V/IX complexes.  GPCRs 
on the platelet surface act as receptors for various agonists such as thrombin, ADP, 
TXA2, epinephrine, and PGI2.  All these receptors serve important functions in 
heomstasis and are potential drug targets for thrombotic diseases. 
 
Platelet Collagen Receptors 
Platelets have two known membrane receptors that bind directly to collagen: α2β1 
and GPVI/FcRγ complex.  Both are platelet surface glycoproteins, however, α2β1 is a 
member of the integrin family and the GPVI/FcRγ complex is associated with the 
immunoglobulin superfamily of proteins.  From the amassed data on these two collagen 
receptors, it appears that for the platelet/collagen interaction, α2β1 serves as the primary 
adhesive receptor and GPVI/FcRγ transduces the activation signal. 
 
α2β1 Integrin 
α2β1 (also known as GPIa/IIa, VLA-2, or CD49b/CD29) is an integrin that 
functions as an ECM receptor for collagens and laminins and is expressed in many 
different cell types as a noncovalently-linked heterodimer composed of α and β subunits  
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FIGURE 2-2:  The Integrin Family and Platelet Integrins.  A, The 24 disitinct integrins 
function as cell adhesion receptors and are composed of heterodimers of α and β subunits.  The 
integrins can be further subgrouped into RGD-binding, collagen-binding, laminin-binding, or 
leukocyte-specific receptors.  The collagen-binding and leukocyte-specific integrins contain an 
extra inserted-domain (I-domain) in their α subunits, which mediates their ligand binding.  B, 
Platelets express an I-domain containing integrin (α2β1) and several integrins that lack an I-
domain (αIIbβ3, αVβ3, α5β1, and α6β1).  Integrin “activation” and transition to a receptor 
conformation with high affinity for the ligand occurs by extension from the bent conformation 
and opening of the headpiece binding domain through the separation of the transmembrane (TM) 
regions of the α and β subunits.  Adapted from Hynes, RO, Cell, 2002 and Luo, BH and Springer, 
TA, Immunol Rev, 2007. 
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(Figure 2-2)(37,38).  α2β1 is part of the subgroup of integrins that bind to ligands through 
an inserted-domain (I-domain) within the α subunit.  The α2β1 I-domain contains a metal 
ion dependent adhesion site (MIDAS) motif that requires the coordination of a metal ion 
(Mg2+ or Mn2+) to bind collagen (39-41).  On human platelets, the average receptor 
density of α2β1 is about 1731 ± 432 sites per platelet (42).  Platelets adhere to collagens I-
VIII through α2β1 (43).  Integrins are thought to be bidirectional signaling receptors 
(inside-out and outside-in signaling mechanisms) that connect the ECM to a cell’s actin 
cytoskeleton and are present in inactive conformations at the surface of cells but convert 
to low or high affinity conformational states upon ligation or through intracellular signals 
(44,45).  α2β1 has been shown to have two binding affinities (high and low) for collagen 
(KD(high)= 9.9 nM; KD(low)= 58 nM) and has the highest affinity for collagen of the two 
platelet collagen receptors (46,47).  The amino acid sequence -GER- in collagen is 
essential for α2β1 binding, and the sequence -GFOGER- (O = hydroxyproline) represents 
the high affinity α2β1 binding site in collagens (48,49).   
α2β1 was initially suggested to be a platelet collagen receptor when a patient with 
a bleeding disorder possessed platelets that did not respond to collagen and were shown 
to lack α2β1 (50).  It has also been shown that the heterogeneity of α2β1 expression can be 
connected to two linked polymorphisms within the gene at nucleotides 807 (T or C) and 
873 (A or G), and these may contribute to clinical phenotypes.  The 807C/873G pair is 
associated with low α2β1 expression levels, whereas the 807T/873A pair is associated 
with high expression levels (51,52).  This heterogeneity of α2β1 expression due to genetic 
variation is associated with altered platelet responses to collagen as seen between 
different mouse strains (53).   
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GPVI/FcRγ Complex 
 GPVI is an immunoglobulin (Ig) plasma membrane protein that contains two Ig-
like domains and a mucin-like Ser/Thr-rich region in its extracellular region and, in 
contrast to α2β1, is only expressed in platelets and megakaryocytes (Figure 2-3) 
(47,54,55).  In platelets, through a salt bridge in the transmembrane domain, GPVI 
constitutively associates with another membrane protein, Fc Receptor γ-chain  (FcRγ), 
which contains an immunoreceptor tyrosine-based activation motif (ITAM) (56,57).  The 
average receptor density of GPVI/FcRγ on platelets is 3730 ± 453 sites per platelet (42).  
GPVI/FcRγ is the lower affinity collagen receptor on platelets and requires receptor 
dimerization to measure a binding affinity (KD(dimer)= 578 nM) (47,58,59).  GPVI/FcRγ 
binds to collagen at -(GPO)n- repeats and requires at least two in a series (60,61).  
Collagen I and III contain repeats of -(GPO)n- making up ~10% of the total amino acid 
sequence and containing series of n = 5 and 3, respectively (27,62).  Similarly to α2β1, 
GPVI/FcRγ was suggested to be a platelet collagen receptor through analysis of a patient 
with a bleeding disorder whose platelets lacked a 62 kDa protein (63).  The association of 
GPVI and FcRγ is necessary to form the receptor on platelets and binding of collagen 
leads to the phosphorylation and activation of the ITAM domain of FcRγ, which 
produces the majority of the collagen signal that activates platelets (56,64,65).  Besides 
GPVI/FcRγ, other receptors on the surface of platelets are able to activate platelets. 
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FIGURE 2-3:  GPVI/FcRγ  Complex and Associated Signaling Pathways.   GPVI/FcRγ is 
thought to exist as a complex of two GPVI molecules associated through salt bridges with two 
covalently linked FcRγ molecules.  Clustering of the GPVI/FcRγ complexes by multivalent 
ligands induces receptor activation and signaling through tyrosine phosphorylation of the FcRγ 
ITAM domain by Src kinases (Fyn/Lyn).  This leads to recruitment and activation of Syk, which 
further propagates the downstream signal leading to activation of PLCγ2 and PI3K.  Adapted 
from Moroi, M and Jung, SM, Thromb Res, 2004. 
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Platelet G Protein-Coupled Receptors 
 Platelets express several GPCRs on their surfaces that serve as receptors for 
platelet activators (thrombin, ADP, and TXA2) as well as for the inhibitor, PGI2 (Figure 
2-4).  GPCRs form a large family (~1000 human genes) of seven-transmembrane 
receptors that are involved in all physiological processes and couple to guanine-
nucleotide regulatory heterotrimeric protein complexes (G-proteins) composed of α and 
βγ subunits that transduce their signals (66).  GPCRs are major targets for the 
development of drugs by pharmaceutical companies especially in therapeutics for 
thrombotic diseases.  Human platelets have two thrombin GPCRs on their surface called 
protease-activated receptors (PARs). 
 
Protease-Activated Receptors 
 The serine protease, thrombin, is known for its role in the coagulation cascade for 
cleaving fibrinogen to form insoluble fibrin, but this coagulase is also a potent activator 
of platelets linking coagulation and hemostasis.  Thrombin stimulates the platelet 
response through two surface receptors, PAR1 and PAR4, by proteolysis of the 
extracellular N-termini of the PARs to form tethered ligands that bind and activate the 
receptors (67).  There are four known PARs (PAR1-4) in humans that are  expressed in 
many cell types including platelets, ECs, and SMCs and respond to multiple extracellular 
proteases.  PAR1 and PAR4 are primarily activated by thrombin, and both associate with 
the G-proteins, Gαq and Gα12/13, where as only PAR1 associates with Gαi (68).  The 
generation of active thrombin at vascular wound sites combined with the permanent  
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FIGURE 2-4:  Platelet GPCRs and Associated Signaling Pathways.  Platelets express several 
GPCRs on their surface important in hemostatic functions.  Thrombin activates PAR1 and PAR4 
through proteolytic cleavage of the extracellular N-terminal tail of the PAR receptor to form a 
tethered ligand that activates the PAR receptor.  PAR1 couples to the G proteins Gαq (activates 
PLCβ), Gαi (inhibits adenylyl cyclase (AC)), and Gα12/13 (activates small GTPases) whereas 
PAR4 couples to Gαq and Gα12/13.  Activated platelets secrete ADP and TXA2, and these agonists 
can activate platelets through GPCRs.  ADP is an agonist for P2Y1 that couples to Gαq and P2Y12 
that couples to Gαi.  TXA2 activates two receptors TPα and TPβ that both couple to Gαq.  These 
GPCR signaling pathways can stimulate processes like platelet shape change, granule secretion, 
and αIIbβ3 activation that all have a part in platelet activation.  PGI2 (an inhibitor of platelet 
activation) has its affect through PGI2-R that couples to Gαs (activates adenylyl cyclase).  
Adapted from Jurk, K., and Kehrel, B. E. Semin Thromb Hemost, 2005. 
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nature of the proteolytic activation of PARs and the production of a ligand connected to 
its receptor makes thrombin a potent activator of platelets. 
 
Platelet Receptor Knockout Mice 
 Knockout (-/-) mice have been very useful models in elucidating the molecular 
mechanisms involved in hemostasis and thrombosis through in vivo and in vitro anlyses 
(8).  Mice deficient in either α2β1 or GPVI/FcRγ have loss of functions to collagen in 
vitro, however the data from in vivo analyses are conflicting.  α2-/- mice have lost α2β1 
expression and show attenuated platelet aggregation to soluble collagen and loss of 
binding to collagen under flow and static conditions in vitro (69,70).  Upon in vivo 
photochemical injury of the carotid artery, the α2-/- mice show attenuated thrombus 
formation (71).  However, another report looking at in vivo thrombus formation induced 
by ligation of the carotid artery showed β1-/- and α2-/- mice were similar to wild-tpye 
(WT) and suggested other platelet receptors could compensate for loss of α2β1 (72).   
GPVI-/- and FcRγ-/- mice have a loss of surface GPVI, and platelets from both 
show an impaired aggregation to collagen in vitro under static and flow conditions but 
maintain platelet adhesion as a monolayer (73,74).  FcRγ-/- mice did have an attenuated 
thrombus formation upon severe (10%) or moderate (8%) FeCl3 injury to mesenteric 
arterioles but did not to laser injury of the arterioles, and this difference was attributed to 
the exposure of collagen at the wound site caused by FeCl3 but not by the laser (74).  
Another study compared the loss of GPVI combined with a loss of Gαq or Gα13 in the 
ability of mouse platelets to adhere to collagen I under flow conditions and found that the 
signaling stimulated by TXA2 through its GPCRs was essential for platelet adhesion to 
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collagen in the absence of GPVI/FcRγ (75).  These data suggest that α2β1 and 
GPVI/FcRγ are important in platelet functions but not essential, and that there is 
cooperation between the collagen receptors themselves as well as other surface receptors 
such as GPCRs in the platelet/collagen interaction. 
Mice deficient in several platelet GPCRs (PAR3, PAR4, P2Y1, or TPα/β) have 
been generated and tested for hemostatic defects.  The thrombin receptors PAR3 and 
PAR4 are expressed on the surface of mouse platelets, which differs from human 
platelets.  The PAR4-/- mice showed attenuated platelet responses to thrombin in vitro and 
increased bleeding times and protection from arteriolar thrombosis in vivo (76).  Mouse 
PAR3 is a receptor that does not transduce a signal when engaged by thrombin but acts as 
a cofactor for PAR4 activation (77).  Interestingly, the PAR3-/- mice showed attenuated 
platelet responses in vitro and in vivo supporting a role in hemostasis for cofactors in 
thrombin receptor activation (78,79).  Other GPCRs that activate platelets, P2Y1 a 
receptor for ADP and TPα/β receptors for TXA2, have been knocked out in mice.  Both 
the P2Y1-/- and the TP-/- mice had attenuated platelet responses to their respective 
agonists in vitro and had protection from in vivo thrombosis assays.  These results taken 
together suggest that platelet surface receptors have overlapping influences on platelet 
activities involved in the complex processes of hemostasis and thrombosis. 
 
The Two-Step, Two-Site Model of Platelet Adhesion to Collagen 
 Blood clot formation is the product of a complex cascade of cellular and 
molecular events, and stable platelet adhesion and activation at the site of the vascular 
injury is a crucial step.  A blood vessel injury that damages the ECs and exposes the 
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vessel wall subendothelial ECM to the blood enables the platelet to interact with 
prothrombotic cellular and molecular factors that initially outweigh the antithrombotic 
factors.  The collagens of the subendothelial ECM are potent thrombogenic molecular 
components of the vessel wall, and fibrillar collagen I is the most abundant.   
 The order in which α2β1 and GPVI/FcRγ bind to collagens and the signaling 
contributions they make towards platelet activation are intensely debated.  The initial 
model for platelet collagen activation, proposed by our laboratory, involved a two-step, 
two-site mechanism that was shown to involve α2β1 and, later, GPVI/FcRγ 
(40,41,56,58,80).  The existing knowledge at present supports two variations that fit the 
two-site, two-step model (Figure 2-1B).  One variation of the model proceeds with α2β1 
binding to collagen I first producing stable adhesion of the platelet leading to α2β1-
specific signals.  This is followed by GPVI/FcRγ binding to collagen I and producing 
GPVI-specific signals that are required to stimulate platelet activation.  The other 
variation has GPVI/FcRγ binding to collagen I first and producing GPVI-specific signals 
that activate the platelet and the integrins through inside-out signaling.  This is followed 
by α2β1 binding to collagen I to form a stable adhesion between the platelet and substrate.  
There is evidence for each scheme to fit the two-site, two-step model (42,81-84), and one 
study proposed that both schemes can occur depending on environmental conditions and 
may also reflect platelet receptor heterogeneity (7).  Other evidence suggests that the 
direct interaction of α2β1 and GPVI/FcRγ with collagen I plays a supportive role to the 
indirect interactions of GPIb/V/IX and αIIbβ3 binding to VWF-associated collagen 
(Figure 2-1B)(4).  This contradictory data shows that there is still a lot to be learned 
about platelet adhesion to the ECM at a vascular wound site. 
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Platelet Surface Receptor Signaling 
 GPVI/FcRγ has been shown to be the primary signaling receptor for collagens on 
platelets, and its signal transduction pathways have been studied extensively (Figure 2-3).  
There is a significant gap in the knowledge of what signals α2β1 contributes to platelet 
activation by collagen (outside-in signaling), as well as how signals from other surface 
receptors (GPCRs and GPVI/FcRγ) affect α2β1 and its interaction with collagen.  There is 
evidence that α2β1 could contribute separate, additive, and synergistic collagen signals in 
platelets (7,83-88).  Collagen signaling in platelets is a very complex process since 
platelet-activating receptors can bind to collagen directly (α2β1 and GPVI/FcRγ) or 
indirectly (GPIb/IX/V and αIIbβ3), and secondary activation can occur through platelet 
granule secretion (ADP and TXA2) and thrombin generation.  However, through the use 
of receptor-specific collagen-related peptides (CRPs), specific molecular inhibitors, and 
knockout mice, a better understanding of platelet collagen signaling has been gained.   
The majority of signals produced through collagen ligation of GPVI/FcRγ 
emanate from the clustering of these receptors and the tyrosine phosphorylation of the 
ITAM domain of FcRγ subunits by the Src kinases, Lyn and Fyn (Figure 2-3)(57,64,89).  
Phosphorylation of ITAM promotes association with Syk (p72syk; a cytoplasmic tyrosine 
kinase) and activation by Fyn/Lyn (57,90).  Activated Syk can then phosphorylate LAT 
which forms a membrane-tethered scaffolding complex with Gads and SLP-76 which 
recruits and promotes activation of phosphoinositide-3-kinase (PI3K) and phospholipase 
C-γ-2 (PLCγ2) (90-92).  PLCγ2 cleaves the membrane phospholipid, PIP2, into soluble 
IP3 and membrane-linked DAG, which activates other downstream effectors and 
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stimulates Ca2+ release into the cytosol that amplifies the signal and leads to platelet 
shape change, granule secretion, and aggregation (15,57).  There is evidence that GPVI 
produces FcRγ-independent signals through Calmodulin and this pathway is necessary 
for normal GPVI-collagen signaling (93).  Collagen activation of GPVI/FcRγ has been 
shown to signal through Protein Kinase B (PKB), c-Src, Focal Adhesion Kinase (FAK), 
and p38 mitogen-activated protein kinase (p38 MAPK), which are important for normal 
platelet responses (94-97).  Most of these findings have utilized a GPVI/FcRγ-specific, 
triple helical, cross-linked CRP (CRP-XL) to confirm GPVI signaling.  A caveat with 
CRP-XL is it may not be biologically relevant since it contains the amino acid sequence -
(GPO)10- that is not present in collagens, thus CRP-XL may act as a super-activator of 
platelets and produce irrelevant signals (98).  Our laboratory has redesigned the CRP for 
GPVI (GPVI-CRP) as well as designed an α2β1-specific CRP (α2-CRP) to make them 
more biologically relevant. 
 The collagen signals α2β1 generates in platelets through outside-in signaling do 
not induce platelet granule secretion or aggregation on their own.  Syk and PLCγ2 
activity in collagen treated platelets is inhibited by jararhagin (a snake venom that 
specifically cleaves the β1 subunit) and by antibodies that block α2β1 adhesion (99,100).  
Src, Syk, and PLCγ2 are activated in platelets adhered to a GFOGER containing CRP 
that specifically binds α2β1 (85).  Also, α2β1 activates c-Src and Lyn in platelets 
stimulated by rhodocytin (a snake venom that specifically binds α2β1 and causes platelet 
aggregation) or in human platelets lacking GPVI/FcRγ that were stimulated with collagen 
(101,102).  FAK is activated by collagen in human platelets under arterial flow 
conditions and has a dependence on α2β1, and FAK activation is seen in platelets 
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adherent to a GFOGER containing CRP (85,103,104).  Signaling by α2β1 in platelets 
adhering to a low collagen density under flow conditions stimulates p38 MAPK activity 
(105).  These data suggest that α2β1 and GPVI/FcRγ have the potential to cooperate in 
platelet collagen adhesion and activation through additive or synergistic signaling. 
 A general characteristic of integrins is their ability to transmit signals 
bidirectionally across the plasma membrane of cells to perform their function as dynamic 
links between the cell body and the extracellular environment.  Inside-out signaling 
initiated by other surface receptors (e.g. GPCRs) and affecting integrin activities (ligand 
affinity and integrin clustering) has been a major research focus, especially for αIIbβ3 and 
the β2 subgroup of leukocyte-specific integrins (44,106).  Signaling from GPVI/FcRγ, 
GPIb/V/IX, and GPCRs have been shown to cause “activation” of αIIbβ3 (defined as a 
change in αIIbβ3 conformation leading to an increased affinity for its ligand) on platelets 
(Figure 2-2B)(107).  The “activation” of αIIbβ3 occurs through stimulation of PLC and 
Rap1 that cause Talin to bind to the c-tail of the β3 subunit and inducing the integrin α/β 
subunits to separate and convert the integrin from a bent to an extended conformation 
with an increased affinity for fibrinogen/fibrin (108).  Clustering of αIIbβ3 (modulation of 
integrin avidity) has been shown to occur along with the affinity change in integrin 
“activation” but remains very controversial (109).  These aspects of integrin biology have 
been explored for α2β1 but still remain unclear, especially in relation to platelet functions. 
 
Summary 
The interactions of platelets with subendothelial collagens exposed at vascular 
wound sites is an important step in the complex process of hemostasis occurring under 
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the high forces of arterial blood flow.  α2β1 and GPVI/FcRγ are the receptors on platelets 
that bind to these exposed collagens and transmit its stimulatory signal.  This dissertation 
will address the functions of α2β1 and GPVI/FcRγ in the platelet-collagen interaction that 
are involved in hemostasis and thrombosis. The goal of this research was to elucidate and 
define the molecular mechanism(s) of α2β1 and GPVI/FcRγ during the platelet’s 
interaction with collagen I.  Our hypothesis was that α2β1 and GPVI/FcRγ have 
cooperative signaling mechanisms that are important for platelet adhesion to collagen I, 
but that α2β1 is the primary receptor required for firm adhesion of the platelets to 
collagen whereas GPVI/FcRγ has a supporting role.  This hypothesis was evaluated by 
utilizing receptor-specific CRPs designed to mimic α2β1 or GPVI/FcRγ binding sites in 
collagen I in cellular, molecular, and biochemical assays. 
The research discussed in this dissertation identifies a priming mechanism for 
α2β1 binding to collagen I that increases platelet adhesion to the substrate. I show that 
this priming mechanism is stimulated by Gαq-linked GPCRs, specifically PAR4, and can 
occur at suboptimal levels of GPCR activation (levels that do not “activate” αIIbβ3 
causing platelet aggregation).  Inhibition of GPCR-induced PLC signaling attenuates the 
priming of α2β1 and reduces the platelet-collagen adhesion to basal levels.  Suboptimal 
activation of PAR4 on mouse platelets corroborates the priming mechanism of α2β1 
observed in human platelets.  I then focus on how suboptimal PAR4 activation causes 
increased platelet adhesion to collagen through α2β1 and demonstrte that it is not caused 
by an affinity change for collagen or an increase in α2β1 at the surface of platelets but 
seems to be caused by a change in α2β1 avidity (integrin clustering).  I then analyze the 
role of GPVI/FcRγ in platelet adhesion to collagen and show support for the concept that 
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GPVI/FcRγ serves primarily as a signaling receptor and a minor role as an adhesive 
receptor.  My data also shows that GPVI/FcRγ activation through convulxin (Cvx; a snale 
venom that activates GPVI/FcRγ) can also increase platelet adhesion through α2β1, 
similar to GPCRs.  I end this dissertation with a discussion of this research, how it fits 
into what is known about the roles of the platelet collagen receptors, and future directions 
for research on α2β1 and GPVI/FcRγ on platelets. 
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CHAPTER III 
 
SUBOPTIMAL ACTIVATION OF PROTEASE-ACTIVATED RECEPTORS 
ENHANCES α2β1 INTEGRIN-MEDIATED PLATELET ADHESION TO 
COLLAGEN1 
 
 Thrombin and fibrillar collagen are potent activators of platelets at sites of 
vascular injury.  Both agonists cause platelet shape change, granule secretion, and 
aggregation to form the primary hemostatic plug.  Human platelets express two thrombin 
receptors, protease-activated receptors 1 and 4 (PAR1 and PAR4) and two collagen 
receptors, the α2β1 integrin (α2β1) and the glycoprotein VI (GPVI)/FcRγ chain complex.  
Although these receptors and their signaling mechanisms have been intensely studied, it 
is not known if and how these receptors cooperate in the hemostatic function of platelets.  
This study examined cooperation between the thrombin and collagen receptors in platelet 
adhesion by utilizing a collagen-related peptide (α2-CRP) containing the α2β1-specific 
binding motif, GFOGER, in conjunction with PAR activating peptides.  We demonstrate 
that platelet adhesion to α2-CRP is substantially enhanced by suboptimal PAR activation 
(agonist concentrations that do not stimulate platelet aggregation) using the PAR4 agonist 
peptide and thrombin.  The enhanced adhesion induced by suboptimal PAR4 activation 
was α2β1-dependent and GPVI/FcRγ-independent as revealed in experiments with α2β1- 
or FcRγ-deficient mouse platelets.  We further show that suboptimal activation of other 
platelet Gq-linked G protein-coupled receptors (GPCRs) produces enhanced platelet                                                         
1 This chapter has been adapted from the paper: Marjoram RJ, Voss B, Pan Y, Dickeson SK, Zutter MM, Hamm HE, Santoro SA. 
Suboptimal activation of protease-activated receptors enhances alpha2beta1 integrin-mediated platelet adhesion to collagen. J Biol 
Chem. 2009 Dec 11;284(50):34640-7. 
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adhesion to α2-CRP.  The enhanced α2β1-mediated platelet adhesion is controlled by 
phospholipase C (PLC), but is not dependent on granule secretion, activation of αIIbβ3 
integrin, or on phosphoinositol-3 kinase (PI3K) activity. In conclusion, we demonstrate a 
platelet priming mechanism initiated by suboptimal activation of PAR4 or other platelet 
Gq-linked GPCRs through a PLC-dependent signaling cascade that promotes enhanced 
α2β1 binding to collagens containing GFOGER sites.  
 
Introduction 
 Platelets are small, anuclear cellular elements that play a central role in 
hemostasis and contribute to vascular pathology.  At sites of intravascular injury, platelets 
are exposed to multiple pro-thrombotic factors that promote thrombus formation and 
trigger firm adhesion of platelets to the subendothelial extracellular matrix.  Thrombin 
and fibrillar collagen are two of the more potent stimuli (110,111).   
Thrombin is an essential serine protease in the coagulation cascade that ultimately 
converts fibrinogen to fibrin.  Thrombin also has a direct signaling effect on cells through 
protease-activated receptors (PARs) which are G protein-coupled receptors (GPCRs) that 
are activated by enzymatic cleavage of the amino-terminus of the receptor to produce a 
tethered ligand (67).  Of the four known PAR isoforms, human platelets express PAR1 
and PAR4.  In platelets, these receptors show different signaling kinetics; PAR1 is 
activated at low thrombin concentrations with a quick signal shut off, whereas, PAR4 is 
activated at higher thrombin concentrations with a slow signal shut off (112-114).  
Thrombin-induced signaling has been shown to modulate ligand affinity of the platelet 
membrane αIIbβ3 integrin (αIIbβ3) to promote αIIbβ3 activation and induce platelet 
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aggregation (115-117).  It is still unclear how thrombin activation of PAR1 and/or PAR4 
might cooperate with the platelet collagen receptors to influence platelet interactions with 
collagens.   
Platelets are exposed to fibrillar collagens following damage to the vessel wall 
endothelial cells. Platelets express two receptors for collagens: the α2β1 integrin (α2β1) 
and glycoprotein VI (GPVI)/FcRγ chain complex (41,63).  Both have important roles in 
the platelet-collagen interaction.  α2β1 is important for stable platelet adhesion under 
shear stress at the injury site, and GPVI/FcRγ complex is required for platelet activation 
(65,71,73,118).  However, there is still considerable debate regarding the precise roles 
and individual contributions of the two receptors. 
The use of collagen-related peptides (CRPs), short peptides that contain repetitive 
collagen-like sequences (GXX’) capable of forming triple helices similar to native 
collagens, represents a major technical advance in the study of the platelet-collagen 
interaction.  α2β1 has been shown to bind to the consensus sequence GXX’GER, 
whereas, GPVI binds to the collagen sequence (GPO)n, where n ≥ 2 and O = 4-
hydroxyproline but not to (GPP)n sequences (119-121).  For this study, we designed a 42 
amino acid CRP (α2-CRP) that contains the high affinity binding motif for α2β1, 
GFOGER, to analyze specifically the platelet α2β1 integrin-collagen interaction. 
We show that α2β1 integrin-mediated platelet adhesion is enhanced by suboptimal 
stimulation (agonist concentrations that do not initiate platelet aggregation) of PAR4, and 
to a lesser extent PAR1, by PAR activating-peptides or thrombin.  We also show that 
suboptimal activation of other Gq-linked GPCRs on platelets (P2Y1, TPα, and TPβ) can 
stimulate enhanced α2β1 integrin-mediated platelet adhesion.  The enhanced platelet 
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adhesion to α2-CRP substrate is mediated through a phospholipase C (PLC)-dependent 
pathway, but not through a PI3K-dependent pathway. Neither activation of αIIbβ3 nor 
granule secretion is required.  We confirm the α2β1 dependence of the process by 
showing that α2β1-deficient mouse platelets lose the ability to adhere to α2-CRP, whereas 
both wild-type and FcRγ-deficient mouse platelets exhibit both basal and PAR4 enhanced 
adhesion. 
 
Experimental Procedures 
Materials and Animals 
Collagen I from rat-tail tendon was purchased from Upstate Cell Signaling 
Solutions.  α2-CRP was synthesized by Celtek Peptides.   U73122, U73343, and 
wortmannin were purchased from Calbiochem.  Bovine serum albumin (BSA), MgCl2, 
EDTA, DMSO, PGE1, ADP, p-nitrophenol-N-acetyl-β-D-glucosaminide, RGDS peptide, 
Apyrase, 3,3’,5,5’-tetramethylbenzidine dihydrochloride, and other chemicals were 
purchased from Sigma Aldrich.  Activating peptides for PAR1 (PAR1-AP; SFLLRN) and 
PAR4 (PAR4-AP; AYPGKF) were purchased from GL Biochem.  Human α-thrombin 
was purchased from Enzyme Research Labs.  U46619 and SQ29,584 were purchased 
from Cayman Chemical.  Anti-human α2 integrin monoclonal antibody (6F1) was a 
generous gift from Dr. Barry S. Coller (The Rockefeller University). Anti-human α2 
integrin I-domain monoclonal antibody (12F1) was purchased from BD Pharmingen. 
Goat anti-mouse secondary antibody conjugated to horseradish peroxidase was purchased 
from Pierce.  Fura2-AM was purchased from Molecular Probes.  Hank’s Balanced Salt 
Solution lacking divalent cations (HBSS-) was purchased from Invitrogen. The α2 
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integrin subunit-deficient mice, originally generated on a C57Bl/6 X 129/SvJ background 
were backcrossed 8 times to the C57Bl/6 background using a microsatellite marker-
assisted selection (“speed congenics”), as previously described (69).  Knock-out mice for 
FcRγ on the C57Bl/6 background were purchased from Jackson Labs.  Animals were 
housed in pathogen-free conditions at Vanderbilt University Medical Center in 
compliance with IACUC regulations.  All animals were appropriately age and sex 
matched. 
Methods 
Platelet Isolation− Platelet-rich plasma (PRP) and washed platelets from human 
blood were prepared from blood obtained from healthy volunteers on the day of the 
experiment according to a protocol approved by the Institutional Review Board as 
described previously (122).  Murine blood was drawn by cardiac puncture of the left 
ventricle after carbon dioxide asphyxiation and mixed 10:1 with acid citrate dextrose 
(ACD; 39 mM citric acid, 75 mM trisodium citrate, 135 mM dextrose) anticoagulant.  
Mouse platelets were isolated similarly as previously described (69).  Human and mouse 
platelets were adjusted to 1-4×108 platelets/mL in adhesion buffer (0.5 % BSA in HBSS-
). 
Platelet Aggregation− Aggregation assays using PRP were performed on a 
BIO/DATA Corporation PAP-4 aggregometer at 37°C with stirring (1200 rpm) as 
described (69).  Agonists were added at designated final concentrations. 
Platelet Adhesion− Adhesion assays were carried out using washed, isolated human 
or mouse platelets (1×108 platelets/mL) in the presence of 2 mM MgCl2 or 5 mM EDTA 
in adhesion buffer (0.5 % BSA in HBSS-).  Substrates were coated to wells of 96-well 
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Immulon 2HB microtiter plates at concentration of 30 µg/mL unless otherwise denoted 
and blocked with adhesion buffer.  When extracellular inhibitors (Apyrase, SQ29,548, 
RGDS, or α2-inhibitory antibody) or intracellular inhibitors (U73122, U73343, or 
wortmannin) were used, platelets were treated for 10 minutes at 21°C before agonist 
treatment.  When agonists (PAR1-AP, PAR4-AP, ADP, U46619, or α-thrombin) were 
used, platelets were treated for 3 minutes at 21°C.  After treatments, platelets were 
allowed to adhere to the substrates for 60 minutes unless otherwise denoted at 37°C.  
Wells were vigorously washed with adhesion buffer plus 2 mM MgCl2 or 5 mM EDTA, 
and images of adherent platelets were taken using a Nikon Eclipse TS100 microscope 
with a Nikon Coolpix P5000 digital camera.  Adherent platelets were quantified by a 
hexosaminidase colorimetric assay using 3.75 mM p-nitrophenol-N-acetyl-β-D-
glucosaminide as the substrate as previously described (122).  The chromogenic reactions 
were stopped by adding 1.5 volumes of 50 mM glycine, 5 mM EDTA (pH 10.4) buffer, 
and the well absorbances were read at 405 nm using a Molecular Devices Emax 
microplate reader.  Each data point was performed in triplicate measurements. 
Calcium Mobilization− Changes in intracellular calcium concentrations were 
measured as described previously (123).  Briefly, washed isolated human platelets were 
incubated with 2.5 µM Fura2-AM at 37°C for 30 minutes and washed.  Platelets were 
resuspended in Tyrodes buffer, and agonist-stimulated calcium mobilization was assayed 
at 37°C with stirring using a Varian Eclipse fluorometer to measure fluorescence 
intensity changes at excitation wavelengths of 340 and 380 nm.  
Cloning, expression and purification of α2 Integrin I Domains− The cloning and 
expression of the α2 integrin I domain was similar to our previously described methods 
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(124).  A cDNA encoding the α2 integrin I domain (P141-G337) was amplified by PCR, 
and cloned into pGEX-5X-1 (GE Healthcare) between BamHI and XhoI sites.  
QuikChange mutagenesis (Stratagene) was used to replace the factor Xa cleavage site 
with the human rhinovirus 14 3C protease cleavage site (125).  The GST fusion protein 
was purified on Glutathione Sepharose FF following the manufacturers instructions (GE 
Healthcare).  The purified fusion protein was cleaved overnight at 4˚C in Cleavage Buffer 
(50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 1 mM EDTA, 1 mM DTT) containing rhinovirus 
14 3C protease (1/50, w/w).  The mixture was passed through a second Glutathione 
Sepharose FF column to remove cleaved GST, any remaining uncleaved fusion protein, 
and 3C protease (also a GST fusion protein).  Flow through fractions containing I domain 
were pooled and dialyzed against 50 mM sodium acetate pH 4.5, 1 mM DTT.  The 
dialyzed material was applied to an SP Sepharose HP column, washed extensively with 
50 mM sodium acetate pH 4.5, 1 mM DTT, and eluted in a 0-1 M linear NaCl gradient.  
The I domain eluted at approximately 300 mM NaCl.  Pooled fractions were dialyzed at 
4˚C against TBS (50 mM Tris-HCl, pH 7.4, 150 mM NaCl). 
α2 I-domain Binding− Recombinant α2 I-domain binding was determined by a solid-
phase binding assay as previously described (126).  Briefly, substrate coated 96-well 
plates were prepared as described above, and wells were blocked with Tris-buffered 
saline (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) with 300 µg/ml BSA.  Purified 
recombinant α2 I-domain was diluted to 100 nM in wash buffer (Tris-buffered saline 
containing 0.05% Tween 20, 30 µg/ml BSA, and 2 mM MgCl2 or 5 mM EDTA) and 
allowed to bind to the substrates at 21°C.  The wells were washed with the appropriate 
wash buffer, and a 1:500 dilution of anti-α2 I-domain antibody (12F1) in the appropriate 
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wash buffer was added and incubated at 21°C.  The wells were washed three times, and a 
1:750 dilution of goat anti-mouse IgG secondary antibody conjugated to horseradish 
peroxidase in the appropriate wash buffer was added and incubated at 21°C.  The wells 
were washed three times, and a solution of tetramethylbenzidine dihydrochloride, 
prepared according to the manufacturer's instructions, was added to the wells. The 
chromogenic reactions were stopped with addition of 4 N H2SO4, and the well 
absorbances were read at 450 nm using a Molecular Devices Emax microplate reader. 
Statistical Analyses− Means, standard deviations (SD), standard error of the means 
(SEM), two-way ANOVA for column statistics, and nonlinear curve fits were calculated 
using GraphPad Prism 4 software.  
 
Results 
Design and Characterization of the α2β1-Specific Collagen-Related Peptide (α2-CRP). 
To examine the cooperation between thrombin receptors and the collagen 
receptor, α2β1 integrin, on platelets, we designed a CRP to which α2β1 specifically binds 
(α2-CRP) in order to isolate the integrin-collagen interaction (Figure 3-1A).  CRPs have 
been extensively characterized and are commonly used to analyze the platelet’s 
interaction with collagen (120).  Based on previous studies, we designed α2-CRP to 
contain a binding sequence for α2β1 (49,119).  α2-CRP was designed as a 42 amino acid 
peptide containing GPP repeats necessary for triple helix formation and the high affinity 
α2β1-specific binding sequence, GFOGER (O = 4-hydroxyproline).  GPVI binds 
specifically to the sequence –(GPO)n–, where n ≥ 2, and GPVI loses the ability to bind  
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FIGURE 3-1:  Characterization of collagen receptor-specific CRPs.  A, the amino acid 
sequence of the 42 mer CRP designed to bind specifically to α2β1 integrin (α2β1 binding motif is 
underlined).  B, platelet adhesion assay to BSA, CNI, or α2-CRP using isolated human platelets 
in the presence of 2 mM MgCl2 or 5 mM EDTA; on the right, representative microscopic images 
(40X) of adherent platelets from adhesion assay. C, platelet adhesion assay to BSA, CNI, or α2-
CRP using isolated human platelets with or without 10µg/mL inhibitory α2 integrin antibody 
(6F1). D, α2 integrin I-domain binding assay using BSA, CNI, or α2-CRP as substrates for the 
recombinant E318A α2 I-domain.  CNI, collagen I; BSA, bovine serum albumin; Mg2+, MgCl2.  
Results are percentages of adherent platelets or absorbances at 450 nm (mean ± SEM of 3 
independent experiments performed in triplicate). 
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when the hydroxyproline residues are changed to prolines (119).  We tested the ability of 
isolated human platelets to adhere in a Mg2+-dependent fashion to α2-CRP, collagen I, 
and BSA substrates (Figure 3-1B).  BSA was used as a negative control and showed no 
platelet adhesion.  In the presence of Mg2+, about 22% of the platelets adhered to 
collagen I, compared to 11% to α2-CRP.  In the presence of EDTA, platelets did not 
adhere to collagen I or α2-CRP.  Light microscopic analysis of platelets adherent to α2-
CRP and collagen I substrates showed platelets adhered evenly as a monolayer in the 
presence of Mg2+ (Figure 3-1B).  Platelet aggregates were not present. 
To further support the receptor specificity of the α2-CRP, we analyzed the effect 
of an inhibitory monoclonal antibody (6F1) directed against the α2β1 integrin (Figure 3-
1C).  In the presence of the inhibitory antibody, adhesion to collagen I and α2-CRP was 
largely attenuated.  We also determined α2β1 integrin binding specificity by using a 
purified activated-mutant α2 integrin inserted-domain (E318A α2 I-domain) (127).  
When Mg2+ was present, the E318A α2 I-domain bound to both collagen I and α2-CRP 
but not to BSA (Figure 3-1D).  No I-domain binding was detected when EDTA was 
present. 
 
Suboptimal PAR Stimulation. 
PAR1 and PAR4 activating peptides (PAR1-AP and PAR4-AP, respectively) 
have been well characterized and are important tools used to study the contributions of 
the two thrombin receptors (117,128).  The amino acid sequence for PAR1-AP is 
SFLLRN and for PAR4-AP is AYPGKF.  We utilized these specific PAR agonists in 
preliminary experiments to identify concentrations below, which they did not stimulate  
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FIGURE 3-2:  Analysis of suboptimal PAR activation.  Platelet aggregation assays were done 
using human PRP to determine suboptimal concentrations of PAR1-AP, PAR4-AP, and α-
thrombin.  Tested concentrations were: 20, 2.5, and 1 µM for PAR1-AP; 200, 100, and 50 µM for 
PAR4-AP; 10, 1, 0.1 nM α-thrombin.  Shown are representative data of three independent 
experiments.  
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platelet aggregation in PRP (Figure 3-2).  For PAR1-AP, 2.5µM initiated aggregation of 
about 15% but by 3 minutes the platelets had disaggregated and returned to baseline; 
1µM did not initiate aggregation but could stimulate platelet shape change.  For PAR4-
AP, 100 µM initiated aggregation of about 15% but by 3 minutes the platelets had 
disaggregated and returned to baseline; 50 µM did not initiate aggregation but could 
stimulate platelet shape change.  We therefore, considered concentrations ≤ 2.5 µM 
PAR1-AP and ≤ 100 µM PAR4-AP to be suboptimal.  In a similar manner, we 
determined suboptimal concentrations of α-thrombin to be ≤ 1nM.  We also determined 
suboptimal concentrations for ADP (≤ 500 nM) and a TXA2 analog, U46619 (≤ 250 nM) 
(data not shown).  To address variability between individual blood donors, we compared 
PRP from six healthy individuals for their ability to aggregate to 1 µM or 20 µM PAR1-
AP and to 50 µM or 200 µM PAR4-AP (Figure 3-3A).  For PAR1-AP, the suboptimal 
concentration (1 µM) induced a final mean platelet aggregation of 3.0% ± 3.7, and 20 µM 
produced a final mean aggregation of 81.5% ± 13.1.  For PAR4-AP, the suboptimal 
concentration (50 µM) had a final mean platelet aggregation of 1.2% ± 3.0, and 200 µM 
produced a final mean aggregation of 65.5% ± 33.2. 
 
Suboptimal PAR Activation Enhances Platelet Adhesion to α2-CRP. 
Knowing that the suboptimal PAR activation was producing platelet shape change 
but not aggregation, we analyzed whether this suboptimal stimulation could affect 
platelet adhesion through α2β1.  To address this, we pretreated isolated human platelets 
with 1 µM PAR1-AP or 50 µM PAR4-AP and allowed the platelets to adhere to α2-CRP  
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Figure 3-3:  Analysis of variability between blood donors.  A, platelet aggregation assays were 
done using human PRP from six healthy donors to determine the variance between the blood 
donors’ platelets by analyzing their ability to aggregate to suboptimal concentrations of PAR1-AP 
(1 µM) or PAR4-AP (50 µM) in comparison to optimal concentrations of PAR1-AP (20 µM) or 
PAR4-AP (200 µM).  Results are presented as the maximum final % aggregation after 8 minutes 
for each individual (n=6) with the bar representing the mean. B, human platelet adhesion assays 
were done using platelets isolated from the blood of the same six donors as above to determine 
the variability of enhanced platelet adhesion to α2-CRP induced by suboptimal activation of 
PAR1 or PAR4. This allowed us to correlate the enhancement of platelet adhesion with the 
absence of platelet aggregation during suboptimal activation of platelet PARs.  Platelets were 
treated with 1 µM PAR1-AP or 50 µM PAR4-AP in the presence of apyrase (1 U) + SQ29,548 (1 
µM) and allowed to adhere to α2-CRP.  Results are percentages of adherent platelets for each 
individual (n=6) with a connecting line between the two different treatments to illustrate the 
enhancement of platelet adhesion. 
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with or without apyrase and SQ29,548 to prevent platelet activation by secreted ADP and 
TXA2, respectively (Figure 3-4A).  In the presence and absence of the inhibitors, both 1 
µM PAR1-AP and 50 µM PAR4-AP increased platelet adhesion to α2-CRP above basal 
levels, though the presence of apyrase and SQ29,548 slightly decreased adhesion levels 
suggesting that some secondary platelet stimulation occurred. We therefore, used apyrase 
and SQ29,548 treatment in all the following assays unless otherwise specified.  The 
increases in platelet adhesion stimulated by PAR4-AP compared to basal levels were 
statistically significant (p < 0.001). To further address variability between individual 
blood donors, we analyzed the platelets’ ability to adhere to the α2-CRP in the presence 
or absence of suboptimal concentrations of the PAR-APs from the same six individuals 
we analyzed for variance in platelet aggregation (Figure 3-3B).  All of the individuals’ 
platelets showed an increase in adhesion to α2-CRP over basal levels when treated with 
1 µM PAR1-AP or 50 µM PAR4-AP, and PAR4 activity produced the greatest increase 
in adhesion in all donors. 
To show that the increase in platelet adhesion to the CRP substrate was not due to 
activation of αIIbβ3 integrin (αIIbβ3) and adhesion of platelet aggregates, we determined 
whether inhibiting αIIbβ3 by using a small peptide, RGDS, affected the enhanced platelet 
adhesion to α2-CRP stimulated by 1 µM PAR1-AP or 50 µM PAR4-AP (Figure 3-4B).  
The presence of RGDS did not affect the enhancement of platelet adhesion to α2-CRP 
stimulated by 1 µM PAR1-AP or 50 µM PAR4-AP.  The increases in platelet adhesion 
stimulated by PAR4-AP compared to basal levels were statistically significant (p < 0.05).  
This finding was consistent with our microscopic examination showing the absence of 
platelet aggregates (data not shown). 
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FIGURE 3-4: Suboptimal PAR activation enhances platelet adhesion to α2-CRP.  A, human 
platelet adhesion assays were done to analyze human platelet adhesion to BSA, CNI, or α2-CRP 
when platelets were treated with 1 µM PAR1-AP or 50 µM PAR4-AP with or without apyrase 
(1 U) + SQ29,548 (1 µM).  Results are percentages of adherent platelets (mean ± SEM of 4 
independent experiments performed in triplicate, *P < 0.001).  B, human platelet adhesion assays 
were done to analyze human platelet adhesion to α2-CRP when platelets in the presence of 
apyrase (1 U) + SQ29,548 (1 µM) were treated with 1 µM PAR1-AP or 50 µM PAR4-AP with or 
without 2 mM RGDS peptide. Results are percentages of adherent platelets (mean ± SEM of 2 
independent experiments done in triplicate, *P < 0.05).  C, dose-response curves for a range of 
PAR1-AP or PAR4-AP concentrations in relation to human platelet adhesion to α2-CRP in the 
presence of apyrase (1 U) + SQ29,548 (1 µM). Results are percentages of adherent platelets 
(mean of 4 independent experiments performed in triplicate).  D, time-courses for human platelet 
adhesion were done to analyze changes in human platelet adhesion to α2-CRP over time when 
platelets in the presence of apyrase (1 U) + SQ29,548 (1 µM) were treated with 1 µM PAR1-AP 
or 50 µM PAR4-AP.  Results are percentages of adherent platelets (mean of 5 independent 
experiments done in triplicate).  E, dose-response curve for a range of α-thrombin concentrations 
in relation to human platelet adhesion to α2-CRP in the presence of apyrase (1 U) + SQ29,548 
(1 µM).  Results are percentages of adherent platelets (mean ± SEM of 3 independent 
experiments each done in triplicate).  CNI, collagen I; BSA, bovine serum albumin; Apyr, 
Apyrase; SQ, SQ29,548. 
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We further analyzed the PAR-stimulated enhancement of platelet adhesion to α2-
CRP by dose-response and time-course analyses.  The dose-response curves for PAR1-
AP and PAR4-AP enhancement (Figure 3-4C) show that a range of suboptimal 
concentrations for both PAR1-AP and PAR4-AP can stimulate greater adhesion of 
platelets to α2-CRP.  Suboptimal stimulation of PAR4 produces a greater maximal 
enhancement than does PAR1.  PAR4-AP initiated enhancement of platelet adhesion at 
1 µM and had a maximum enhancement of 2.1 fold at 100 µM.  PAR1-AP started to 
show enhancement of platelet adhesion at 0.1 µM and had a maximum enhancement of 
1.7 fold at 5 µM.  This difference between PAR1 and PAR4 is also evident in the time-
course analysis (Figure 3-4D).  We examined adhesion of PAR1-AP (1 µM) or PAR4-AP 
(50 µM) treated platelets to α2-CRP over 60 minutes, and we observed that PAR4-AP 
treated platelets exhibited an increased rate of adhesion to α2-CRP compared to PAR1-
AP treated and untreated platelets.  PAR1-AP treatment had a minimal increase in rate of 
platelet adherence compared to the basal rate.  To link this PAR activity to their 
physiological activator, thrombin, we determined the dose-response curve for α-thrombin 
in relation to platelet adhesion to α2-CRP (Figure 3-4E). Previously, we determined 
suboptimal concentrations of α-thrombin to be ≤ 1 nM (Figure 3-2).  We then used a 
range of suboptimal concentrations of α-thrombin to treat platelets and analyze their 
adhesion to α2-CRP, and we show 0.1 and 1 nM α-thrombin can also stimulate 
enhancement of platelet adhesion to the CRP.  Interestingly, the enhancement decreased 
at the highest concentration (10 nM) of thrombin tested.   
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Enhanced Platelet Adhesion to α2-CRP is PLC-Dependent and also Induced by Other 
Platelet Gq-Linked GPCRs. 
 Since both PAR1 and PAR4 can link and signal through the G-protein Gq, we 
analyzed suboptimal PAR activation by determining if 1 µM PAR1-AP or 50 µM PAR4-
AP could stimulate intracellular Ca2+ mobilization (Figure 3-5A).  Both 1 µM PAR1-AP 
and 50 µM PAR4-AP stimulated intracellular Ca2+ mobilization with the PAR4 response 
being greater and longer in duration than PAR1.  1 µM PAR1-AP resulted in a limited 
extent of calcium mobilization compared to that produced by 20 µM PAR1-AP, whereas, 
50 µM PAR4-AP stimulated a calcium mobilization similar to that produced by 200 µM 
PAR4-AP in intensity but which was not sustained over time.  10 nM thrombin was used 
as a positive control. 
Since suboptimal activation of both PAR1 and PAR4 stimulated intracellular Ca2+ 
mobilization, we determined whether these GPCRs were producing the enhanced platelet 
adhesion via Gq and PLCβ2/β3 signaling pathway (Figure 3-5B).  Platelets treated with 
the solvent (DMSO) maintained enhanced adhesion when stimulated by 1 µM PAR1-AP 
or 50 µM PAR4-AP.  When platelets were treated with 10 µM U73122, a PLC inhibitor, 
the enhanced platelet adhesion stimulated by 1 µM PAR1-AP or 50 µM PAR4-AP was 
attenuated and decreased to basal levels.  When platelets were treated with 10 µM 
U73343, a U73122 negative control molecule (differs from U73122 by an absence of a 
double bond), the enhanced platelet adhesion stimulated by 1 µM PAR1-AP or 50 µM 
PAR4-AP remained intact.  We also determined if PI3K played a role in the enhanced 
platelet adhesion using the PI3K inhibitor, wortmannin.  When platelets were treated with  
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FIGURE 3-5: Enhanced platelet adhesion to α2-CRP is PLC-dependent and also enhanced 
by other platelet Gq-linked GPCRs.  A, human platelet intracellular Ca2+ mobilization assays 
were done to analyze changes in intracellular [Ca2+] of platelets loaded with FURA-2-AM and 
stimulated by 1 µM PAR1-AP or 50 µM PAR4-AP in comparison to optimal concentrations 
(20 µM PAR1-AP or 200 µM PAR4-AP), 10 nM thrombin, and no treatment (control).  Results 
are the ratio of measured absorbances 340 nm/380 nm (mean ± SEM of 3 independent 
experiments done in triplicate).  B, human platelet adhesion assays were done to analyze adhesion 
to α2-CRP when platelets in the presence of apyrase (1 U) + SQ29,548 (1 µM) with or without 
10 µM U73122, 10 µM U73343, or 1 µM wortmannin were treated with 1 µM PAR1-AP or 
50 µM PAR4-AP.  Results are percentages of adherent platelets (mean ± SEM of 5 independent 
experiments carried out in triplicate).  C, human platelet adhesion assays were done to analyze 
adhesion to α2-CRP when platelets in the absence of apyrase + SQ29548 and with or without 
10 µM U73122 were treated with 1 µM PAR1-AP, 50 µM PAR4-AP, 0.5 µM ADP, or 0.25 µM 
U46619.  Results are the mean percentages of adherent platelets (mean ± SEM of 4 independent 
experiments done in triplicate).  DMSO, dimethyl sulfoxide; Wort, wortmannin. 
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100 nM wortmannin the enhanced platelet adhesion stimulated by 1 µM PAR1-AP or 
50 µM PAR4-AP was not affected. 
The ADP receptor, P2Y1, and the TXA2 receptors, TPα and TPβ, are also platelet 
GPCRs that signal through Gq proteins.  To investigate their effects on platelet adhesion 
to α2-CRP, we employed an approach similar to that which we used to study the PAR 
receptors except apyrase and SQ29,548 were excluded from the adhesion assay.  We 
determined suboptimal concentrations of ADP and U46619 (a TXA2 analog) to be 
500 nM and 250 nM, respectively (data not shown).  Platelets in the absence of apyrase 
and SQ29,548 showed enhanced adhesion compared to basal when stimulated by 1 µM 
PAR1-AP, 50 µM PAR4-AP, 500 nM ADP, or 250 nM U46619 (Figure 3-5C).  When 
platelets were treated with 10 µM U73122 the enhanced platelet adhesion stimulated by 
1 µM PAR1-AP, 50 µM PAR4-AP, 500 nM ADP, or 250 nM U46619 was attenuated, 
but platelets still bound at basal levels. 
 
PAR4 Stimulated Enhanced Adhesion of Mouse Platelets. 
To further support a PAR-driven priming mechanism for enhanced α2β1 integrin-
mediated adhesion, we analyzed the adhesion of platelets from wild-type (α2+/+), α2β1-
deficient (α2-/-) and FcRγ-deficient (α2+/+ FcRγ-/-) mice on the pure C57Bl/6 background 
to collagen I and α2-CRP (Figure 3-6).  First, we determined adhesion levels to BSA, 
collagen I, or α2-CRP by wild-type, α2-deficient, or FcRγ-deficient mouse platelets 
(Figure 3-6A).  Both wild-type platelets and FcRγ-deficient platelets adhered to collagen 
I and α2-CRP, but platelet adhesion to the substrates was completely lost in α2-deficient 
platelets.  No platelet adhesion was seen on BSA substrates.  Next, we analyzed the effect  
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FIGURE 3-6: PAR4 stimulated enhanced adhesion of mouse platelets.  A, wild-type (α2+/+), 
α2-deficient (α2-/-), and FcRγ-deficient (α2+/+ FcRγ-/-) mouse platelets on a pure C57/BL6 
background were used in adhesion assays to analyze cell adhesion to BSA, CNI, or α2-CRP in 
the presence of apyrase (1 U) + SQ29,548 (1 µM).  B, wild-type (α2+/+), α2-deficient (α2-/-), 
and FcRγ-deficient (α2+/+ FcRγ-/-) mouse platelets were used in adhesion assays to analyze 
adhesion to α2-CRP when platelets in the presence of apyrase (1 U) + SQ29,548 (1 µM) were 
treated with 1 µM PAR1-AP or 50 µM PAR4-AP. 10 µM U73122 was used to inhibit PLC 
activity.  Results are the mean percentages of adherent platelets (mean ± SEM of 4 independent 
experiments done with duplicate measurements, *P < 0.01). 
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of suboptimal activation of PAR4 (mice do not express PAR1 on platelets) on wild-type, 
α2-deficient, or FcRγ-deficient mouse platelets on adhesion to α2-CRP (Figure 3-6B).  
Similar to human platelets, treatment of wild-type mouse platelets with 50µM PAR4-AP 
did not produce platelet aggregation and was determined to be suboptimal (data not 
shown).  Wild-type, α2-deficient, or FcRγ-deficient mouse platelets were treated with 
50 µM PAR4-AP, 1 µM PAR1-AP (negative control) or vehicle and adhesion to α2-CRP 
was measured.  Wild-type platelets showed a basal level of adhesion when treated with 
vehicle or 1 µM PAR1-AP, but when treated with 50 µM PAR4-AP, platelet adhesion 
substantially increased.  α2-deficient platelets exhibited no adhesion even when treated 
with 50 µM PAR4-AP.  FcRγ-deficient platelets showed adhesion similar to that of wild-
type platelets.  They adhered at a basal level when treated with vehicle, but with 50 µM 
PAR4-AP treatment, platelet adhesion increased markedly.  The PAR4-AP stimulated 
enhancement of wild-type and FcRγ-deficient platelets to α2-CRP was abolished by the 
PLC inhibitor, U73122 (Figure 3-6B).  These experiments were also carried out with 
wild-type (α2+/+), α2β1-deficient (α2-/-) and GPVI-deficient (α2+/+ GPVI-/-) mice on a 
mixed background (C57Bl/6 X 129/SvJ).  The results of these studies were entirely 
concordant with those presented above for mice on the pure C57Bl/6 background (data 
not shown).  
 
Discussion 
This study provides further insight into the mechanisms giving rise to stable 
adhesion of platelets to collagen at sites of vascular injury.  The data reveal cooperation 
between the platelet receptors for thrombin, ADP, and TXA2 with the collagen receptor, 
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α2β1 integrin.  Specifically, the results show that suboptimal stimulation of PAR4, and 
other platelet Gq-linked GPCRs (P2Y1, TPα/β, and to a lesser degree PAR1) can trigger a 
PLC-dependent priming mechanism of α2β1 integrin that enhances platelet adhesion to 
collagen.  This GPCR-mediated enhancement of platelet adhesion through the α2β1 
integrin suggests the presence of an additional, novel GPVI-independent mechanism to 
the multi-stage model of platelet adhesion to collagen at vascular injury sites.   
For this study, we utilized the α2-CRP as a platelet adhesion substrate that 
exclusively utilizes the α2β1 integrin-specific interaction (GFOGER) and mimics the 
triple-helical structure of collagens while eliminating the GPVI/FcRγ complex interaction 
and other indirect platelet-collagen interactions.  This separation of interactions was 
necessary because the individual roles of α2β1 integrin and GPVI/FcRγ complex during 
platelet collagen adhesion and their relevance in hemostasis have been debated intensely 
(83,121,129,130).  The GFOGER sequence is primarily found in collagens I, II, and IV, 
which are constituents of the vascular subendothelial extracellular matrix (120).  α2-CRP 
supported α2β1 integrin-specific binding with a metal ion-dependence consistent with 
previous studies utilizing similar CRPs (85,120,131).  Using the α2-CRP substrate, we 
demonstrated that suboptimal concentrations of PAR1-AP, PAR-4AP, α-thrombin, ADP, 
and U46619 enhanced platelet adhesion mediated by the α2β1 integrin.  Suboptimal PAR 
activation enhanced platelet adhesion independently of platelet secretion or αIIbβ3 
integrin activation.  The apparent activation of α2β1 integrin and not αIIbβ3 integrin was 
surprising and suggests there are different activation mechanisms or differences in the 
threshold for activation between these two platelet integrins.  
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Our observations and conclusions are entirely consistent with evidence presented 
by others.  Jung et al. showed enhanced binding of soluble collagen III by platelets 
stimulated with optimal concentrations of thrombin, ADP, and U46619 (46,132).  
Siljander et al. (131) showed enhanced platelet adhesion to CRPs containing various 
lower affinity GXXGER motifs upon stimulation with ADP.  Furthermore, Inoue et al. 
(85) showed ADP enhanced adhesion and spreading of FcRγ-deficient mouse platelets to 
a GFOGER containing CRP.  Our data indicate that this enhancing or priming effect on 
platelet adhesion to collagen may be mediated by several different platelet GPCRs and 
occurs without full activation of the GPCR.  The combined use of the CRP specific for 
the α2β1 integrin and of platelets deficient in GPVI/FcRγ expression has allowed us to 
demonstrate that the enhanced adhesion to collagen results from an effect on the α2β1 
integrin and that GPVI/FcRγ is not required, either directly or indirectly, for the adhesion 
enhancing effect. 
To understand how suboptimally activated PAR1 and PAR4 transmit signals to 
enhance α2β1 integrin-mediated platelet adhesion, we analyzed whether the signal 
transductions were through the Gq pathway of PLC activation shared by these GPCRs.  
Analysis of platelets treated with optimal PAR1-AP, PAR4-AP, and thrombin verified 
intracellular Ca2+ mobilization and showed the expected differences between the kinetics 
of PAR1 and PAR4, in agreement with previous studies (112,114).  A dramatic 
difference in intracellular Ca2+ mobilization was observed between suboptimal PAR1-AP 
and PAR4-AP; whereas 1 µM PAR1-AP produced weak calcium mobilization, 50 µM 
PAR4-AP resulted in a level of calcium mobilization similar to that produced by 200 µM 
of the activating peptide except the mobilization was not sustained.  The calcium 
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mobilization correlated with the levels of enhanced adhesion produced by each PAR and 
suggested that PLC was being activated to induce the enhancement. Inhibition of PLC 
with U73122 completely eliminated the PAR-enhanced adhesion, but left the basal level 
of adhesion unaltered.  In contrast, inhibition of PI3K had no effect on the enhancement 
of platelet adhesion.  This latter observation is in contrast with the report of Jung et al. 
who observed in their analysis of activated platelet binding of soluble collagen III a 
dependence upon PI3K (46).  This discrepancy may be due to fundamental differences 
between platelet adhesion to solid-phase substrates and the binding of soluble ligands as 
observed by our group and others (85).  These data support a GPCR-mediated α2β1 
integrin priming mechanism for platelet adhesion to collagen through PLC.  Other 
molecules involved in the priming mechanism remain to be determined.  Future studies 
might provide insight into whether the enhanced adhesion is due to a change in affinity or 
avidity of α2β1 integrin for collagen. 
Both PAR1 and PAR4 are able to stimulate enhanced platelet adhesion to α2-
CRP, but PAR4 is more effective.  This could be attributed to the different signaling 
kinetics of PAR1 and PAR4 as evident in the intracellular Ca2+ mobilization data and 
supported by previous studies (113,114).  Suboptimal concentrations of α-thrombin, the 
physiologic agonist of PAR1 and PAR4, also stimulated enhanced platelet adhesion to 
α2-CRP.  The level of enhanced adhesion observed with suboptimal thrombin 
stimulation resembles that observed with PAR4, suggesting further cooperation between 
PAR1 and PAR4 on human platelets.  Similar to PAR3 on mouse platelets, PAR1 may 
serve as a cofactor for PAR4 activation by thrombin as shown previously due to their 
ability to heterodimerize (77,78,133).  Interestingly, the thrombin dose response curves 
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show less enhancement of adhesion at the highest concentration tested (10 nM).  This 
could be due to PAR desensitization and internalization.  Alternatively or additionally, 
inhibition of thrombin by platelet secreted factors (antithrombin) may contribute (134).  
These data suggest that suboptimal activation of platelets by thrombin through 
PAR1 and PAR4 at vascular injury sites can prime platelets to adhere more avidly to 
collagens that contain the GFOGER binding sequence and in theory to other GXXGER 
sequences in collagens (121).  This mechanism is further supported by the recent findings 
regarding the role of thrombin in platelet adhesion to collagen under conditions of flow.  
Van der Meijden et al. (135) described separate but complimentary roles of thrombin 
produced subsequent to the contact activation of factor XII by collagen, and GPVI/FcRγ 
signaling on human platelet adhesion to collagen.  Furthermore, inhibition of thrombin 
resulted in diminished platelet adhesion to collagen.  Mangin et al. (136) reported that 
thrombin was able to compensate for the effect of GPVI/FcRγ deficiency in mouse 
platelets in in vivo models of thrombosis.  The mechanism we describe, selective 
enhancement of the adhesive activity of the α2β1 integrin via PAR4 activation, is the 
likely explanation for the observations of van der Meijden et al. (135) and Mangin et al. 
(136).  
Our group originally proposed a two-step, two-site model of platelet adhesion and 
activation to collagen in which the higher affinity collagen receptor, α2β1 integrin, binds 
first followed by the subsequent engagement of a lower affinity, signal-transducing co-
receptor (80) which was shown to be the GPVI/FcRγ complex (56,137).  There has been 
much debate regarding the roles of α2β1 integrin and GPVI/FcRγ complex in the two-
step, two-site model (7,82).  It has been suggested that engagement of GPVI may be 
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required for activation of the α2β1 integrin (7,82,129).  We have previously shown that 
platelets from α2β1-deficient mice have delayed thrombus formation in vivo within the 
carotid artery (71), and that under flow conditions in vitro, GPVI/FcRγ complex and α2β1 
integrin both play independent and vital roles in platelet adhesion and aggregation to 
collagen (138).  Data from the present study suggests that platelets exposed to low levels 
of thrombin, ADP, or TXA2 prior to contact with collagen at sites of vascular injury 
would have an increased affinity or avidity towards exposed α2β1 integrin binding sites 
on collagens as a result of inside-out activation of α2β1 integrin induced by GPCR signals 
through PLC to promote more stable adhesion.  This supports an alternate, GPVI/FcRγ-
independent pathway towards stable adhesion of platelets to collagen at sites of vascular 
injury.  Future studies under in vitro or in vivo flow conditions will be necessary to test 
this GPCR priming mechanism of α2β1 integrin.  A recent report (139) supports the 
concept.  In Summary, we have shown that suboptimal activation of the thrombin 
receptors and other Gq-linked GPCRs can enhance adhesion through α2β1 integrin to 
GFOGER sites of collagens via a PLC-dependent priming mechanism.  The data shed 
new light on the contributions that GPCRs and PLC signaling make toward platelet 
integrin-extracellular matrix interactions and could have implications in the design and 
application of novel therapeutic agents that target platelet GPCRs. 
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CHAPTER IV 
 
SUBOPTIMAL ACTIVATION OF PROTEASE-ACTIVATED RECEPTOR 4 
ENHANCES α2β1 INTEGRIN-MEDIATED PLATELET ADHESION TO 
COLLAGEN BY MODULATING INTEGRIN AVIDITY 
 
Adhesion of platelets to exposed collagens of the subendothelial matrix at sites of 
vascular injury is a vital step in hemostasis.  Under the shear conditions of arterial blood 
flow, platelets bind to fibrillar collagens through α2β1 integrin (α2β1) to induce stable 
adhesion.  Thrombin is activated at injury sites and can stimulate enhanced platelet 
adhesion to collagen through protease-activated receptor 1 and 4 (PAR1 and PAR4).  In 
this study, we analyzed how suboptimal activation of PAR4 (activity levels that do not 
cause platelet aggregation) produces enhanced platelet adhesion to collagen by binding 
through α2β1.  We utilized a specific PAR4 activating peptide (PAR4-AP; AYPGKF) and 
a platelet substrate, α2β1-specific collagen-related peptide (α2-CRP), that contains the 
high affinity α2β1 binding sequence, GFOGER.  We analyzed the enhanced platelet 
adhesion stimulated by suboptimal activation of PAR4 by PAR4-AP in the presence of 
Mn2+ (an inducer of the high affinity conformation of integrins) and observed an increase 
in platelet adhesion over the basal level.  The PAR4-induced enhanced adhesion is not 
caused by an increased sedimentation rate or interaction area of the platelet because no 
increase was seen on poly-lysine.  An increase in the number of α2β1 at the platelet 
surface was not observed with suboptimal PAR4 activation, however, an increase was 
seen with optimal activation of PARs.  We determined through competitive and 
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noncompetitive inhibition of α2β1 that the PAR4 enhanced adhesion is not due to an 
increase in affinity of α2β1 for α2-CRP.  PAR4-AP treated platelets bound to the same 
effective concentration of α2-CRP substrate.  Suboptimal PAR4-AP did not activate α2β1 
on human platelets but did cause α2β1 to transiently increase its association with the 
insoluble actin cytoskeleton.  These data suggest that suboptimal PAR4 activation 
produces an increase in platelet adhesion to collagen through actin cytoskeleton dynamics 
that modulate α2β1 avidity. 
 
Introduction 
 Platelets are small, anuclear cytoplasts that play a central role in arterial 
hemostasis.  Exposure of platelets to multiple pro-thrombotic factors occurs at vascular 
injury sites and triggers stable adhesion of platelets to the subendothelial extracellular 
matrix.  Thrombin and fibrillar collagens are potent stimuli of platelets at sites of blood 
vessel injury (110,111).  
 Thrombin is a protease in the coagulation cascade that can also stimulate cellular 
activities through protease-activated receptors (PARs).  The four PAR isoforms are G 
protein-coupled receptors (GPCRs) that are activated by enzymatic cleavage of the 
receptor amino-terminus to produce a tethered ligand (67).  Human platelets express 
PAR1 and PAR4, and both of these receptors link to and signal through Gαq to stimulate 
PLC activation (67).  In platelets, thrombin-induced signaling through PARs has been 
shown to activate and increase the affinity of αIIbβ3 integrin (αIIbβ3) for RGD-containing 
ligands that causes platelet aggregation (115,116).  This type of integrin activation by 
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thrombin has also been demostrated to occur for α2β1 and increase its affinity for 
collagen (140). 
Platelets express two receptors for collagens: the α2β1 integrin (α2β1) and 
glycoprotein VI (GPVI)/FcRγ chain complex (41,63).  α2β1 is important for stable 
platelet adhesion to collagen under shear stress at the injury site, and GPVI/FcRγ 
complex is required for platelet activation by collagen (65,71,73,118).  A useful tool in 
studying receptor-specific collagen interactions are collagen-related peptides (CRPs), 
short peptides that contain repetitive collagen-like sequences (GXX’) capable of forming 
triple helices similar to native collagens.  α2β1 has been shown to bind to the consensus 
sequence GXX’GER, and the sequence GFOGER is a high affinity binding site (120).  
We designed a 42 amino acid CRP (α2-CRP) that contains this high affinity binding 
motif for α2β1 within GPP repeats to specifically analyze the platelet α2β1-collagen 
interaction.  
 Integrins are heterodimeric (composed of α and β subunits) adhesion receptors on 
the surface of cells that can be subgrouped by ligand binding specificity, leukocyte 
expression, or the presence of an inserted-domain (I-domain) on some of the α subunits 
that serves as the ligand-binding site.  Platelets express five integrins that bind to various 
ligands: an I-domain containing integrin (α2β1) and four integrins that lack I-domains 
(αIIbβ3, αVβ3, α5β1, and α6β1) (107).  The activation of integrins through ligand binding 
or inside-out signaling changes their conformation from bent/inactive to extended/high 
ligand affinity states with intermediate affinity states detectable for some integrins 
(106,141-143).  There is also data supporting cells regulating integrin valency for their 
ligand through redistribution of integrins (clustering) on the cell surface (109,144-146).  
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For α2β1, the activation of the integrin by inside-out or outside-in signaling mechanisms 
has been shown to induce an intermediate and high affinity conformations that promote 
collagen binding (132,147), but there is also evidence for the redistribution of α2β1 on the 
plasma membrane in promoting collagen binding (148,149).  The level of involvement 
between modulation of integrin affinity and valency in cell adhesion still remains unclear, 
specifically in platelet adhesion to collagen. 
 Previously, we showed that suboptimal levels of thrombin (levels where αIIbβ3 
integrin is not activated) triggered PAR signaling that increased platelet adhesion to 
collagen through an α2β1-dependent priming mechanism (150).  In this study we wanted 
to characterize the integrin activation that suboptimal PAR4 stimulation caused to 
enhance α2β1-mediated platelet adhesion to collagen.  We hypothesized that the sub-
threshold PAR4 activity triggered a conformational change in α2β1, which increased the 
affinity for the collagen substrate.  However, we observed enhanced platelet adhesion to 
α2-CRP with suboptimal PAR4 activation when α2β1 was activated by Mn2+.  We 
determined that the affinity of α2β1 for α2-CRP was similar for platelets treated with or 
without 50 µM PAR4-AP.  The activated conformation of α2β1 was not stimulated by 
suboptimal activation of PAR4 as detected by HUTS-4 immunoprecipitation.  We also 
ruled out an increased level of α2β1 surface expression on platelets treated with 50 µM 
PAR4-AP.  We analyzed this PAR4-priming mechanism on other substrates (collagen I, 
poly-lysine, or laminin) and showed the specificity of the mechanism for α2β1 with a 
collagen substrate and revealed a role for GPVI/FcRγ in priming α2β1 and signaling 
crosstalk with PAR4.  Finally, we showed that suboptimal activation of PAR4 causes a 
temporary increase of α2β1 that is associated with the actin cytoskeleton of the platelet.  
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Taken together, the data supports an α2β1-specific priming mechanism triggered by 
suboptimal activation of PAR4 that modulates integrin avidity through interactions with 
the actin cytoskeleton that do not cause an increase in the affinity of α2β1 for collagen. 
 
Experimental Procedures 
Materials and Animals 
 Collagen I from rat-tail tendon was purchased from Upstate Cell Signaling 
Solutions.  The α2-CRP, GPK(GPP)5GFOGER(GPP)5GPK, was synthesized by Celtek 
Peptides.  Bovine serum albumin (BSA), Laminin, poly-lysine, MgCl2, MnCl2, PGE1, p-
nitrophenol-N-acetyl-β-D-glucosaminide, Apyrase, and other chemicals were purchased 
from Sigma Aldrich.  Activating peptides for PAR1 (PAR1-AP; SFLLRN) and PAR4 
(PAR4-AP; AYPGKF) were purchased from GL Biochem.  Human α-thrombin was 
purchased from Enzyme Research Labs.  SQ29,584 were purchased from Cayman 
Chemical.  Anti-human α2 integrin monoclonal antibody (6F1) was a generous gift from 
Dr. Barry S. Coller (The Rockefeller University).  Anti-human α2 integrin I-domain 
monoclonal antibody (12F1) labeled with PE, anti-α2 monoclonal antibody (clone 2), and 
anti-β1 integrin monoclonal antibody (clone 18) were purchased from BD Pharmingen. 
Anti-actin polyclonal antibody (C11) and anti-P-selectin antibody was purchased from 
Santa Cruz Biotechnology. Anti-activated β1 integrin antibody (HUTS-4) was purchased 
from Millipore.  Goat anti-mouse and Mouse anti-goat secondary antibodies conjugated 
to horseradish peroxidase and West-femto chemiluminescence substrate were purchased 
from Pierce.  Protein G agarose (PGA) beads were purchased from CalBiochem.  Hank’s 
Balanced Salt Solution lacking divalent cations (HBSS-) was purchased from Invitrogen. 
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 The α2 integrin subunit-deficient mice, originally generated on a C57Bl/6 X 
129/SvJ background were backcrossed 8 times to the C57Bl/6 background using a 
microsatellite marker-assisted selection (“speed congenics”), as previously described 
(69).  Knock-out mice for FcRγ on the C57Bl/6 background were purchased from 
Jackson Labs.  Animals were housed in pathogen-free conditions at Vanderbilt University 
Medical Center in compliance with IACUC regulations.  All animals were appropriately 
age and sex matched. 
Methods 
 Platelet Isolation− Washed platelets from human and mouse blood were prepared 
from blood obtained on the day of the experiment according to protocols described in 
chapter III.  
 Platelet Adhesion Assay− Adhesion assays were carried out using washed, isolated 
human platelets (1×108 platelets/mL) as done previously in chapter III.  When 
extracellular inhibitors (Apyrase, SQ29,548, mα2-CRP, or 6F1 antibody) were used, 
platelets were treated for 10 minutes at 21°C before agonist treatment.  When PAR4-AP 
was used, platelets were treated for 3 minutes at 21°C.  After treatments, platelets were 
allowed to adhere to the substrates (30 µg/mL unless otherwise denoted) for 60 minutes 
unless otherwise denoted at 37°C.  Each data point was performed in triplicate 
measurements. 
 FACS analysis− Washed platelets were resuspended at a concentration of 2 × 107 
platelets/mL in adhesion buffer (0.5 % BSA in HBSS-) containing 2 mM MgCl2.  
Platelets were treated with inhibitors 1 U/mL Apyrase and 1 µM SQ29,548 followed by 
PAR4-AP, PAR1-AP, or α-thrombin stimulation of platelets for 3 minutes at 21°C.  
62 
 
Aliquots of 50 µL of platelets were added to polystyrene analysis tubes (5 mL).  
Additions of 1-5 µg/mL of PE-labeled anti-α2 integrin antibody (12F1) or anti-P-selectin 
antibody were made to the platelets followed by an incubation for 30 minutes at 37°C.  A 
1:10 dilution of the platelets in the analysis tubes was made using adhesion buffer 
followed by analysis on the 3-laser BD LSRII.  Flow Cytometry experiments were 
performed in the VMC Flow Cytometry Shared Resource with help from David K. 
Flaherty and Brittany Matlock.  The VMC Flow Cytometry Shared Resource is supported 
by the Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive 
Disease Research Center (DK058404). 
 HUTS-4 Immunoprecipitation and analysis− Platelets were resuspended at a 
concentration of 5 × 108 platelets/mL in HBSS- containing 2 mM MgCl2 or 2 mM MnCl2.  
Platelets were treated with 1 U/mL Apyrase and 1 µM SQ29,548 fot 10 minutes at 21°C.  
Where indicated platelets were stimulated with 50 µM or 200 µM PAR4-AP for 
3 minutes at 21°C.  HUTS-4 (2.5 µg/mL) was added to platelets and incubated for 
30 minutes at 37°C.  Platelets were lysed using a 1:1 addition of ice-cold 2X RIPA lysis 
buffer (2% Triton X-100, 2% sodium deoxycholate, 2% sodium dodecyl sulfate, 0.15 M 
sodium chloride, 0.01 M sodium phosphate; pH 7.2).  Lysates were incubated at 4°C on 
rotor for 30 minutes.  PGA beads were added to lysates and incubated on rotor at 4°C for 
1.5 hours.  Beads were pellet by centrifugation at 1,000 rpm for 1 minute at 4°C and an 
aliquot of the platelet lysate was saved (output lysate).  Beads were washed 3 times in 1X 
RIPA lysis buffer by pelleting the beads and aspirating the supernatant.  SDS-PAGE 
sample buffer was added to the beads, which were then boiled for 10 minutes and run on 
a reducing 8% SDS-PAGE gel.  The proteins were transferred to a nitrocellulose 
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membrane followed by immunoblot analysis with anti-α2 integrin (1:2000), anti-β1 
integrin (1:2000), or anti-actin (1:2000) antibodies.  Appropriate secondary antibodies 
linked with horseradish peroxidase were used with a chemiluminescence substrate to 
image and quantitate the labeled protein bands using a BioRad ChemiDoc with Quantity 
One software. 
 Triton X-100 insoluble actin cytoskeleton precipitation− Platelets were resuspended 
at a concentration of 1 × 109 platelets/mL in HBSS- containing 2 mM MgCl2.  Platelets 
were treated with 1 U/mL Apyrase and 1 µM SQ29,548 fot 10 minutes at 21°C.  Next, 
platelets were left untreated or stimulated with 50 µM PAR4-AP for 0.5, 1, and 3 minute 
intervals at 21°C.  Platelets were lysed using a 1:1 addition of ice-cold 2X TX100 lysis 
buffer (2% Triton X-100, 0.15 M sodium chloride, 0.01 M sodium phosphate; pH 7.2).  
Lysates were incubated at 4°C on rotor for 15 minutes.  The TX100 insoluble actin 
cytoskeleton was pelleted by centrifugation at 14,000 rpm for 30 minutes at 4°C and an 
aliquot of the platelet lysate was saved (output lysate).  Pelleted actin cytoskeletons were 
washed once with 1X TX100 lysis buffer by pelleting and aspirating the supernatant.  
SDS-PAGE sample buffer was added to the pellets of actin cytoskeleton, which were 
then boiled for 10 minutes and run on a reducing 10% SDS-PAGE gel.  The proteins 
were transferred to a nitrocellulose membrane followed by immunoblot analysis with 
anti-α2 integrin (1:2000) or anti-actin (1:2000) antibodies.  Appropriate secondary 
antibodies linked with horseradish peroxidase were used with a chemiluminescence 
substrate to image and quantitate the labeled protein bands using a BioRad ChemiDoc 
with Quantity One software. 
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 Statistical Analyses− Means, standard deviations (SD), standard error of the means 
(SEM), one-way and two-way ANOVA for column statistics, linear and nonlinear curve 
fits, IC50 and EC50 values were calculated using GraphPad Prism 4 software.  
 
Results 
 We have previously shown that suboptimal activation of protease-activated 
receptors enhances human and mouse platelet adhesion to a collagen substrate through 
α2β1 integrin (150).  In this study, we wanted to determine the change that occurs at the 
level of the α2β1 (a change in integrin affinity and/or avidity) to produce the enhanced 
adhesion stimulated by PAR4 in human platelets.  We hypothesized that the PAR4-
stimulated enhanced platelet adhesion to collagen is produced by an affinity change of 
surface α2β1 for the collagen substrate. 
 
PAR4-Stimulated Enhanced Platelet Adhesion to α2-CRP in the Presence of Mg2+ or 
Mn2+. 
 To test whether or not suboptimal activation of PAR4 by 50 µM PAR4-AP 
stimulated an affinity change in α2β1 and caused the enhanced platelet adhesion to α2-
CRP, we analyzed the platelet adhesion in the presence Mn2+, an inducer of activated-
integrin conformations. The binding interaction between α2β1 and collagens, as well as 
α2-CRP, is metal ion-dependent, and Mg2+ is thought to be the metal ion involved in this 
interaction.  However, Mn2+ can replace Mg2+ in its function and, unlike Mg2+, induce a 
higher affinity conformation of the integrin.  We hypothesized that forcing α2β1 into a  
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FIGURE 4-1: PAR4-stimulated enhanced platelet adhesion to α2-CRP in the presence of 
Mg2+ or Mn2+.  Time-courses for human platelet adhesion were done to analyze changes in 
human platelet adhesion to α2-CRP over time when platelets in the presence of 2 mM MgCl2 
(Mg2+) or 2 mM MnCl2 (Mn2+) and apyrase (1 U/mL) + SQ29,548 (1 µM) were pretreated with or 
without 50 µM PAR4-AP.  Results are percentages of adherent platelets (mean of 4 independent 
experiments done in triplicate measurements). 
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high affinity conformation using Mn2+ would cause an increase in platelet adhesion equal 
to the level stimulated by 50 µM PAR4-AP/Mg2+ and render the PAR4 activity obsolete. 
 As we have shown previously, suboptimal activation of PAR4 by 50 µM PAR4-
AP stimulated enhanced platelet adhesion over time to α2-CRP in the presence of Mg2+ 
compared to Mg2+ alone (Figure 4-1).  Interestingly, Mn2+ increased platelet adhesion 
over the level achieved with Mg2+ but was not to the level of 50 µM PAR4-AP/Mg2+.  
Surprisingly, 50 µM PAR4-AP caused a similar enhancement of platelet adhesion as 
observed with Mg2+ but in the presence of Mn2+ where all α2β1 are in the high affinity 
state.  All adhesion assays were done in the presence of apyrase (1 U/mL) and SQ29,548 
(1 µM) to inhibit potential platelet activation by secreted ADP and TXA2.  This data 
suggested that the enhanced platelet adhesion to α2-CRP stimulated by suboptimal 
activation of PAR4 is not due to an affinity change in α2β1. 
 
Suboptimal PAR4 Activation Does Not Increase the Affinity of α2β1 for α2-CRP on 
Platelets. 
 To further support the evidence that suboptimal activation of PAR4 does not 
stimulate an increase in affinity of the α2β1 for α2-CRP in human platelets, we carried 
out a series of experiments.  First, we analyzed the ability of platelets pretreated with an 
inhibitory antibody (6F1; known to bind the I-domain of the α2 subunit and block the 
association of the integrin with collagen) to adhere to α2-CRP, and we hypothesized that 
more 6F1 would be required to inhibit adhesion of platelets treated with 50 µM PAR4-AP 
compared to untreated if the affinity of α2β1 was increased.  In these experiments, we 
observed the increased platelet adhesion over control stimulated by suboptimal PAR4-AP 
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(50 µM).  However, we observed similar 6F1 dose response curves for control and 
PAR4-AP treated platelets, which had IC50 values of 0.054 ± 0.01 µg/mL and 0.067 ± 
0.02 µg/mL, respectively (Figure 4-2A) suggesting that there is no increase in affinity of 
α2β1 for α2-CRP.  We calculated the IC50 values for each of the three independent 
experiments and determined that there was no significant difference between the mean 
IC50 values (P > 0.05) for control and PAR4-AP treated platelets (Figure 4-2A, inset). 
 We conducted further analyses to identify a change in the affinity of α2β1 for α2-
CRP upon stimulation of platelets with PAR4-AP by using soluble, monomeric α2-CRP 
(mα2-CRP) as a competitive inhibitor of platelet adhesion to the solid-phase α2-CRP 
(Figure 4-2B).  We hypothesized that if suboptimal PAR4 activation caused an increase 
in the affinity of α2β1 for α2-CRP, then PAR4-AP treated platelets would require less 
mα2-CRP to inhibit adhesion to the α2-CRP substrate.  Human platelets treated with 
50µM PAR4-AP showed enhanced adhesion to α2-CRP, but the adhesions were inhibited 
at similar concentrations of mα2-CRP (IC50 values for control = 17.41 ± 10.4 µg/mL and 
PAR4-AP = 26.44 ± 6.41 µg/mL).  Like before, we calculated the IC50 values for each of 
the three independent experiments and plotted this data to determine if there was any 
significant change between control and PAR4-AP treated platelets (Figure 4-2B, inset).  
This data showed there was no significant difference between the mean IC50 values (P > 
0.05). 
 Another approach we used to determine if PAR4 stimulates a change in affinity of 
α2β1 for α2-CRP was to analyze platelet adhesion to varying concentrations of the α2-
CRP substrate (Figure 4-2C).  Here we hypothesized if PAR4 altered α2β1 affinity, then 
platelets treated with 50 µM PAR4-AP would be able to adhere to a lower α2-CRP  
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FIGURE 4-2: Suboptimal PAR4 activation does not increase the affinity of α2β1 for α2-CRP 
on human platelets.  A, Dose-response curves of the α2β1 inhibitory antibody (6F1) on platelet 
adhesion to α2-CRP.  Control platelets or platelets pretreated with 50 µM PAR4-AP in a range of 
concentrations of 6F1 and in the presence of apyrase (1 U) + SQ29,548 (1 µM) were allowed to 
adhere to α2-CRP.  Results are percentages of adherent platelets (mean of 3 independent 
experiments performed in triplicate).  Inset, Pairwise analysis of the IC50 values obtained from the 
3 independent experiments.  B, Dose-response curves of inhibition by soluble monomeric α2-
CRP  (mα2-CRP) on platelet adhesion to α2-CRP.  Control platelets or platelets pretreated with 
50 µM PAR4-AP in a range of concentrations of mα2-CRP and in the presence of apyrase (1 U) 
+ SQ29,548 (1 µM) were allowed to adhere to α2-CRP.  Results are percentages of adherent 
platelets (mean of 3 independent experiments performed in triplicate).  Inset, Pairwise analysis of 
the IC50 values obtained from the 3 independent experiments.  C, Dose-response curves of platelet 
adhesion to a range of α2-CRP substrate coating concentrations.  Control platelets or platelets 
pretreated with 50 µM PAR4-AP in the presence of apyrase (1 U) + SQ29,548 (1 µM) were 
allowed to adhere to a range of α2-CRP substrate concentrations.  Results are percentages of 
adherent platelets (mean of 3 independent experiments performed in triplicate).  Inset, Pairwise 
analysis of the EC50 values obtained from the 3 independent experiments. 
69 
 
coating concentration when compared to untreated platelets.  Platelets treated with or 
without 50 µM PAR4-AP showed similar dose response curves measuring platelet 
adhesion to varying α2-CRP coating concentrations.  The mean EC50 values for control 
platelets adhering to α2-CRP was measured at 0.76 ± 0.44 µg/mL and at 0.61 ± 
0.39 µg/mL for PAR4-AP treated platelets.  We calculated the EC50 values for each of the 
three independent experiments and plotted this data to determine if there was any 
significant change between control and PAR4-AP treated platelets (Figure 4-2C, inset).  
This data showed no significant difference between the mean EC50 values (P > 0.05).  
Taken together, these data suggest the affinity of α2β1 for α2-CRP is not altered by 
suboptimal PAR4 activation. 
 
Suboptimal PAR4 Activation Does Not Induce the Activated Conformation of α2β1 on 
Platelets. 
 Inside-out signaling stimulated by GPCRs is known to regulate integrin 
conformation, so we determined whether or not suboptimal PAR4 activation induced the 
activated conformation of α2β1 on the surface of platelets.  To do this, we utilized a 
monoclonal antibody (HUTS-4) that recognizes an epitope exposed on the β1 subunit 
when β1 integrins are in activated conformations.  We analyzed HUTS-4 binding to 
activated α2β1 on the surface of human platelets that had been stimulated with 50 µM or 
200 µM PAR4-AP by immunoprecipitation and western blot analysis (Figure 4-3).  
Platelets in the presence of Mn2+ instead of Mg2+ were used as a positive control for α2β1 
activation and showed the greater presence of α2 and β1 in the immunoprecipitation (IP) 
compared to the other treatments (Figure 4-3A).  Suboptimal PAR4 activation (50 µM  
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FIGURE 4-3: Suboptimal PAR4 activation does not induce the activated conformation of 
α2β1 on platelets.  A, Western blot analysis of immunoprecipitates of activated β1-subunit using 
HUTS-4 antibody from control and PAR4 stimulated human platelets.  In the presence of 2 mM 
MgCl2, control platelets or platelets treated with 50 µM or 200 µM PAR4-AP for 3 minutes and 
lysed.  Platelets in the presence of 2 mM MnCl2 were also lysed and used as a positive control 
(Mn2+) for the activated conformation of β1.   Immunoprecipitation (IP) of activated β1 was done 
using 2.5 µg HUTS-4 and run on a gel with 1/20 volume of the IP output lysates, a whole cell 
platelet lysate as protein positive control (+).  The gel was then transferred to a membrane for 
immunoblot analysis using antibodies for α2 and β1 subunits and actin.  B, Quantification of α2 
or β1 bands from the IP lanes of 5 independent experiments by measuring the mean band 
intensities and normalizing them to actin. Results are the mean band intensity in arbitrary units 
(AU) (average of 4 independent experiments performed in triplicate). 
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PAR4-AP) had a similar amount of activated α2β1 as the untreated control, whereas 
200 µM PAR4-AP had a small increase of activated α2β1.  When the band intensities of 
α2 or β1 proteins were normalized to actin and quantitated, 50 µM or 200 µM PAR4-AP 
did not significantly increase the amount of activated α2β1 unlike the levels of activated 
α2β1 observed with Mn2+ (p < 0.001 for α2 and p < 0.05 for β1; Figure 4-3B).  This data 
shows that suboptimal PAR4 activation does not induce the activated conformation of 
α2β1 and further rejects an affinity change of α2β1 causing the enhanced adhesion. 
 
Suboptimal PAR4 Stimulation Does Not Increase Surface α2β1 on Platelets. 
 Another possible way PAR-activated platelets could increase their ability to 
adhere to α2-CRP is through modulating their avidity by increasing the surface 
expression of α2β1.  We tested this by analyzing the binding of a monoclonal antibody 
(12F1) to the α2 I-domain of PAR agonist treated platelets using fluorescence-activated 
cell sorting (FACS) analysis (Figure 4-4A).  With suboptimal concentrations of PAR4-
AP (50 µM), PAR1-AP (1 µM), and α-thrombin (1 nM) the levels of surface α2β1 
remained unchanged compared to untreated platelets.  Interestingly, with optimal 
concentrations of PAR1-AP (20 µM) and α-thrombin (10 nM) there was a statistically 
significant increase (23.9% and 21.4%, respectively) in surface α2β1 but not with 200 µM 
PAR4-AP.  This increase of surface α2β1 with optimal PAR activation correlated with α-
granule secretion by the platelets (Figure 4-4B).  We determined the surface expression 
of P-Selectin (a marker of α-granule secretion) on platelets under the same suboptimal 
and optimal treatments.  With suboptimal concentrations of PAR4-AP (50 µM) or PAR1- 
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FIGURE 4-4: Optimal but not suboptimal activation of PARs stimulated increased surface 
α2β1 or P-selectin on human platelets.  A, Flow cytometric analysis of control platelets or 
platelets treated for 5 minutes with 50 µM or 200 µM PAR4-AP, 1 µM or 20 µM PAR1-AP, or 
1 nM or 10 nM α-thrombin (αThr) and stained with the anti-α2 subunit monoclonal antibody 
(12F1) linked to phycoerythrin.  Results are the percentages of control of the mean fluorescence 
intensity (MFI) (average of 4 independent experiments).  B, Flow cytometric analysis of control 
platelets or platelets treated for 5 minutes with 50 µM or 200 µM PAR4-AP, 1 µM or 20 µM 
PAR1-AP, or 10 nM α-thrombin (αThr) and stained with the anti-P-selectin monoclonal antibody 
(CTB201) linked to phycoerythrin.  Results are the mean fluorescence intensities (MFI) (average 
of 6 independent experiments). 
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AP (1 µM), the presence of P-Selectin on the platelet surface was not detected.  However, 
with optimal concentrations of PAR4-AP (200 µM), PAR1-AP (20 µM), and α-thrombin 
(10 nM) there was a significant increase in surface P-Selectin evidence that α-granule 
secretion occurred.  This data suggests that an increase in surface α2β1 through secretion 
of α-granules is not the cause of enhanced platelet adhesion stimulated by suboptimal 
PAR4 activation. 
 
The PAR4-Stimulated Enhanced Platelet Adhesion is Integrin Mediated and Specific for 
Collagen Substrates. 
 Suboptimal PAR4 activation stimulates platelet shape changes, and the different 
platelet morphologies may cause the enhanced adhesion through an increased 
sedimentation rate and/or an increased surface area involved in the platelet/substrate 
interaction.  We tested this by measuring human platelet adhesion to other substrates 
(collagen I, poly-lysine, or laminin) when treated with or without 50 µM PAR4-AP 
(Figure 4-5A).  Platelets did not adhere to the negative control substrate (BSA).  On α2-
CRP, as seen before, we observed a basal level of platelet adhesion that was significantly 
increased with 50 µM PAR4-AP.  However, to poly-lysine (a nonspecific substrate) or 
laminin (an α6β1-specific substrate) platelets adhered but the adhesion was not increased 
above basal levels with 50 µM PAR4-AP treatment.  Platelet adhesion to collagen I (a 
substrate for α2β1 and GPVI/FcRγ) had the highest platelet adhesion, and interestingly, 
this level was slightly reduced with suboptimal PAR4 activation.  This PAR4-stimulated 
decrease was unexpected and suggested that the platelet interaction with collagen is more 
complex when GPVI/FcRγ is involved.   
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FIGURE 4-5: PAR4-stimulated enhanced adhesion is α2β1-mediated and specific for 
collagen substrates.  A, platelet adhesion assay to 30 µg/mL BSA, CNI, α2-CRP, poly-lysine (p-
Lys), or laminin (Lam) using isolated human platelets with or without pretreatment with 50 µM 
PAR4-AP.  Results are the mean percentages of adherent platelets (mean ± SEM of 4 independent 
experiments done with triplicate measurements).  B, wild-type (α2+/+), α2-deficient (α2-/-), and 
FcRγ-deficient (α2+/+ FcRγ-/-) mouse platelets were used in adhesion assays to analyze adhesion 
to collagen I when platelets in the presence of apyrase (1 U) + SQ29,548 (1 µM) were treated 
with 50 µM PAR4-AP.  U73122 (10 µM) was used to inhibit PLC activity.  Results are the mean 
percentages of adherent platelets (mean ± SEM of 4 independent experiments done with duplicate 
measurements). 
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 To address this new complexity that GPVI/FcRγ contributes to PAR4-stimulated 
platelet adhesion to collagen, we used collagen receptor knockout mice for α2β1 (α2-/-) or 
GPVI/FcRγ (α2+/+ FcRγ-/-)(Figure 4-5B).  We determined mouse platelet adhesion to 
collagen I with 50 µM PAR4-AP and observed a similar decrease in wildtype mouse 
platelet (α2+/+) adhesion that we saw with human platelets.  When α2β1 expression was 
lost, platelets did not adhere to collagen I under any of the treatments.  However, when 
expression of GPVI/FcRγ was lost (α2+/+ FcRγ-/-), we observed a statistically significant 
(p < 0.001) increase in platelet adhesion with suboptimal PAR4 activation, similar to that 
seen on α2-CRP.  When PLC was inhibited with U73122, platelet adhesion decreased 
beyond the basal levels seen in the controls.  Taken together, this data suggests 
suboptimal PAR4 activation stimulates an α2β1-specific priming mechanism that 
increases platelet adhesion to collagen, and when the GPVI/FcRγ interaction is involved 
the platelet adhesion phenotype has an added complexity. 
 
Suboptimal PAR4 Activation Causes a Temporary Increase of α2β1 Association with the 
Actin Cytoskeleton. 
 Integrins are receptors that link the actin cytoskeleton of a cell with the 
extracellular environment, and this association has been linked to focal adhesion 
formation and clustering.  We analyzed the amount of α2β1 that is linked to the actin 
cytoskeleton during suboptimal PAR4 activation by western blot analysis of precipitated 
Triton X-100 insoluble actin cytoskeletons (Figure 4-6).  With no PAR4-AP treatment we 
observed a small amount of α2β1 associated with the insoluble actin cytoskeleton.  After 
0.5 minutes, human platelets treatment with 50 µM PAR4-AP showed a slight increase in  
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FIGURE 4-6: Suboptimal PAR4 activation causes a temporary increase of α2β1 association 
with the actin cytoskeleton of human platelets.  Quantification of α2 subunit protein bands 
detected by western blot analysis of Triton X-100 insoluble precipitates from control and PAR4 
stimulated human platelets over time.  In the presence of 2 mM MgCl2, control platelets or 
platelets treated with 50 µM PAR4-AP for 0.5, 1, or 3 minutes were lysed with Triton X-100.  
The insoluble precipitates were pelleted, washed, and run on a gel.  The gel was transferred for 
immunoblot analysis using antibodies for the α2 subunit and actin.  Quantification of band 
intensities was done using the α2 proteins that precipitate with the actin cytoskeleton from 5 
independent experiments. Results are the fold change over control for the mean band intensities 
that are normalized to actin (average of 4 independent experiments performed in triplicate). 
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the amount of α2β1 associated with the actin cytoskeleton.  At 1 minute, the amount of 
α2β1 linked to the platelet cytoskeleton almost doubled, and by 3 minutes, the level had 
receded to almost basal levels.  This data suggests that the increased adhesion stimulated 
by suboptimal PAR4 activation occurs temporally through α2β1 association with the 
platelet actin cytoskeleton. 
 
Discussion 
 In this study we provide further insight into the platelet priming mechanism of 
α2β1 integrin for collagens that is initiated by suboptimal activation of PAR4 and 
increases adhesion of the platelets to collagen substrates.  Our data show: (i) the α2β1-
specifc priming mechanism stimulated by 50 µM PAR4-AP is maintained when α2β1 is 
activated by Mn2+; (ii) suboptimal activation of PAR4 does not increase the affinity of 
α2β1 for α2-CRP, induce the α2β1 activated conformation detected by HUTS-4, or 
increase α2β1 expression on the platelet surface; (iii) the PAR4-stimulated priming 
mechanism occurs on collagen I but not on poly-lysine or laminin; and (iv) suboptimal 
activation of PAR4 does transiently increase the amount of α2β1 associated with the 
platelet actin cytoskeleton.  Taken together, these results suggest that suboptimal PAR4 
activation causes a change in α2β1 avidity by increasing the association of α2β1 to the 
actin cytoskeleton of the platelet without changing the affinity of α2β1 for collagen.   
 The activation of integrins by extracellular stimuli (outside-in activation) has been 
shown to induce conformational changes in the integrins and cause a higher affinity state 
of the integrin for its ligand (106).  The modulation of integrin affinity and conformation 
is a dynamic equilibrium between the low-affinity integrin conformation (closed/bent), 
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intermediate affinity confromation(s), and the high-affinity integrin conformation 
(open/extended) (44,106).  The replacement of the physiological metal ion in the ligand 
binding domains of integrins (αIIbβ3 and αVβ3) with Mn2+ is known to activate and 
change the integrin conformation to the high affinity, open/extended conformer and Mn2+ 
is used as a positive control for integrin activation (141,142).  This effect of Mn2+ on 
integrins has also been demonstrated for α2β1 (132,151).  We used Mn2+ as a positive 
control for α2β1 activation in our analyses and show that Mn2+ can increase platelet 
adhesion to α2-CRP when compared to adhesion in the presence of the natural metal ion, 
Mg2+, as well as induce the activated conformation detected by HUTS-4.  Interestingly, 
the treatment of human platelets in Mn2+ with suboptimal concentrations of PAR4-AP 
(50 µM) produced an increase in platelet adhesion over the basal level (untreated platelets 
in Mn2+).  This increase is similar to what is seen in the presence of Mg2+ except both the 
basal and PAR4-AP levels in Mn2+ have an overall upwards shift in platelet adhesion 
produced by the activated α2β1.  This data suggested the enhanced α2β1-mediated platelet 
adhesion stimulated by suboptimal activation of PAR4 was not caused by an increase in 
affinity of α2β1 for α2-CRP. 
 We further ruled out an induced change in the affinity of α2β1 for α2-CRP 
stimulated by 50 µM PAR4-AP by using inhibitors for blocking the α2β1/collagen 
interaction.  Both a non-competitive inhibitor (6F1 antibody) and a competitive inhibitor 
(mα2-CRP) were able to inhibit platelet adhesion to the α2-CRP substrate for both 
untreated and 50 µM PAR4-AP treated platelets with similar IC50 values.  Similar results 
have been seen previously looking at inhibition with 6F1 or a GFOGER-containing CRP 
of unstimulated platelet adhesion to collagen (49).  If the 50 µM PAR4-AP treatment 
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caused an affinity change in α2β1, it would take more 6F1 antibody to inhibit the treated 
platelets than the control, but platelet adhesion for both was inhibited by similar amounts 
of antibody.  For the inhibitor mα2-CRP, if PAR4 stimulated an affinity change in α2β1, 
the treated platelets would be inhibited by a smaller concentration of mα2-CRP since 
they would have a higher affinity for the inhibitor as well; however, we observed 
inhibition by mα2-CRP at similar concentrations.   
 Another way we addressed the affinity of α2β1 was to compare adhesion of 
50 µM PAR4-AP treated platelets to controls on low substrate coating concentrations.  If 
the affinity of α2β1 increased with PAR4-AP treatment, then the treated platelets would 
be able to adhere to lower substrate coating concentrations of α2-CRP.  We did not 
observe this, and treated and control platelets adhered to the α2-CRP with similar EC50 
values.  These data, taken together, show that the suboptimal activation of PAR4 does not 
increase the affinity of α2β1 for the α2-CRP substrate on platelets to produce the 
enhanced cell adhesion. 
 Another tool used to determine the activation state of integrins are conformation-
sensitive antibodies that bind to epitopes exposed on integrins in a particular activation 
state (115,152,153).  We utilized the HUTS-4 antibody that binds to a site on the β1 
subunit exposed upon integrin activation to immunoprecipitate activated β1 integrins 
from PAR4-AP treated platelets and untreated controls.  PAR4-AP treatments did not 
induce the activated conformation of α2β1 beyond basal levels like the Mn2+ positive 
control did.  The implication that the enhanced α2β1-mediated platelet adhesion triggered 
by suboptimal PAR4 activation is not caused by an affinity change of the integrin 
correlates with the fact that αIIbβ3 is not being activated on these platelets.  It is 
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interesting that we did not see a significant amount of the activated α2β1 conformer with 
the optimal concentration of PAR4-AP (200 µM), because this concentration of PAR4-
AP does induce platelet α-granule secretion (P-selectin) as well as the activated 
conformation of αIIbβ3 on platelets as determined by PAC-1 binding (117).  This may be 
due to an inherent difference between mechanisms of activation for α2β1 and αIIbβ3 that 
will require further analysis. 
 Cells can modulate their adhesiveness to a substrate by varying the expression 
level of the receptor for that substrate.  The importance of the available level of surface 
receptors in adhesion is demonstrated for α2β1 in our inhibition data and has been shown 
previously with α2-deficient mouse platelets and induced expression of α2β1 on K562 
cells (69,154).  An increase in the surface expression of α2β1 on platelets stimulated by 
50 µM PAR4-AP would promote increased platelet adhesion to α2-CRP, but we do not 
detect more surface α2β1 with suboptimal treatments.  However, we show that full 
activation of the platelet PARs can stimulate platelets to move more α2β1 to their cell 
surface and this correlates with P-selectin mobilization to the surface through α-granule 
secretion.   The increase in surface α2β1 seems to be PAR1-mediated and is another 
means for platelets to adjust their avidity for a collagen substrate at a vascular injury site. 
 Another possible mechanism induced by suboptimal PAR4 activation to increase 
platelet adhesion could be a morphology change of the platelet that leads to an increase in 
the interacting surface area between the platelet membrane and substrate or to an increase 
in the rate of platelet sedimentation.  If a platelet morphology change was the cause, we 
would predict that other receptor-binding substrates (laminin and collagen I) as well as a 
non-specific/ionic substrate (poly-lysine) would adhere more platelets stimulated with 
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50 µM PAR4-AP.  We did not see an increase in platelet adhesion on laminin or poly-
lysine with suboptimal PAR4 activation suggesting that a platelet shape change was not 
the cause.  The lack of enhanced adhesion to laminin (an α6β1-specific substrate) also 
suggested the effect was α2β1-specific (155).  Interestingly, we observed with the 50 µM 
PAR4-AP treated human platelets a small but significant attenuation to the basal level of 
platelet adhesion on collagen I and not an increase like that seen on α2-CRP.    
 We wanted to analyze this difference between collagen I and α2-CRP further to 
see whether or not the involvement of GPVI/FcRγ in the collagen I interaction was 
causing the attenuation.  The use of α2-/- and FcRγ-/- mouse platelets elucidated that the 
difference was caused by the interaction of GPVI/FcRγ with collagen I.  Wild-type 
mouse platelets treated with 50 µM PAR4-AP showed a decrease in platelet adhesion 
similar to human platelets.  Mouse platelets that lacked α2β1 (α2-/-) completely lost the 
ability to adhere to collagen I supporting the fact that the interaction of GPVI/FcRγ with 
collagen I is dependent on α2β1 binding to collagen I.  When α2β1 is the only interacting 
receptor with collagen through loss of expression of GPVI/FcRγ (α2+/+ FcRγ-/-), the basal 
level of platelet adhesion to collagen I was decreased compared to wild-type, but with 
suboptimal PAR4 activation the level of platelet adhesion increased.  An important thing 
to note is this analysis was done under static adhesion conditions and not under flow.  
The static adhesion conditions can promote GPVI/FcRγ interactions with collagen that 
are not present under flow unless α2β1 has bound to collagen first (69).  The decrease in 
adhesion to collagen I observed between control and PAR4-AP treated wild-type platelets 
could be because the PAR4-AP treated platelets are primed before their interaction with 
collagen whereas the control platelets are in a resting/unactivated state, which could 
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cause the activating effect of GPVI/FcRγ ligation to be processed differently.  The lower 
level of basal platelet adhesion (control) seen with the FcRγ-deficient platelets compared 
to wild-type suggests that GPVI/FcRγ might be able to strengthen the interaction of α2β1 
with collagen similar to the PAR4-stimulated priming mechanism.  GPVI/FcRγ signaling 
through PLCγ2 could induce a change in α2β1 valency and promote α2β1 binding to lower 
affinity binding sites (GQRGER and GASGER) (27).  This supports the role of α2β1 in 
platelet adhesion to collagens under flow conditions where GPVI/FcRγ plays a supportive 
role in platelet adhesion but an essential role in platelet activation and thrombus 
development (73).  The role of GPVI/FcRγ in strengthening α2β1-mediated binding to 
collagen will require further examination. 
 Another surprising observation was the degree to which platelet adhesion was 
attenuated by inhibition of PLC activity (U73122).  One study showed that platelets 
adhering to a GFOGER-containing CRP could stimulate PLCγ2 activity and raise 
intracellular Ca2+ levels (85).  It is interesting to postulate that α2β1 can induce an 
increase in its own avidity to collagen through PLC signaling similar to Gαq-linked 
GPCRs (PAR4).  However, the level obtained with the activity stimulated by α2β1 is not 
maximal since PAR4 can induce a further increase in platelet adhesion to collagen.  This 
reduced effect could be caused by the variable type of Ca2+ mobilization stimulated by 
α2β1 or by the variety of α2β1 binding sites with different affinities (Gxx’GEx’) that 
collagen I contains (27,85).  These data suggest that suboptimal activation of PAR4 can 
cause enhanced platelet adhesion to collagen I through α2β1, but in the presence of 
multiple types of receptor interactions, the platelet adhesion to collagen I becomes more 
complex. 
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 The suboptimal activation of PAR4 induces a morphology change in platelets as 
shown previously (150).  Platelet shape change involves actin cytoskeleton dynamics, 
and a purpose integrins serve is to link a cell’s actin cytoskeleton with the extracellular 
environment (156).  The α2 subunit’s cytoplasmic tail has been shown to directly link to 
F-actin, and the β1 subunit is known to indirectly link to actin through talin (157,158).  
We show that platelets stimulated with 50 µM PAR4-AP have a transient increase in the 
amount of α2 subunits associated with the platelet’s Triton X-100 insoluble actin 
cytoskeleton with a maximum acheived 1 minute after stimulation.  This data suggests 
that the enhanced platelet adhesion induced by suboptimal PAR4 activation is a result of 
the modulation of α2β1 avidity through its dynamic linkage to the actin cytoskeleton of 
the platelet.  It is interesting to speculate that this avidity change is caused by a 
redistribution of surface α2β1 that increases the number of adhesive bonds at the 
interaction site with collagen (106). 
 Taken together, these data show that the priming mechanism of α2β1-mediated 
adhesion to collagen by suboptimal activation of PAR4 occurs through modulation of 
avidity through a transient association with the actin cytoskeleton that does not cause a 
change in affinity of α2β1.  The priming mechanism does not affect α6β1 and seems to be 
α2β1-specific.  It is possible that GPVI/FcRγ might regulate α2β1 avidity similar to PAR4. 
Further studies are necessary to determine the validity of these speculations, as well as to 
determine how the avidity of α2β1 is changing. 
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CHAPTER V 
 
IN VIVO AND IN VITRO ANALYSES OF GLYCOPROTEIN VI (GPVI)/ Fc 
RECEPTOR γ  CHAIN (FcRγ) COMPLEX ON PLATELETS IN HEMOSTASIS 
AND THROMBOSIS 
 
 Hemostasis is a vital process in mammals that maintains vascular integrity.  An 
important step in hemostasis and thrombosis is the interaction of platelets with exposed 
subendothelial fibrillar collagens at sites of vascular injury to induce adhesion, activation, 
and aggregation.  Two receptors on platelets allow for direct binding of collagens, α2β1 
integrin (α2β1) and Glycoprotein VI (GPVI)/Fc Receptor γ-chain (FcRγ) complex.  These 
receptors and their signaling mechanisms have been heavily studied, but there is still 
more to learn about how these receptors cooperate in the hemostatic function of platelets.  
This study examined the collagen receptors in platelet adhesion by utilizing two collagen-
related peptides: α2-CRP containing the α2β1-specific binding motif (GFOGER) and 
GPVI-CRP containing the GPVI/FcRγ-specific binding sequence (GPO)5.  We show that 
under static adhesion conditions GPVI/FcRγ can serve as an adhesion receptor but it is 
dependent upon platelet aggregation.  Activation of GPVI/FcRγ by convulxin can 
stimulate an increase in α2β1-dependent platelet adhesion.  In this study, we also 
conducted a comparative study of mice deficient in α2 subunit, GPVI, or FcRγ on pure 
(C57Bl/6J) or mixed (129×1/SvJ × C57Bl/6J) backgrounds using in vivo and in vitro 
assays to analyze platelet activation and thrombosis.  Our data support the importance of 
α2β1 under conditions where platelets experience shear stress.  Unexpectedly, FcRγ-
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deficient mice (FcRγ-/-) differed from GPVI-deficient mice (GPVI-/-) in vivo and in vitro.  
FcRγ-/- mice had carotid artery occlusion times similar to wild-type and fewer pulmonary 
emboli than GPVI-/-.  Scanning electron micrographs of GPVI-/- and FcRγ-/- platelets 
adhering to collagen substrates showed that there were not any morphology differences 
between genotypes.  We determined that the phospho-tyrosine protein profile of resting 
GPVI-/- and FcR-/- platelets is different and this difference needs further examination.  
This data supports α2β1 being the major collagen adhesive receptor on platelets under 
flow conditions where as GPVI/FcRγ is important in activating platelets to induce 
aggregation and support stable adhesion.  
 
Introduction 
 Hemostasis is a highly regulated balance of prothrombotic and antithombotic 
components that prevent blood loss from the vasculature while at the same time 
maintaining its fluidity.  The hemostatic balance found in mammals that maintain an 
intact blood circulation system within an organism involves multiple overlapping 
mechanisms.  Platelets play a central part in this balance especially during arterial 
hemostasis and pathological thrombosis and serve as nodes that weigh all the 
prothrombotic and antithrombotic stimuli that guage their response.  A potent 
prothrombotic stimulus that platelets are exposed to at vascular injury sites is 
subendothelial collagen.   
Platelets express two receptors for collagens: the α2β1 integrin (α2β1) which 
serves as the primary adhesion receptor for collagen and glycoprotein VI (GPVI)/FcRγ 
chain complex which acts as the major signaling receptor for collagen (41,63,65).  GPVI 
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is a single-span transmembrane protein and a member of the immunoglobulin 
superfamily (137).  FcRγ is also a single-span membrane protein that contains a 
cytoplasmic signaling domain called an immunoreceptor tyrosine-based activation motif 
(ITAM) and exists as a covalently linked (extracellular disulfide bond) homodimer at the 
plasma membrane of cells (47,159).  GPVI and FcRγ associate through a salt bridge 
between residues in the transmembrane domains, and this association is important to 
form the functional collagen signaling receptor (47,160).  GPVI/FcRγ complex is thought 
to be composed of two covalently linked FcRγ proteins in ionic association with two 
GPVI molecules.  This is supported by the facts that only the GPVI dimer shows a 
measurable affinity (KD = 0.5 µM) for fibrillar collagen whereas monomeric GPVI does 
not, and the crystal structure of the collagen binding domain of GPVI was arranged as a 
back-to-back dimer (47,58,59). 
Loss of GPVI/FcRγ complex on the surface of human platelets through mutations 
in the Gp6 gene or caused by anti-GPVI antibodys results in mild bleeding phenotypes in 
these patients (63,161-163).  Genetic deletion of either GPVI or FcRγ or antibody-
mediated depletion of GPVI from mouse platelets causes loss of platelet activation 
stimulated by collagen as well as attenuated thrombus formation under flow conditions in 
vivo and in vitro (73,74,118,164,165).  The loss of the ability of GPVI and FcRγ to 
associate through the salt bridge interaction causes the receptor to become nonfunctional, 
and even receptor density has a part in its ability to function as a collagen receptor 
(160,166).  In this study we utilize the GPVI-deficient (GPVI-/-) and FcRγ-deficient 
(FcRγ-/-) mice in comparison to α2β1-deficient (α2-/-) mice in in vivo and in vitro 
analyses. 
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GPVI/FcRγ utilizes the ITAM motif to conduct the majority of its signal 
transduction.  Binding of collagen, CRP, or convulxin (a C-type lectin from the venom of 
Crotalus durissus terrificus) activates GPVI/FcRγ through clustering of the receptors, 
which causes the tyrosine phosphorylation of the ITAM motif by association and 
activation of the Src family tyrosin kinases Fyn and Lyn (61,107).  The phosphorylation 
of the ITAM domain causes the association of another tyrosine kinase Syk which iduces 
the activation of downstream effectors like PLCγ2, PI3K, and small GTPases that all 
contribute to platelet activation and aggregation (107).   
Receptor-specific collagen-related peptides (CRPs), short peptides that contain 
repetitive collagen-like sequences (GXX’) capable of forming triple helices similar to 
native collagens, are useful tools.  GPVI/FcRγ has been shown to bind to the amino acid 
sequence (GPO)n where n ≥ 2, and chemical crosslinking of CRPs containing these 
motifs bestows the ability to activate platelets (119,120).  We designed a 42 amino acid 
CRP (GPVI-CRP) that contains the GPVI binding motif found in collagen I (GPO)5 
within GXX’ repeats to specifically analyze the interaction of platelets with collagen 
through GPVI/FcRγ.  
In this study, we wanted to further analyze the role of GPVI/FcRγ on platelets 
during hemostasis and thrombosis.  We utilized a GPVI-specific CRP (GPVI-CRP) and 
collagen receptor deficient mice in in vivo and in vitro assays to elucidate the functions of 
GPVI/FcRγ on platelets.  We show data that further support the role of GPVI/FcRγ on 
platelets as a signaling receptor important in platelet activation. We also shed some new 
insight into the effect of convulxin on platelet adhesion to collagen, as well as identify a 
difference between GPVI-/- and FcRγ-/- platelets. 
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Experimental Procedures 
Materials and Animals 
 Collagen I from rat-tail tendon was purchased from Upstate Cell Signaling 
Solutions.  The α2-CRP, GPK(GPP)5GFOGER(GPP)5GPK, and the GPVI-CRP, 
GPK(GPO)5GFOGDR(GPP)5GPK were synthesized by Celtek Peptides. U73122, 
U73343, and RGDS peptide were purchased from Calbiochem.  Convulxin was 
purchased from Enzo Life Sciences.  Bovine serum albumin (BSA), DMSO, 
glutarahldehyde, EDTA, MgCl2, PGE1, p-nitrophenol-N-acetyl-β-D-glucosaminide, 
Apyrase, and other chemicals were purchased from Sigma Aldrich.  The activating 
peptide for PAR4 (PAR4-AP; AYPGKF) was purchased from GL Biochem.  SQ29,584 
were purchased from Cayman Chemical.  Anti-human α2 integrin monoclonal antibody 
(6F1) was a generous gift from Dr. Barry S. Coller (The Rockefeller University).  Anti-
phosphotyrosine monoclonal antibody (p-Tyr-100) was purchased from Cell Signaling 
Technology.  Anti-actin polyclonal antibody (C11) was purchased from Santa Cruz 
Biotechnology. Goat anti-mouse and Mouse anti-goat secondary antibodies conjugated to 
horseradish peroxidase and West-femto chemiluminescence substrate were purchased 
from Pierce.  Hank’s Balanced Salt Solution lacking divalent cations (HBSS-) was 
purchased from Invitrogen. 
The α2 integrin subunit-deficient mice, originally generated on a C57Bl/6 X 
129/SvJ background were used as well as mice backcrossed 8 times to the C57Bl/6 
background using a microsatellite marker-assisted selection (“speed congenics”), as 
previously described (69).  Knock-out mice for FcRγ on the C57Bl/6 and C57Bl/6 X 
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129/SvJ background were purchased from Jackson Labs.  GPVI deficient mice on a 
C57Bl/6 X 129/SvJ background were a kind gift from Dr. Thomas J. Kunicki (Scripps 
Research Institute). GPVI deficient mice were backcrossed 8 times to the C57Bl/6 
background using a microsatellite marker-assisted selection (“speed congenics”), as 
previously described.  Animals were housed in pathogen-free conditions at Vanderbilt 
University Medical Center in compliance with IACUC regulations.  All animals were 
appropriately age and sex matched. 
Methods 
 Platelet Isolation− PRP or washed platelets from human and mouse blood were 
prepared from blood obtained on the day of the experiment according to protocols 
described in chapter III.  
 Platelet Adhesion Assay− Adhesion assays were carried out using washed, isolated 
human platelets (1×108 platelets/mL) as done previously in chapter III.  When 
extracellular inhibitors (Apyrase, SQ29,548, RGDS, U73122, U73343, or 6F1 antibody) 
were used, platelets were treated for 10 minutes at 21°C before agonist treatment.  When 
PAR4-AP was used, platelets were treated for 3 minutes at 21°C.  After treatments, 
platelets were allowed to adhere to the substrates (30 µg/mL unless otherwise denoted) 
for 60 minutes unless otherwise denoted at 37°C.  Each data point was performed in 
triplicate measurements. 
Platelet Aggregation− Aggregation assays using PRP were performed on a 
BIO/DATA Corporation PAP-4 aggregometer at 37°C with stirring (1200 rpm) as 
described (69).  Agonists were added at designated final concentrations. 
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Cloning, expression and purification of α2 Integrin I Domains− The cloning and 
expression of the α2 integrin I domain was similar to our previously described methods 
(124) and as detailed in chapter III.  
α2 I-domain Binding− Recombinant α2 I-domain binding was determined by a solid-
phase binding assay as previously described (126) and as described in chapter III.  
Purified recombinant α2 E318A I-domain was used at 100 nM. 
 In vivo photochemical injury of the carotid artery of mice− Carotid artery thrombosis 
was induced as described previously (71).  Briefly, male mice approximately 12 weeks of 
age were anesthetized with an intraperitoneal injection of sodium pentobarbital, secured 
in the supine position, and placed under a dissecting microscope. The right common 
carotid artery was isolated through a midline cervical incision, and an ultrasonic flow 
probe (Model 0.5 VB; Transonic Systems) was applied.  A 1.5-mW, 540-nm laser beam 
(Melles Griot) was applied to the artery from a distance of 6 cm.  Rose bengal dye (Fisher 
Scientific), 50 mg/kg body weight, was then injected into the tail vein, and flow in the 
vessel was monitored until complete occlusion occurred. 
 In vivo collagen-induced pulmonary thromboembolism in mice− Collagen-induced 
thrombosis was carried out as previously described (71).  Wild-type, α2β1 integrin-
deficient, and FcRγ-deficient female mice were anesthetized by intraperitoneal injection 
of 100 to 150 µL of a mixture of ketamine and xylazine.  Blood was collected into 
EDTA-coated microtainer tubes for determination of the baseline platelet count and 
hematocrit.  25 µg of collagen (equine tendon type I fibrillar collagen) along with 1 µg 
epinephrine (Sigma) in phosphate-buffered saline (PBS), or PBS alone, were injected into 
the right jugular vein; 1 minute after injection a second blood sample was taken and cell 
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counts were measured.  Mice were humanely killed 3 minutes after injection and lungs 
were collected and placed in formalin.  Quantitation of pulmonary thrombosis was done 
on lung sections stained with hematoxylin and eosin were digitally imaged using an 
Olympus Camedia C-3040 Zoom camera.  Five random x 20 fields were photographed 
for each specimen. Analysis of thrombus number for each mouse was made using 
Olympus Camedia Master 2.5 software, and then expressed as thrombi per square 
millimeter ± SEM. 
 Scanning electron microscopy− Platelet adhesion assays were done similar to those 
described in chaprter II with some minor changes.  Platelets at a concentration of 2 × 107 
platelets/mL were adhered substrates (30 µg/mL) bound to round glass coverslips 
(Electron Microscopy Sciences; 22 mm diameter) for 1 hour at 37°C.  Coverslips were 
washed 3 times with adhesion buffer.  Platelets adhered to the coverslips were fixed using 
2% glutaraldehyde for 30 minutes at 21°C and then washed 3 times with 0.1 M sodium 
cacodylate buffer and further processing (fixation, drying, and sputter coating) were 
performed in part through the use of the VUMC Cell Imaging Shared Resource and the 
EM Core.  Imaging was done using a Hitachi S-4200 Scanning Electron Microscope. 
 Mouse platelet phosphotyrosine analysis− Mouse platelets were resuspended at a 
concentration of 5 × 108 platelets/mL in HBSS- containing 2 mM MgCl2.  Platelets were 
left untreated or stimulated with 10 µg/mL collagen I, 10 µg/mL α2-CRP, or 200 µM 
PAR4-AP for 1 minute at 21°C after which an excess of ice-cold HBSS- was added to 
stop the interaction.  Platelets were pelleted at 4,000 rpm for 4 minutes at 4°C and the 
supernatant was aspirated off.  Platelets were lysed using SDS-PAGE sample buffer 
containing protease and phosphatase inhibitors, which were then boiled for 10 minutes 
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and run on a reducing 10% SDS-PAGE gel.  The proteins were transferred to a 
nitrocellulose membrane followed by immunoblot analysis with anti-phosphotyrosine 
(1:2000) or anti-actin (1:2000) antibodies.  Appropriate secondary antibodies linked with 
horseradish peroxidase were used with a chemiluminescence substrate to image the 
labeled protein bands using a BioRad ChemiDoc with Quantity One software.  
 Statistical Analyses− Means, standard deviations (SD), standard error of the means 
(SEM), one-way and two-way ANOVA for column statistics, and nonlinear curve fits 
were calculated using GraphPad Prism 4 software.  
 
Results 
Design and Characterization of GPVI/FcRγ-Specific Collagen-Related Peptide (GPVI-
CRP). 
 Similar to α2-CRP, we designed a GPVI/FcRγ-specific CRP (GPVI-CRP) that 
replaced one of the series of five GPP repeats with a series of five GPO repeats for 
GPVI/FcRγ binding and changed the amino acid E to D to eliminate α2β1 binding (Figure 
5-1A).  We examined human platelet adhesion under static conditions to a range of 
coating concentrations of GPVI-CRP in comparison to α2-CRP and observed that an 
optimal coating concentration for both CRPs is 30 µg/mL (Figure 5-1B).  To ensure α2β1 
was not involved in the platelet adhesion to GPVI-CRP, we analyzed platelet adhesion to 
these substrates in the presence of an α2β1-specific inhibitory antibody (6F1).  We 
observed a loss of platelet adhesion in the presence of 6F1 to collagen I and α2-CRP, but 
platelet adhesion to GPVI-CRP was not affected by 6F1 (Figure 5-1C).  This data was 
supported by the observation that the recombinant activated-mutant (E318A) α2 I- 
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FIGURE 5-1: Design and characterization of GPVI/FcRγ-specific collagen-related peptide 
(GPVI-CRP). A, the amino acid sequences of the 42 mer CRPs designed to bind specifically to 
either GPVI/FcRγ (GPVI-CRP; GPVI binding motif is underlined) or α2β1 integrin (α2-CRP; 
α2β1 binding motif is underlined).  B, Dose-response curves of platelet adhesion to a range of 
substrate coating concentrations for GPVI-CRP or α2-CRP.  Results are percentages of adherent 
platelets (mean of 3 independent experiments performed in triplicate).  C, platelet adhesion assay 
to BSA, CNI, α2-CRP, or GPVI-CRP using isolated human platelets in the presence of 2 mM 
MgCl2 with or without 10µg/mL inhibitory α2 integrin antibody (6F1).  Results are percentages 
of adherent platelets (mean of 6 independent experiments performed in triplicate).  D, α2 integrin 
I-domain binding assay using BSA, CNI, α2-CRP, or GPVI-CRP as substrates for the 
recombinant activated mutant (E318A) α2 I-domain in 2 mM MgCl2.  Results are absorbances at 
450 nm (mean of 3 independent experiments performed in triplicate).  E, Platelet aggregation 
assays were done using human PRP to determine concentrations of GPVI-xCRP and α2-xCRP.  
Shown are representative data of three independent experiments. CNI, collagen I; BSA, bovine 
serum albumin. 
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domain did not bind to GPVI-CRP but did bind to collagen I and α2-CRP (Figure 5-1D).  
CRPs that contain GPVI/FcRγ recognition motifs have been shown to require chemical 
cross-linking into polymeric complexes to stimulate GPVI/FcRγ-specific platelet 
activation (120).  We chemically cross-linked GPVI-CRP (GPVI-xCRP) or α2-CRP (α2-
xCRP) and tested their abilities to stimulate platelet aggregation (Figure 5-1E).  GPVI-
xCRP was able to induce dose-dependent platelet aggregation similar to collagen I, 
whereas a very high concentration of α2-xCRP did not.  Taken together, this data shows 
that the GPVI-CRP functions as a GPVI/FcRγ-specific ligand that mimics the receptor’s 
interaction with collagen I. 
 
GPVI-Mediated Platelet Adhesion Under Static Conditions is Dependent on Aggregation. 
 We further investigated platelet adhesion through GPVI/FcRγ because we were 
surprised to see platelet adhesion to GPVI-CRP when there was no platelet adhesion seen 
on collagen I when the α2β1 interaction was blocked (6F1; Figure 5-1C).  We also 
noticed that adhesion of platelets to GPVI-CRP under static conditions could be highly 
variable.  We analyzed platelet adhesion to these collagen substrates as well as to a 1:1 
mixture of α2-CRP and GPVI-CRP in the presence of 2 mM MgCl2 or 5 mM EDTA 
(Figure 5-2A).  All substrates showed platelets adhering in the presence of Mg2+ with 
collagen I and the 1:1 CRP mix having the highest levels of adhesion.  When platelet 
adhesion was observed microscopically, we saw individual platelets adhering and 
spreading on collagen I with some aggregation, and the platelets adhered to the 1:1 CRP 
mix closely resembled those on collagen I.  On α2-CRP, we saw individual platelets  
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FIGURE 5-2: GPVI-mediated platelet adhesion under static conditions is dependent on 
aggregation.  A, Platelet adhesion assay to BSA, CNI, α2-CRP, GPVI-CRP, or a 1:1 mix of α2- 
and GPVI-CRP using isolated human platelets in the presence of 2 mM MgCl2 or 5 mM EDTA; 
on the right, representative microscopic images (40X) of adherent platelets from the adhesion 
assay.  Results are percentages of adherent platelets (mean of 5 independent experiments 
performed in triplicate).    B, Platelet adhesion assay to BSA, CNI, α2-CRP, GPVI-CRP, or a 1:1 
mix of α2- and GPVI-CRP using isolated human platelets with or without 1 µM RGDS to inhibit 
αIIbβ3 integrin.  Results are percentages of adherent platelets (mean of 3 independent experiments 
performed in triplicate).    C, Platelet adhesion assay to GPVI-CRP using isolated human platelets 
treated with DMSO, 10 µM U73122 (PLC inhibitor), or 10 µM U73343 (negative control). 
Results are percentages of adherent platelets (mean of 5 independent experiments performed in 
triplicate). 
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adhering with less spreading and no aggregation.  On GPVI-CRP, most of the platelet 
adhesion observed was platelet aggregates, but we did see a few individual spread 
platelets adhering.  This was further supported by SEM analysis of adherent mouse 
platelets (Figure 5-6).  In the presence of EDTA, adhesion was lost on collagen I, α2-
CRP, and the 1:1 CRP mix, and adhesion on the GPVI-CRP was significantly attenuated. 
 We wanted to determine what role αIIbβ3 was playing in platelet adhesion to 
GPVI-CRP since chelation of metal ions with EDTA had an effect on adhesion to GPVI-
CRP as well as the presence of platelet aggregates on GPVI-CRP.  We analyzed platelet 
adhesion to these same substrates in the presence or absence of 1 mM RGDS (a peptide 
that binds to αIIbβ3 and inhibits platelet aggregation)(Figure 5-2B).  In the presence of 
RGDS, a small decrease was seen on collagen I and no decrease was seen on α2-CRP.  
However, a significant decrease in platelet adhesion was seen on the 1:1 CRP mix, and a 
loss of platelet adhesion was seen on GPVI-CRP.  This data suggested that platelet 
adhesion to GPVI-CRP under static conditions was dependent on platelets forming 
aggregates through inside-out activation of αIIbβ3.  This was further supported by 
analyzing platelet adhesion to GPVI-CRP during inhibition of PLC, an important 
downstream signaling molecule in the GPVI/FcRγ pathway (Figure 5-2C).  Platelets were 
pretreated with the PLC inhibitor (U73122), the negative control molecule (U73343), or 
DMSO and allowed to adhere to GPVI-CRP.  Almost a complete loss of platelet adhesion 
was seen when PLC was inhibited by U73122 compared to the other controls.  This data 
supports the fact that GPVI/FcRγ does not serve as an adhesion receptor but does support 
its role in platelet activation and aggregation. 
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Convulxin Stimulates Enhanced Platelet Adhesion to α2-CRP. 
 The ability of GPCRs to prime α2β1 through a PLC-dependent mechanism and 
increase platelet adhesion to collagen suggested to us that the activation of GPVI/FcRγ 
might be capable of stimulating a similar effect.  Snake venoms contain toxins that affect 
platelet activities; convulxin (Cvx) is a C-type lectin from venom that binds to and 
activates GPVI/FcRγ (167).  We hypothesized that activation of GPVI/FcRγ prior to 
contacting collagen could enhance platelet adhesion to collagen by priming α2β1.  First, 
we determined what concentrations of Cvx stimulated human platelet aggregation and 
found 0.1 and 0.5 nM Cvx to be suboptimal and 1 and 10 nM Cvx to be optimal 
concentrations (Figure 5-3A).  Using this range of Cvx concentrations, we tested this 
hypothesis by pretreating platelets with the different Cvx concentrations in the presence 
or absence of 1 mM RGDS and measured platelet adhesion to α2-CRP (Figure 5-3B).  
We observed an increase in platelet adhesion that was independent of platelet aggregation 
and was largest at 10 nM Cvx.  We next compared the GPVI/FcRγ-stimulated enhanced 
adhesion to what we see with suboptimal PAR4 activation (Figure 5-3C).  With 5 nM 
Cvx, we saw a significant increase in platelet adhesion over basal.  This platelet adhesion 
was similar in level to the increase stimulated by 50 µM PAR4-AP and independent of 
platelet aggregation as shown in the platelet images.  This data suggests that optimal 
activation of GPVI/FcRγ by Cvx can prime the platelet for α2β1-mediated adhesion to 
collagen. 
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FIGURE 5-3: Convulxin (Cvx) stimulates enhanced platelet adhesion to α2-CRP.  A, Platelet 
aggregation assays were done using human PRP to determine effective concentrations of 
convulxin (Cvx).  Shown are representative data of three independent experiments.  B, Dose-
response curve for a range of Cvx concentrations in relation to human platelet adhesion to α2-
CRP (30 µg/mL) in the presence of apyrase (1 U/mL) + SQ29,548 (1 µM) with or without 1 µM 
RGDS.  Results are percentages of adherent platelets (mean ± SEM of 3 independent experiments 
each done in triplicate).  C, Platelet adhesion assay to α2-CRP using isolated human platelets in 
the presence of 2 mM MgCl2, apyrase (1 U/mL), and SQ29,548 (1 µM) and treated with 5 nM 
Cvx or 50 µM PAR4-AP with or without 1 µM RGDS; on the right, representative microscopic 
images (40X) of adherent platelets from the adhesion assay.  Results are percentages of adherent 
platelets (mean of 6 independent experiments performed in triplicate). 
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Carotid Artery Thrombosis in α2β1 or GPVI/FcRγ Deficient Mice. 
 To analyze the individual roles the collagen receptors have in vivo, we utilized 
mice deficient in α2β1 or GPVI/FcRγ.  We compared α2-/-, FcRγ-/-, and GPVI-/- mice on a 
129/SvJ × C57BL/6J (mixed) genetic background in an in vivo model of arterial 
thrombosis that involves shear stresses to look at the roles of the platelet collagen 
receptors.  This assay uses laser-activated Rose Bengal dye to produce photochemical 
injury of the carotid artery in order to measure the time to complete vessel occlusion 
(Figure 5-4A).  We hypothesized that the α2-/-, FcRγ-/-, and GPVI-/- mice would have 
delayed times to arterial occlusion compared to wild-type mice.  However, the carotid 
artery occlusion time for the FcRγ-/- mice was 39.3 ± 15.9 minutes (mean ± SD) and was 
similar to wild-type mice (44.4 ± 7.8) in comparison to the α2-/- (74.5 ± 19.8) and GPVI-/- 
(74.6 ± 28.3) occlusion times.  FcRγ-/- occlusion times were not significantly different 
than wild-type (p > 0.05), whereas α2-/- and GPVI-/- occlusion times were statistically 
significant (p < 0.05) compared to wild-type and FcRγ-/-.  This was a surprising result and 
could be an effect of the mixed genetic background, so we measured the time to carotid 
artery occlusion in α2-/-, FcRγ-/- and wild-type mice on a pure genetic background 
(C57BL/6J) (Figure 5-4B).  The FcRγ-/- mice on the pure background had an occlusion 
time of 54.8 ± 13.7 minutes (mean ± SD), which was similar to wild-type (52.4 ± 7.4) 
when compared to α2-/- (66.4 ± 21.7), although the α2-/- difference was not statistically 
significant.  These data show that mice deficient in FcRγ do not have a defect in carotid 
artery thrombosis induced by photochemical injury like GPVI-/- and α2-/-. 
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FIGURE 5-4: Carotid artery thrombosis in α2β1 or GPVI/FcRγ deficient mice.  A, In vivo 
analysis of arterial thrombosis using laser-activated Rose Bengal dye to produce a photochemical 
injury of the carotid artery.  Measurements of the time to complete vessel occlusion were 
recorded in wild-type (WT), FcRγ-/-, GPVI-/-, and α2-/- mice on the mixed genetic background 
(129/SvJ × C57BL/6J).  B, In vivo analysis of arterial thrombosis using laser-activated Rose 
Bengal dye to produce a photochemical injury of the carotid artery.  Measurements of the time to 
complete vessel occlusion were recorded in wild-type (WT), FcRγ-/-, and α2-/- mice on the pure 
genetic background (C57BL/6J). 
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Collagen Induced Pulmonary Thromboembolism in α2β1 or GPVI/FcRγ Deficient Mice. 
 To further analyze the roles of the collagen receptors in vivo, we tested α2-/-, 
FcRγ-/-, GPVI-/-, and wild-type mice on the 129/SvJ × C57BL/6J (mixed) background or 
the pure C57BL/6J background using a model of pulmonary thromboembolism.  This 
assay initiates intravascular thrombosis independent of shear stress by the intravenous 
injection of collagen I.  Since the FcRγ-/- mice differed from the GPVI-/- mice in the 
carotid artery thrombosis assay, we postulated that the FcRγ-/- mice would have more 
incidences of thromboembolisms than GPVI-/- mice.  One readout for this assay is to 
count the number of thrombi/mm2 present in the lungs (Figure 5-5).  On the mixed 
background, wild-type mice had 28.4 ± 5.3 thrombi (mean ± SD) and α2-/- mice had 29.5 
± 6.8 thrombi in their lungs (Figure 5-5A).  The FcRγ-/- mice had a slightly higher 
amount of thrombi (8.4 ± 1.9) compared to the GPVI-/- mice (1.5 ± 0.5) and this was 
statistically significant (p = 0.0002).  Both thrombi counts for FcRγ-/- and GPVI-/- mice 
were significant when compared to wild-type and α2-/- mice.  The loss of α2β1 expression 
on the mouse platelets did not affect thrombi formation when compared to wild-type 
mice.  A similar trend was seen with the thrombi counts from α2-/-, FcRγ-/-, GPVI-/-, and 
wild-type mice on a pure genetic background (Figure 5-5B) where FcRγ-/- mice had 7.0 ± 
1.7 thrombi and GPVI-/- mice had 2.7 ± 0.7, which were statistically significant from α2-/- 
and wild-type mice.  Interestingly, the thrombi counts between FcRγ-/- and GPVI-/- were 
also significantly different (p = 0.0002).  There was no significant difference between the 
numbers of thrombi in α2-/- and wild-type mice. 
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FIGURE 5-5: Collagen induced pulmonary thromboembolism in α2β1 or GPVI/FcRγ 
deficient mice.  A, In vivo analysis of pulmonary thromboembolism induced by injection of 
25 µg collagen and 1 µg epinephrine.  Measurements of the number of thrombi observed per mm2 
in 5 random 20X fields (left side) and the percent decrease in platelet number caused by the 
collagen injection (right side) were determined for wild-type (WT), FcRγ-/-, GPVI-/-, and α2-/- 
mice on the mixed genetic background (129/SvJ × C57BL/6J).  B, In vivo analysis of pulmonary 
thromboembolism induced by injection of 25 µg collagen and 1 µg epinephrine.  Measurements 
of the number of thrombi observed per mm2 in 5 random 20X fields (left side) and the percent 
decrease in platelet number caused by the collagen injection (right side) were determined for 
wild-type (WT), FcRγ-/-, GPVI-/-, and α2-/- mice on the pure genetic background (C57BL/6J). 
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 Another readout for the pulmonary thromboembolism assay is to measure the 
platelet decrement in the blood before and after collagen treatment (Figure 5-5).  On the 
mixed background, the wild-type mice had an average platelet decrease of 78.7% ± 5.7 
(mean ± SD) and the α2-/- mice had 77.6% ± 8.3 and the difference between these groups 
was not significant (Figure 5-5A).  However, GPVI-/- mice had the lowest decrease in 
circulating platelets (12.3% ± 4.1) and FcRγ showed an intermediate decrease (38.7% ± 
15.3).  The difference in platelet decrement between FcRγ-/- and GPVI-/- again was 
significant (p = 0.0002).  A similar pattern was observed with α2-/-, FcRγ-/-, GPVI-/-, and 
wild-type mice on the pure background (Figure 5-5B).  GPVI-/- mice had the most 
significant decrease in circulating platelets (9.6% ± 2.1) and FcRγ-/- showed an 
intermediate decrease (49.6% ± 12.8), and the difference in platelet decrement between 
FcRγ-/- and GPVI-/- was significant (p = 0.0002).  These data further support the role of 
GPVI/FcRγ in in vivo thrombosis, but also highlight an innate difference between platelet 
activities in FcRγ-/- and GPVI-/- mice. 
 
Morphologies of Wild-Type, α2-/-, GPVI-/-, and FcRγ-/- Mouse Platelets Adhering to 
Collagen Substrates. 
 We analyzed α2-/-, GPVI-/- and FcRγ-/- mouse platelets using scanning electron 
microscopy to determine if there were variances in platelet morphology during adhesion 
and interaction with collagen substrates that was producing the difference in the in vivo 
analyses (Figure 5-6).  Individual platelets with filopodial extensions were observed on 
collagen I and α2-CRP for wild-type, GPVI-/-, and FcRγ-/- but not for α2-/-.  On the GPVI-
CRP, only aggregates of platelets were seen for wild-type and α2-/- genotypes but were  
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FIGURE 5-6: Morphologies of wild-type, α2-/-, GPVI-/-, and FcRγ-/- mouse platelets adhering 
to collagen substrates.  Scanning electron micrographs of wild-type, α2-/-, GPVI-/-, or FcRγ-/- 
mouse platelets adhering to BSA, CNI, α2-CRP, or GPVI-CRP in 2 mM MgCl2 adhesion buffer. 
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not detected for GPVI-/- or FcRγ-/-.  This data suggests the differences seen between 
GPVI-/- and FcRγ-/- in vivo are not caused by differences in their ability to interact with 
collagen. 
 
Protein Phospho-Tyrosine Analysis of Wild-Type, GPVI-/-, and FcRγ-/- Mouse Platelets. 
 The difference between the in vivo activities of GPVI-/- and FcRγ-/- platelets was 
further analyzed through in vitro analysis of phophorylation of tyrosines on platelet 
proteins to determine levels of platelet activation (Figure 5-7).  Mouse platelets were left 
untreated or stimulated with 10 µg/mL collagen I, 10 µg/mL α2-CRP, or 200 µM PAR4-
AP for 5 minutes and then lysed and proteins containing phosphorylated tyrosines were 
detected through immunoblot analysis.  Interestingly, untreated platelets showed a 
differential phospho-tyrosine profile when comparing wild-type, GPVI-/-, and FcRγ-/- 
platelets that was maintained through treatments.  Protein bands of interest were at 
molecular weights of about 25, 50, and 65 kDa.  This data further supports an innate 
difference between platelet activities in FcRγ-/- and GPVI-/- mice. 
 
Discussion 
 In this study, we provide further insight into the role of GPVI/FcRγ on platelets 
during hemostasis and thrombosis.  Our data show: (i) in static adhesion assays, platelets 
adhered to GPVI-CRP in an α2β1-independent manner, however, the adhesion is 
dependent on inside-out signaling through PLC and platelet aggregation mediated by 
αIIbβ3.; (ii) chemical crosslinking of GPVI-CRP (GPVI-xCRP) was able to stimulate  
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FIGURE 5-7: Protein phospho-tyrosine analysis of wild-type, GPVI-/-, and FcRγ-/- mouse 
platelets. Western blot analysis of wild-type (WT), GPVI-/- (GPVI KO), or FcRγ-/- (FcR KO) 
mouse platelets.  In the presence of 2 mM MgCl2, control platelets or platelets treated with 
10 µg/mL CNI, 10 µg/mL α2-CRP, or 200 µM PAR4-AP for 5 minutes and then lysed.  Platelet 
lysates were run on a gel that was then transferred to a membrane for immunoblot analysis using 
antibodies for phospho-tyrosine and actin.  Protein bands of interest were at molecular weights of 
about 25, 50, and 65 kDa. 
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platelet aggregation; (iii) activation of GPVI/FcRγ by Cvx stimulated an enhancement of 
α2β1-mediated platelet adhesion to collagen; and (iv) GPVI-/- and FcRγ-/- mice show 
differences in thrombosis.  Taken together, these results further support GPVI/FcRγ being 
an important platelet signaling receptor during hemostasis and thrombosis and identify a 
caveat with the use of genetic knockout mice for GPVI/FcRγ in thrombotic studies. 
 CRPs are important tools in studying the individual contributions of the platelet 
collagen receptors, α2β1 and GPVI/FcRγ.  The GPVI-CRP we utilized in this study 
confirms what others have seen with similar GPVI-specific CRPs when compared to 
collagen (60,120).  Smethwurst et al. showed the amount of GPO repeats has an effect on 
the adhesiveness of the CRP as a substrate, where increasing the number of repeats (2 to 
10 repeats) increases the platelet adhesion (119).  It is worth noting that the GPVI-
specific CRP that has been the model CRP in the field contains the sequence (GPO)10 
which is not physiologically relevant; GPVI-specific CRPs like GPVI-CRP that contain 
GPO sequences found in native collagens are less effective than (GPO)10 but mimic 
platelet activities observed with collagen to a higher degree.   
 We further analyzed platelet adhesion to GPVI-CRP and compared it to collagen 
I, α2-CRP (α2β1-specific substrate), or a 1:1 mix of GPVI-CRP and α2-CRP.  
Interestingly, the majority of platelet adhesion to the GPVI-CRP was dependent on 
platelet aggregation mediated by αIIbβ3.  Verkleij et al. also observed platelet aggregates 
predominantly adhering to another GPVI-specific CRP (168).  The 1:1 mix of CRPs 
resembled collagen I the best and further supported the fact that GPVI/FcRγ does not 
serve as an adhesive receptor but is an important platelet activating receptor.  When 
GPVI/FcRγ signaling through PLC is inhibited platelet adhesion to GPVI-CRP is lost.  
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This data supports the dependence of GPVI/FcRγ on integrin ligation, whether it is 
through α2β1 or αIIbβ3, for its interaction with collagen and suggests caution be used in 
the interpretation of data obtained using GPVI-specific CRPs that contain (GPO)n where 
n ≥ 6. 
 The fact that we did not observe an increase in α2β1-mediated platelet adhesion to 
the 1:1 mix of CRPs suggested further that α2β1 must bind to collagen first followed by 
GPVI/FcRγ.  In our previous studies, we identified a GPCR-mediated PLC-dependent 
priming mechanism of α2β1-specific platelet adhesion to collagen (150).  In this study, 
we show that optimal activation of GPVI/FcRγ by Cvx can stimulate an increase in α2β1-
mediated platelet adhesion similar to what PAR4 can induce.  This data shows that 
GPVI/FcRγ activation can prime α2β1 prior to the receptor binding the collagen substrate.  
This suggests that GPVI/FcRγ can stimulate stabilization of an already adherent platelet, 
but since it engages collagen after α2β1, GPVI/FcRγ cannot prime α2β1 but could induce 
strengthening of the α2β1-collagen interaction.  However, a GPVI/FcRγ agonist like Cvx 
that has its influence prior to the platelet contacting collagen would be able to prime α2β1 
and enhance the initial platelet adhesion to collagen. 
 The role of GPVI/FcRγ in hemostasis and thrombosis was further explored using 
collagen receptor deficient mice in in vivo assays.  We utilized a laser-induced 
photochemical injury of the carotid artery of mice to model arterial thrombosis.  This 
injury model supported an important role for α2β1 in stable thrombus formation under 
conditions of high shear stress, but surprisingly the two types of GPVI/FcRγ deficient 
mice (GPVI-/- or FcRγ-/-) gave conflicting results.  Where GPVI-/- mice had an attenuated 
thrombus formation similar to α2-/-, FcRγ-/- mice were able to form occlusive thrombi 
109 
 
similar to wild-type.  We checked to see if the mouse genetic background (129/SvJ × 
C57BL/6J) was causing this unexpected result by comparing it with mice on a pure 
imbred background (C57BL/6J).  Previously, a study by Cheli et al. determined that the 
C57BL/6J genetic background contained a modifier of hemostasis that modulated the 
effect that loss of GPVI had on the bleeding phenotype of mice during in vivo thrombosis 
assays (169).  We determined if this modifier of hemostasis was having a similar effect in 
the FcRγ-/- mice by analyzing laser-induced photochemical injury of the carotid artery in 
FcRγ-/- mice on the pure background (C57BL/6J).  The FcRγ-/- mice had the same 
phenotype as wild-type on both pure (C57BL/6J) and mixed (129/SvJ × C57BL/6J) 
genetic backgrounds suggesting the modifier is not regulating thrombus formation in 
these mice.  This meant that there was some other difference between the hemostatic 
functions of GPVI-/- or FcRγ-/- mice. 
 We further tested the in vivo thrombotic capabilities of GPVI-/- or FcRγ-/- mouse 
platelets using a collagen-induced pulmonary thromboembolism assay.  The data from 
this assay supported what had been seen in the carotid artery thombosis model. GPVI-/- 
mice showed complete protection from collage-induced pulmonary thromboembolism, 
whereas FcRγ-/- mice showed an intermediate level of protection when compared to α2-/- 
and wild-type mice.  This difference was observed in mice of both pure and mixed 
genetic backgrounds.  Taken together, these data confirm an innate difference in the in 
vivo hemostatic functions of platelets in GPVI-/- and FcRγ-/- mice and suggests a 
dominant-negative effect caused from the deletion of GPVI. 
 For in vitro platelet aggregation assays, neither GPVI-/- nor FcRγ-/- platelets 
respond to collagen stimulation.  However, the collagen-induced pulmonary 
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thromboembolism assay is an in vivo aggregation assay, but FcRγ-/- platelets are able to 
aggregate and produce a small amount of thromboembolism compared to GPVI-/-.  We 
wanted to determine why FcRγ-/- platelets were responding differently to collagen 
compared to GPVI-/- platelets, so we determined if their interaction with collagen was 
different.  We show that GPVI-/- and FcRγ-/- platelets interact with collagen substrates in a 
similar fashion when comparing platelet morphologies by scanning electron microscopy.  
We next determined if GPVI-/- and FcRγ-/- platelets had a different phosphotyrosine 
protein profile upon activation or ligation of surface receptors.  Interestingly, we found 
that GPVI-/- and FcRγ-/- platelets had different phosphotyrosine protein profiles when at 
rest and this difference was maintained during activation.  Phosphotyrosine protein 
profile bands were not able to be identified but were of molecular weights of 
approximately 25, 50, and 65 kDa.  These protein bands show more phosphorylation in 
GPVI-/- platelets, an intermediate level in FcRγ-/- platelets, and a low level in wild-type 
platelets.  This data suggests that resting GPVI-/- and FcRγ-/- platelets have different levels 
of proteins with tyrosine phosphorylations, which may explain the differences observed 
with their hemostatic functions.  However, more work needs to be done to identify the 
proteins in these bands whose phosphotyrosine statuses are varied and determine if that 
correlates with the level of GPVI-/- or FcRγ-/- platelet activity.  
In this study, we further analyzed the role of GPVI/FcRγ on platelets during 
hemostasis and thrombosis.  We utilized a GPVI-specific CRP (GPVI-CRP) and collagen 
receptor deficient mice in in vivo and in vitro assays to elucidate the functions of 
GPVI/FcRγ on platelets.  These data further support the role of GPVI/FcRγ on platelets 
as a signaling receptor important in platelet activation and not as an adhesive receptor. 
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We also shed new insight on the effect of Cvx on platelet adhesion to collagen, as well as 
identified a difference between GPVI-/- and FcRγ-/- platelets.  Further understanding of 
the functions of GPVI/FcRγ on platelets is important as this receptor is a potential target 
for antithrombotic therapy. 
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CHAPTER VI 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 The studies presented in this dissertation examine the complex process of 
hemostasis in vertebrates and focus on the interaction of platelets with collagens at 
vascular wound sites.  The mechanisms that contribute to normal hemostasis are also 
involved in pathological conditions of the cardiovascular system.  Thrombosis is the 
production of a pathological blood clot, that can give rise to cardiovascular disease 
(CVD) and stroke, the leading causes of morbidity and mortality in the United States and 
the developed world (18,170).  Platelets in the blood have a central role in cardiovascular 
thrombosis since they adhere to sites of vascular injury (e.g. a ruptured atherosclerotic 
plaque) where the subendothelial matrix composed of collagens is exposed to blood and 
leads to platelet aggregation and occlusion of the blood vessel.   
 A lot of research has been conducted on understanding platelet activation 
processes involved in hemostasis and thrombosis.  From this research, pharmaceutical 
companies have been able to identify and develop some useful antiplatelet drugs to treat 
and prevent thrombosis such as aspirin, clopidogrel, and αIIbβ3 antagonists.  However, 
these therapies still have limitations: aspirin is a weak inhibitor of platelet activation; 
clopidgrel has a slow onset of action because it has to be metabolized first and the 
metabolic rate is variable between patients; αIIbβ3 antagonists must be delivered 
intravenously; and overall, antiplatelet treatments cannot be separated from bleeding 
events (170).  Development of more effective antiplatelet drugs for these and other 
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targets (α2β1, GPVI/FcRγ, PARs, ect.) can improve upon therapies for thrombosis and 
further reduce mortality and morbidity caused by CVD and stroke.   
 For this reason, research has been conducted on the platelet collagen receptors 
(α2β1 and GPVI/FcRγ) to understand the individual and cooperative functions they serve 
on platelets during hemostasis and thrombosis.  Both collagen receptors are being 
pursued as pharmacological targets for antiplatelet treatments (170-172).  However, there 
still remains some debate as to the roles α2β1 and GPVI/FcRγ play (4,82).  Currently, the 
consensus in the field seems to be that α2β1 serves as the primary adhesive receptor 
contributing some intracellular signaling, whereas GPVI/FcRγ serves as the primary 
signaling receptor for activation with a secondary role in adhesion (27,62).   
 Our goal for these studies was to determine the contributions that the two platelet 
surface receptors, α2β1 and GPVI/FcRγ, make toward the platelet interactions with 
collagens at vascular wound sites.  The studies presented in this dissertation on α2β1 and 
GPVI/FcRγ have led to some novel observations on the interactions of platelets with 
collagens.  In chapter III, we show that α2β1-mediated platelet adhesion to collagens can 
be increased through suboptimal activation (levels where αIIbβ3 is not activated) of Gαq-
linked GPCRs (specifically PAR4) utilizing a PLC-dependent signaling pathway.  We 
further analyze this PAR4-induced α2β1 priming mechanism of platelet adhesion to 
collagen in chapter IV and show that PAR4 induces a modulation of α2β1 avidity that is 
not caused by a change in α2β1 conformation or its affinity for collagen but does seem to 
be linked with a possible change in α2β1 valency through a transient association with the 
platelet actin cytoskeleton.  In chapter V, we analyzed aspects of GPVI/FcRγ-mediated 
platelet processes involved in hemostasis and thrombosis and show the importance of 
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GPVI/FcRγ as the primary signaling receptor for collagen as well as reveal a surprising 
difference between GPVI-/- and FcRγ-/- mice in platelet function.  In this chapter, we will 
summarize some of our key findings and propose future research directions. 
 
Downstream Signaling Molecules of GPCRs Involved in Priming of α2β1 on 
Platelets. 
 In chapter III, we identified a GPCR priming mechanism of α2β1 on platelets that 
could increase platelet adhesion to collagen by approximately twofold.  We showed that 
suboptimal activation of GPCRs on platelets with the agonists: thrombin, PAR-APs, 
ADP, or TXA2 could induce this enhanced adhesion.  The GPCRs for these agonists are a 
part of a large, versatile family of membrane receptors that are commonly used as targets 
for therapeutic drugs and share the ability to transduce their signals by coupling to one or 
more of the four subtypes of G proteins: Gαs, Gαi, Gαq, and Gα12/13 (66).  The platelet 
GPCRs activated by thrombin and PAR-APs (PAR1 and PAR4), ADP (P2Y1), or TXA2 
(TPα and TPβ) all share the ability to associate with Gαq (67).  Upon ligation, Gαq-
linked GPCRs activate PLCβ isoforms which hydrolyze phosphatidylinositol 4,5-
bisphosphate (PIP2) into inositol 3,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
(Figure 5-4).  IP3 and DAG further propagate and amplify the signal through mobilization 
of intracellular Ca2+ stores and activation of other effectors (e.g. protein kinase C (PKC)) 
that induce a multitude of cellular processes many of which involve integrins (173).   
 A study by Lian et al. suggested that the deletion of both PLCβ2 and β3 
(PLCβ2/β3-/-) from mouse platelets caused a rescue in an in vivo carotid artery injury 
model using FeCl3, as well as partial attenuation in thrombin- or ADP-stimulated platelet 
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aggregation and Ca2+ mobilization (174).  They demonstrated the importance of 
PLCβ2/β3 in the signaling pathways of thrombin and ADP receptors on platelets.  We 
determined in chapter III that the suboptimal activation of the thrombin receptors (PAR1 
and PAR4) induced intracellular Ca2+ mobilization, and inhibition of PLC signaling 
(U73122) during suboptimal activation of PAR1 or PAR4 blocks the enhanced platelet 
adhesion.  Interestingly, the level of Ca2+ mobilization stimulated by suboptimal 
activation of PAR1 and PAR4 correlated with the effectiveness at increasing platelet 
adhesion to α2-CRP (chapter III); whereas, suboptimal PAR4 activation had a greater, 
more sustained Ca2+ mobilization that coincides with a greater increase in platelet 
adhesion. Similar effects in blocking enhanced platelet adhesion were seen with PLC 
inhibition during suboptimal activation of P2Y1 or TPα/β.  This suggested that PLCβ 
signaling in platelets regulates the priming of α2β1 downstream of Gαq-linked GPCRs.  
Future studies will further analyze known downstream effectors of PLCβ signaling. 
 We hypothesize that both of the PLC signal propagators (IP3 and DAG) serve to 
trigger the enhanced platelet adhesion.  This is supported by the fact that a DAG analog 
phorbol-12-myristate-13-acetate (PMA) can induce a partial increase in α2β1-mediated 
platelet adhesion compared to 50 µM PAR4-AP (Figure 6-1).  When IP3-stimulated 
intracellular Ca2+ mobilization is inhibited by chelation to BAPTA-AM, α2β1-mediated 
platelet adhesion (both basal and enhanced) is completely lost (data not shown).  These 
results suggest that both IP3 and DAG have a signaling role in the priming of α2β1.  
Signaling molecules (PKC isoforms (α and β) or CalDAG-GEF), which are activated 
downstream of both IP3 and DAG, will be studied since mouse platelets deficient in these 
molecules have hemostatic defects (175-177). 
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FIGURE 6-1: PMA treatment stimulates an intermediate level of enhanced α2β1-mediated 
platelet adhesion. A, Platelet adhesion assay to α2-CRP using isolated human platelets in the 
presence of 2 mM MgCl2, apyrase (1 U/mL), and SQ29,548 (1 µM) and treated with 0, 1, 10, 50, 
100, 500 nM PMA or 50 µM PAR4-AP; on the right, representative microscopic images (40X) of 
adherent platelets from the adhesion assay.  Results are the fold change in adherent platelets over 
basal (mean of 6 independent experiments performed in triplicate).  B, Platelet adhesion assay to 
α2-CRP using isolated human platelets in the presence of 1 mM RGDS, 2 mM MgCl2, apyrase 
(1 U/mL), and SQ29,548 (1 µM) and treated with 0, 1, 10, 50, 100, 500 nM PMA or 50 µM 
PAR4-AP; on the right, representative microscopic images (40X) of adherent platelets from the 
adhesion assay.  Results are the fold change in adherent platelets over basal (mean of 6 
independent experiments performed in triplicate). 
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 Rap1 is another cytoplasmic molecule that is downstream of PLCβ and CalDAG-
GEF signaling.  Rap1 is a member of the Ras family of small GTPases and has been 
shown to be involved in cellular adhesion, polarity, differentiation, and growth (178).  
Rap1b is highly expressed in human and mouse platelets, and loss of Rap1b in mouse 
platelets disrupts platelet hemostatic functions (179).  Rap1 has been shown to activate 
β1 and β3 integrins as well as regulate actin and microtubule cytoskeletal dynamics 
(178).  Interestingly, we have obtained preliminary data that shows the activation of Rap1 
in human platelets increases within 30 seconds of suboptimal PAR4 activation (Figure 6-
2).  Further studies will need to be performed to determine if the Rap1 activity produced 
by suboptimal PAR4 activation contributes to α2β1 priming. 
 Lian et al. also showed that PLCβ2/β3-/- platelets failed to assemble filamentous 
actin upon thrombin stimulation when compared to wild-type and PI3K-/- platelets, and 
that PLCβ2/β3-/- platelets did not spread on a fibrinogen substrate (174).  This data 
supports our findings that upon treatment of platelets with 50 µM PAR4-AP, α2β1 
transiently increases its association with filamentous actin within three minutes of 
stimulation (chapter IV) and that inhibition of PI3K with wortmanin had no effect on 
PAR4-stimulated enhancement of platelet adhesion (chapter III).  A study by Calaminus 
et al. identified actin-rich, punctate structures in platelets (actin nodules) that formed 
during the early stages of adhesion to various substrates and were dependent on actin 
polymerization (180).  Another study showed that actin polymerization and cdc42 
activity were necessary for the interaction of α2β1 with collagen during platelet adhesion 
through redistribution of α2β1 on the platelet surface, whereas αIIbβ3 activation was not 
associated with actin cytoskeleton dynamics (149).  Contrary to this αIIbβ3 data, other  
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FIGURE 6-2: Rap1 activation in PAR4-stimulated human platelets. Western blot analysis of 
Ral GDS-RBD-agarose pull-down of Rap1-GTP (the activated form of Rap1) from PAR4 
stimulated human platelets after 0, 0.5, 1, 5, 10, and 15 minutes.  In the presence of 2 mM MgCl2, 
platelets were treated with 50 µM or 200 µM PAR4-AP for in the presence or absence of 100 µM 
aspirin (ASA) and 1 µM SQ29,584.  Platelets were stimulated for the indicated times and lysed.  
Ral GDS-RBD-agarose was used to pull-down activated Rap1 and run on an SDS-PAGE gel.  
The gel was then transferred to a membrane for immunoblot analysis using an antibody for Rap1. 
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studies have shown that αIIbβ3 does increase its association with the actin cytoskeleton in 
platelets stimulated by thrombin and is important in the signal transduction and 
stabilization of the αIIbβ3-ligand interaction (181,182).  A study by Kovascovics et al. 
showed that upon thrombin activation of platelets, GPIb-V-IX associates with the actin 
cytoskeleton and is redistributed through a myosin II-dependent process (183).  This 
evidence points to the actin cytoskeletal dynamics as being a possible connection 
between Gαq-linked GPCR signaling and α2β1-mediated platelet adhesion.  Future 
studies will focus on the dynamics of the actin cytoskeleton and early morphologies of 
platelets stimulated with suboptimal concentrations of PAR4 agonists.  It will be 
important to address the specificity of the α2β1-priming mechanism in relation to other 
platelet integrins (αIIbβ3, αVβ3, α5β1, and α6β1). 
 Actin cytoskeletal dynamics have been shown to be important in cell adhesion 
and integrin function as well as in cooperation with GPCR signaling during directed cell 
migration (184-186).  The reorganization of the actin cytoskeleton is crucial for the 
functions of the platelet in hemostasis and the amount of filamentous actin contributing to 
the cytoskeleton can double upon activation (187).  Several intracellular proteins (Talin, 
ILK, and FAK) that are associated with focal adhesions and their formation are known to 
serve as indirect links of integrins to the actin filaments that form the cytoskeleton of 
cells.  We have looked at the activation state of Talin, ILK, and FAK (detection of 
phosphorylation at activation sites) or their association with α2β1 (co-
immunoprecipitation with α2β1) in platelets treated with 50 µM PAR4-AP and did not 
observe any changes in activation or α2β1 association compared to control (data not 
shown).  Other integrin-associated cytoplasmic proteins (filamin, α-actinin, vinculin, and 
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Kindlin-3) that have direct or indirect connections with the actin cytoskeleton have been 
shown to be involved in platelet hemostatic functions (188-191).  Future studies will look 
at filamin, α-actinin, vinculin, and Kindlin-3 in PAR4-stimulated priming of α2β1 on 
platelets. 
 Another future direction will be to determine the relevance of the α2β1-priming 
mechanism triggered by suboptimal GPCR (PAR1, PAR4, P2Y1, TPα, or TPβ) activation 
on platelet adhesion to α2-CPR under flow conditions.  We hypothesize that suboptimal 
GPCR stimulation can increase platelet adhesion above basal levels under normal and 
pathological flow conditions.  This hypothesis is supported by two studies that show a 
role for PAR activation in the platelet’s interaction with collagen under flow conditions 
either in vivo or in vitro (136,139).  It will also be interesting to determine if VWF 
binding to GPIb/V/IX is also capable of priming α2β1 and increasing the adhesiveness of 
platelets to collagen (Figure 6-4) since GPIb/V/IX has been shown to stimulate PLCγ2 
and regulate actin cytoskeletal dynamics (192). 
 
PAR4-Stimulated Modulation of α2β1 Avidity on Platelets. 
 We further analyzed the α2β1 priming mechanism induced by suboptimal 
activation of PAR4 on platelets in chapter IV to determine what changes to α2β1 were 
mediating the increased platelet adhesion to collagen.  Cell adhesion that utilizes 
integrins to bind to a substrate is regulated through two mechanisms that increase the 
avidity (overall adhesiveness) of the cell for the substrate: 1) modulation of the strength 
of the individual integrin-ligand bond (affinity) and 2) modulation of the number and 
spatial organization of the integrin-ligand bonds (valency) (106).  Both of these 
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mechanisms seem to be important in cell adhesion and migration, but the contribution of 
valency regulation especially in leukocyte and platelet adhesion is still unclear 
(106,144,186).  Both affinity and valency modulation have been shown to have 
complimentary roles in cell adhesion mediated through αLβ2 and αIIbβ3 (193,194).  
Interestingly, there is also evidence of differential regulation of affinity and valency 
between β1 and β2 integrins by chemoattractant activation of GPCRs on eosinophils 
(195).  Another study showed that chemokine activation of GPCRs on monocytes 
differentially and sequentially regulated the adhesiveness through α4β1 and α5β1 (196).  
Taken together, these data reveal the complexity of integrin avidity modulation on a cell 
and suggest differences in regulation between integrin types on the same cell. 
 Integrins are surface receptors that undergo long-range conformational changes 
upon either ligation to an extracellular substrate (collagen) or association of intracellular 
molecules (Talin) to the cytoplasmic tails of integrins (44). The conformation of the 
integrin determines the affinity of the integrin for its ligand; such as when the integrin is 
in a bent, inactivated conformation it has a low affinity for its ligand, but when the 
integrin is transformed to an extended, activated conformation it has a high affinity for its 
ligand (45).  Generally, integrins are believed to be in the inactivated, low affinity 
conformation until they are induced into the activated conformation.  This is evident for 
circulating platelets where an inactivated state for αIIbβ3 is maintained to avoid it binding 
to the abundant fibrinogen in the plasma and causing pathological thrombus formation 
(Figure 6-4). However, when the platelet is stimulated by thrombin, TXA2, or ADP, 
αIIbβ3 is converted into the activated conformation through inside-out signaling from the 
GPCRs of these agonists and now binds to the plasma fibrinogen with high affinity 
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causing platelet aggregation.  This degree of inactivation does not seem to apply to all 
integrins since α2β1 and α6β1 do not require an activating inside-out signal in order to 
bind to their ligands (chapter IV) (155).  This highlights the idea that there is a dynamic 
equilibrium between the conformations of each integrin and the possibility that 
intermediate conformations and affinities are plausible as well as their regulation being 
variable between different types of integrins (45).  
 This equilibrium concept is further supported by structural studies of the α2 I-
domain complexed with or without a GFOGER-containing CRP, which indicate the α2 I-
domain is in a closed conformation that changes to an open conformation when the I-
domain is bound to GFOGER (39,197).  Emsley et al. suggest that the conformational 
rearrangement induced by ligation of the α2 I-domain to the GFOGER-containing CRP 
can be transmitted through the rest of the integrin and the transmittance can be 
bidirectional.  While there is not a full protein structure of α2β1, the x-ray crystal 
structure of an integrin with an αI-domain was recently determined for αXβ2 in the bent 
conformation with a closed αI-domain (198).  Xie et al. showed that the αXβ2 inactivated 
structure was different than the structures obtained for the integrins that lack αI-domains: 
αVβ3 (199) and αIIbβ3 (200).  The bent structure of αXβ2 has a different orientation of its 
α and β legs when compared to αIIbβ3 and αVβ3, and the αI-domain is highly flexible 
allowing for three conformational states and greater ligand accessibility.  These data 
suggest that α2β1 might be able to have several conformations each with different 
affinities for collagen.   
 In chapter IV, we analyzed whether or not suboptimal PAR4 stimulation was 
causing a change in the conformation of α2β1 to the activated state and increasing the 
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integrin’s affinity for the ligand.  We show by several methods that suboptimal activation 
of PAR4 is not changing the affinity or inducing the activated conformation of α2β1.  
Also when the activated conformation of α2β1 is induced by Mn2+, the PAR4-stimulated 
enhancement of platelet adhesion to collagen is still observed.  The fact that α2β1 is not 
being activated and having its affinity increased also correlates with αIIbβ3 not being 
activated by the suboptimal activation of PAR4.  However, some cellular process is 
acting on α2β1 to increase platelet adhesion to collagen, and our data suggests that the 
process is linked to actin cytoskeletal dynamics and is specific to α2β1 since enhancement 
of platelet adhesion is not seen for another substrate/integrin interaction (e.g. 
laminin/α6β1).  Future studies will further test the specificity of the PAR4-stimulated 
priming mechanism for α2β1 as well as determine what mechanism is modulating α2β1 
avidity on the platelet surface. 
 We hypothesize that PAR4 is modulating the avidity of α2β1 on the platelet 
surface through actin cytoskeletal dynamics that cause a reorganization of α2β1 to 
increase the number of α2β1 molecules interacting with collagen.  The concept of integrin 
valency modulation (clustering) on platelets is controversial, because it has been very 
difficult to analyze clustering due to the small size of platelets and this cell type’s 
inaccessibility to genetic manipulation.  However, a few studies on platelets support a 
role of αIIbβ3 clustering on activated platelets (109,182,201).   Bunch used a monovalent 
Fab of the PAC-1 IgM (an antibody that binds to the activated conformation of αIIbβ3) to 
show thrombin stimulation of platelets induced clustering of αIIbβ3 and not its higher 
affinity conformation.  Fox et al. showed that αIIbβ3 on platelets upon ligation becomes 
associated with the actin cytoskeleton and is redistributed on the surface in order to 
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stabilize the ligand interaction.  A study by Isenberg et al. showed that clustering of 
αIIbβ3 on thrombin- or ADP-activated platelets occurs upon αIIbβ3 binding to fibrinogen 
or RGDS.  Clustering of β2 and β3 integrins has also been demonstrated in other cell 
types such as leukocytes and genetically manipulated CHO cells (145,202,203).  These 
data suggest that valency modulation of α2β1 on platelets is a plausible mechanism for 
avidity regulation. 
 An area of contention in the analyses of α2β1 changes in affinity is found in how 
the affinity changes are measured.  Reports on α2β1 affinity changes have used 
multivalent ligands in their assays.  This means that the proposed affinity change cannot 
be separated from the interaction possibly being a valency change or a combination of the 
two processes.  The multivalent ligands that have been used to study α2β1 affinity 
changes on activated platelets are soluble and fibrillar collagens that contain multiple 
α2β1 binding sites of varying affinities for α2β1 (132,204).  We sought to produce a 
monovalent α2β1-specific ligand with a fluorescent tag for use in affinity studies by using 
the α2-CRP, but upon labeling the α2-CRP with hydrophobic fluorophores, the ligand 
acquires non-specific binding capabilities towards platelets.  We have generated an α2-
CRP that is biotinylated and plan to utilize this tool in future studies addressing α2β1 
affinity/valency modulation on platelets. 
 One way we are probing the effect of suboptimal PAR4 activation on platelets in 
modulating the avidity of α2β1 for α2-CRP is by utilizing an optical trap-based force 
measurement assay (Figure 6-3A) (205).  Optical trap-based assays have been widely 
used to measure forces in biological systems (206), for a wide range of applications from 
measuring the extensions of single DNA (207,208) or RNA (209) molecules, to pulling  
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FIGURE 6-3: Optical trap-based force measurements of bond ruptures between platelet 
α2β1 and α2-CRP coated beads.  A, The conjugation of external, anchoring bonds utilized in 
our assays is depicted (Left).  The different compliances within the system are depicted in order 
to ensure that in the analysis of our data we account for all the different bonds that might stretch. 
This is particularly important due to the fact that upon application of a point pulling force to a 
plasma membrane, it is possibly to deform the conjugating bonds or membrane preferentially 
instead of the integrin molecule. In order to avoid this we used biotin-streptavidin bonds as well 
as covalent bonds to produce the α2-CRP coated 1 µm microspheres.  A typical platelet-integrin-
microsphere force extension assay is shown (Right). The balance of forces over the microsphere 
in our assay is depicted. Tether formation in extreme cases of membrane deformation is also 
depicted. We incorporate membrane deformation into our analysis since it cannot be discounted.  
B, Interaction forces between an optically trapped microsphere and platelets in the presence of 
5 mM EDTA (green traces) or 2 mM Mg2+ (purple traces) are depicted. The first inset for the 
Mg2+ experiments indicates tether formation rather than pure force extension of the integrin-
receptor bond. We indented the microsphere by the exact same amount into each platelet, and the 
probe and the platelet were allowed to interact for a few seconds and then the stage was then 
translated away at a constant velocity (200nm/s and 1000nm/s). The stiffness of the optical trap 
was ~0.8pN/nm in all our assays, resulting in force loading rates of 160-800 pN/s. The result was 
extension of the integrin molecule super-imposed on top of the platelet membrane deformation. 
Sharp drops in force indicated the rupturing of the integrin molecules. The optical trap was 
calibrated by applying known viscous forces and observing how xTrap[t], the displacement of an 
optically trapped particle from the centre of the optical trap, changed with force. The slope of the 
graph of xTrap, Max, the maximum displacement from the centre of the trap, versus FApplied, 
the applied force gives us kTrap, the stiffness of the optical trap. 
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membrane tethers (210,211) from live cells and giant unilamellar vesicles (GUVs) (212), 
to measuring the force extension curves of integrin molecules in vitro (213) as well as in 
the context of platelets (214-216).  
 In order to test the feasibility of these experiments, we have developed control 
assays to probe whether we can detect a change in the affinity of integrin molecules for 
their substrate in the presence and absence of metal ions.  We used an optical trap to 
measure the force required to extend and rupture the bond between α2β1 and α2-CRP in 
the presence of metal ions (Mg2+) or their absence (EDTA)(Figure 6-3B).  Similar 
measurements on integrins using optical trap assays have revealed that the integrin bond 
behaves like a catch bond, i.e. over certain regimes of applied force the molecules affinity 
increases for its substrate (217).  We observed similar behavior in our assays, as indicated 
by the force plateaus seen in distance-time records of the platelet interaction with α2-
CRP in the presence of Mg2+ (Figure 6-3B).  Since a lot of different information (binding 
kinetics, force of a single integrin bond, number of bond ruptures, surface area of 
interaction) can be captured from optical trap analysis, we plan to use the optical trap-
based approach in future studies on the platelet’s interaction with α2-CRP after 
suboptimal PAR4 activation.  Using different metal ions (Mg2+ or Mn2+) in the analyses 
of platelet α2β1 binding forces, as well as analyzing the interactions of recombinant α2 I-
domains (wild-type and E318A) with α2-CRP, we plan to determine specifically if 
suboptimal PAR4 activation is causing a modulation of α2β1 valency on platelets. 
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GPVI/FcRγ  Cooperation with α2β1 in the Platelet-Collagen Interaction. 
 In chapter V, we determined how GPVI/FcRγ-mediated platelet processes are 
involved in hemostasis and thrombosis.  We further support the importance of 
GPVI/FcRγ as the primary signaling receptor for platelet activation by collagen as GPVI-
CRP stimulates platelet aggregation unlike α2-CRP.  Our data does not support 
GPVI/FcRγ serving as a primary adhesive receptor as platelet adhesion to GPVI-CRP 
requires platelet aggregation.  However, our data suggests that GPVI/FcRγ may 
strengthen α2β1-mediated adhesion to collagen by triggering a similar clustering 
mechanism induced by Gαq-linked GPCRs since Cvx can stimulate an increase in α2β1-
dependent adhesiveness in platelets. 
 Future studies will further analyze the cooperative mechanism of GPVI/FcRγ 
supporting α2β1-mediated binding to collagen.  We hypothesize that GPVI/FcRγ can 
induce clustering of α2β1 on the platelet surface.  Similar to the optical trap based assay 
using α2-CRP, we have generated a biotinylated GPVI-CRP and will measure bond 
forces between the GPVI-CRP and GPVI/FcRγ on platelets.  We will then analyze the 
interaction of beads coated with a 1:1 mix of α2-CRP and GPVI-CRP with platelets and 
determine bond rupture forces.  Another future direction will be to determine if 
GPVI/FcRγ uses the PLCγ2 signaling pathway to induce the increase in α2β1-mediated 
platelet adhesion stimulated by covulxin.  The GPVI-/- or FcRγ-/- mice will be useful tools 
in analyzing the cooperation of GPVI/FcRγ with α2β1, but first it will be important to 
resolve the discrepancy between hemostasis observed between GPVI-/- or FcRγ-/- mice.  
Determining if the unaltered expression of FcRγ in the GPVI-/- platelets is producing a 
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dominant-negative phenotype will be important.  Other studies using GPVI-/- or FcRγ-/- 
mice show differences in platelet functions between these two genotypes (218,219). 
 
Summary 
 The studies presented in this dissertation examined the complex process of 
hemostasis in vertebrates and focused on the interaction of platelets with collagens at 
vascular wound sites.  We identified a priming mechanism of α2β1 through stimulation of 
Gαq-linked GPCRs or GPVI/FcRγ that increases resting platelets’ adhesiveness towards 
collagens through PLC signaling pathways (Figure 6-4).  This priming mechanism of 
α2β1 is triggered by suboptimal concentrations of GPCR agonists, a condition that would 
temporarily exist after the initial injury to the blood vessel wall due in part to the diluting 
factor of blood flow.  Suboptimal activation of GPCRs increases α2β1-mediated platelet 
adhesion to collagen while maintaining αIIbβ3 and α2β1 in low affinity, inactivated 
conformations thus enhancing the ability of individual platelets to adhere to an arterial 
wound site under shear stresses and promote stable adhesion before platelet aggregation.  
We postulate that this priming mechanism modulates the receptor valency through actin 
cytoskeletal dynamics that redistributes α2β1 into clusters.  Optimal activation of platelets 
by Gαq-linked GPCRs and GPVI/FcRγ induces the α2β1 priming mechanism but also 
modulates integrin affinity and increases avidity through platelet aggregation mediated by 
αIIbβ3 binding to fibrinogen.  These processes all cooperate to promote stable adhesion of 
platelets to collagen at vascular wound sites.  Our studies shed new light onto the roles of 
α2β1 and GPVI/FcRγ in hemostasis and thrombosis. 
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FIGURE 6-4: A mechanism for platelet adhesion to collagen.  Platelets circulate through the vasculature 
in a resting state where integrins are in low affinity conformations and unable to bind to ligands due to their 
low affinity for the ligand (fibrinogen; Fg), masked binding epitopes (von Willebrand Factor; VWF), or 
blockade by endothelial cells (EC) (collagens).  However when the platelet experiences an arterial vascular 
wound site, the platelet encounters activating stimuli that promote platelet adhesion, activation, and 
aggregation to form a stable thrombus.  Under flow conditions, soluble activators require time to 
accumulate to effective concentrations while working against the diluting factor of blood flow.  We 
identified a priming mechanism of α2β1-mediated platelet adhesion to collagen that is triggered by 
suboptimal concentrations of agonists (those that do not activate αIIbβ3 causing platelet aggregation) for 
Gαq-linked GPCRs (receptors for thrombin, ADP, and TXA2).  This priming mechanism works through the 
PLCβ signaling pathway (DAG and IP3) and other downstream effectors causing an increase in α2β1 
avidity not through an affinity change in α2β1 but through an association with the actin cytoskeleton 
possibly clustering α2β1 that leads to an enhanced adhesiveness to collagen.  This priming mechanism of 
α2β1 would promote stable platelet adhesion to the wound site at the early stages of thrombus formation 
where collagen remains exposed and activator concentrations are low.  Optimal concentrations of activators 
can also trigger the α2β1-priming mechanism as well as induce the high affinity conformations of α2β1 and 
αIIbβ3, which all further increase the adhesiveness of the platelet to collagen as well as initiate platelet 
aggregation.  Full activation of GPVI/FcRγ by convulxin can prime α2β1-mediated platelet adhesion, and it 
is interesting to speculate that PLCγ2 signaling stimulated by GPVI/FcRγ binding to collagen could induce 
α2β1 clustering to further strengthen platelet adhesion to collagen.  It is also interesting to speculate that 
α2β1 might be able to positively reinforce its own interaction with collagen through PLCγ2 activation.  
Question marks denote areas of future studies. 
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 Cardiovascular disease and stroke are the leading causes of morbidity and 
mortality in the United States and the developed world, and blood platelets play a central 
role in cardiovascular thrombosis.  Platelet adhesion to sites of vascular injury such as a 
ruptured atherosclerotic plaque, where the subendothelial matrix composed of collagens 
is exposed to blood, can lead to platelet aggregation and occlusion of the blood vessel.  
Understanding how platelets interact with collagens through the receptors α2β1 and 
GPVI/FcRγ as well as how the collagen receptors’ activities integrate into the overall 
hemostatic function of the platelet will be important in development of new and more 
effective antiplatelet drugs.
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